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1.  Summary 
The hematopoietic, atypical GTPase RhoH is reported to function as a negative regulator of progenitor cell 
differentiation, proliferation and survival. IL-3 is an important cytokine, signalling mainly via the JAK-
STAT pathway and by this promoting hematopoiesis, progenitor cell survival and differentiation of 
myeloid cells, such as mast cells. This study aimed to investigate the role of RhoH and important 
components in the signalling network of RhoH in IL-3 mediated signal transduction. It was attempted to 
link published, as well as the gained, information of this study to profile hematopoietic malignancies with 
aberrant RhoH expression. Finally, complementary studies were performed with in vitro IL-3 derived mast 
cells to address the role of RhoH in IL-3 mediated cell differentiation and its function in mast cell mediated 
processes, such as anaphylaxis.  
RhoH overexpression in BaF3 cells resulted in inhibition of IL-3 induced proliferation correlating with 
increased STAT1 and decreased STAT5 activity. Downregulation of RhoH was followed by an increase in 
IL-3 proliferation associated with enhanced STAT5 phosphorylation. Altered STAT1 activation induced 
increased expression of the cell cycle inhibitors (CDKIs) p21waf/cip and p27kip. Enforced IL-3 induced 
STAT5 activation in cells with low RhoH expression led to enhanced sensitivity of cells to IL-3, as a result 
of an upregulation of the STAT5 dependent transcription factor IRF-1 which induced increased IL-3 alpha 
chain (CD123) surface expression. RhoH expression was tested in lymphoma cell lines which were 
characterised based on their immunophenotype, STAT and GTPase activity. RhoH was strongly 
underexpressed in almost every cell line, suggesting that RhoH plays an important role in the formation of 
hematopoietic cancer types. To gain further insight into the IL-3 dependent signalling networks of RhoH, 
cytokine treatment dependent proteomic experimebyents were performed with IL-3 dependent BaF3 cells. 
A cytokine dependent pattern of protein interactions was identified. The interaction with RhoH was verified 
in HEK cells for two proteins: Cofilin-1 and PTP1B. Both of these proteins were found to have effects that 
can be related to the previous findings of this study in IL-3 mediated signalling. Finally, experiments in 
mast cells were performed to identify the role of RhoH for IL-3 dependent cell differentiation and function, 
indicating that RhoH deficiency does not affect the IL-3 induced differentiation. However, the loss of 
RhoH has functional consequences on mast cell biology, such as decreased cytokine production and mast 
cell mediator release.  
These findings link RhoH expression and RhoH modulated IL-3 induced proliferation on the one hand to 
STAT1 dependent induction of CDKIs and on the other hand to the increased STAT5 dependent CD123 
expression. It is suggested that RhoH is a tandem regulator of IL-3 dependent STAT5/STAT1 activation, 
most likely by newly discovered interactions with key signalling proteins such as PTP1B and Cofilin-1. 
Altered RhoH expression pattern in different hematopoietic disorders also suggests that the identified role 
of RhoH in IL-3 dependent signalling is transferrable to aberrant signalling in cancerogenous diseases. 
Furthermore, it was postulated that, although RhoH is dispensable for IL-3 mediated myeloid mast cell 
differentiation, the lack of RhoH has serious impact on mast cell mediated effects.
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1.  Zusammenfassung 
Die hämatopoetische GTPase RhoH ist ein negativer Regulator für die Vorläuferzelldifferenzierung, 
Proliferation sowie für das Überleben hämatopoetischer Stammzellen. Die Regulation der Differenzierung 
und des Überlebens dieser Zellen erfolgt hauptsächlich über den IL-3 abhängigen JAK-STAT Signalweg. 
Ziel dieser Studie war es die Rolle von RhoH in der IL-3 abhängigen Signaltransduktion zu untersuchen 
und neue Komponenten der RhoH vermittelten Signaltransduktion zu identifizieren. Zusätzlich wurde 
anhand von Hinweisen aus der Literatur verschiedene Lypmhoma Zellinien hinsichtlich ihrer RhoH 
Expression im Zusammenhang mit der Aggressivität der jeweiligen Tumorzellen analysiert. Ausserdem 
sollte der Einfluss von RhoH auf die IL-3 abhängige Mastzelldifferenzierung und deren Funktion (z.B. 
Anaphylaxie) mittels in vitro generierter Mastzellen geklärt werden.  
Die Überexpression von RhoH in der murinen Pro-B-Zelllinie Baf3 korrelierte mit der Inhibition IL-3 
vermittelter Proliferation einhergehend mit einer erhöhten STAT1 und verminderter STAT5 
Phosphorylierung. Umgekehrt führte die Inhibition der RhoH Expression zu einer verstärkten IL-3 
vermittelten Proliferation, verbunden mit einer erhöhten STAT5 Phosphorylierung. Die verstärkte STAT1 
Aktivität induzierte eine erhöhte Expression der Zell Zyklus Inhibitoren (CDKIs) p21waf/cip1 und p27kip1 in 
RhoH überexprimierenden Zellen, während die erhöhte STAT5 Aktivierung in RhoH defizienten Zellen in 
einer gesteigerten Expression des STAT5 abhängigen Transkriptionsfaktors IRF-1 resultierte. Dies führt 
wiederum zur Überexpression der IL-3 α Kette CD123 an der Zelloberfläche.  
Verringerte RhoH Expression konnte in verschiedenen Lymphoma Zelllinien nachgewiesen werden, die 
aufgrund ihres Immunophentoyps sowie ihrer veränderten STAT und GTPase Aktivitäten ausgewählt 
wurden. In verschiedenen RhoH Proteomanalysen wurden Zytokin abhängige Bindungsmuster mit RhoH 
interagierenden Proteinen festgestellt. Es konnten Interaktionen von RhoH mit Cofilin-1 und PTP1B in 
HEK Zellen nachgewiesen werden. Diese beiden Proteine können potentiell an den in dieser Studie 
gefundenen RhoH abhängigen Modulationen im IL-3 abhängigen Signalweg beteiligt sein. Abschließend 
konnte in Mastzellen gezeigt werden, dass RhoH keinen Einfluss auf die IL-3 vermittelte 
Zelldifferenzierung nimmt. Der Verlust von RhoH hatte jedoch schwerwiegende funktionelle 
Konsequenzen in den Mastzellen, wie eine verminderte Zytokin- und Histaminsekretion. Schlussfolgernd 
kann gesagt werden, dass RhoH die IL-3 vermittelte Signaltransduktion und vor allem die IL-3 abhängige 
Proliferation beeinflusst. Dies geschieht zum einen durch eine Modulation der STAT1 Aktivität und der 
Expression von STAT1 abhängigen CDKIs und zum anderen durch die Veränderung der STAT5/IRF-1 
abhängigen CD123 Expression. RhoH wird eine Rolle als Tandem-Regulator in der IL-3 induzierten 
STAT5/STAT1 Aktivität zugeschrieben, die wahrscheinlich durch die Interaktion mit den Proteinen 
PTP1B und Cofilin-1 zustande kommt. Anhand der nachgewiesenen Expressionmuster von RhoH in 
Lymphoma Zellinien wird angenommen, dass RhoH eine wichtige Rolle in der Krankheitsentstehung als 
auch in deren Verlauf spielt. Für Mastzellen konnte gezeigt werden, dass RhoH keinen Einfluss auf die IL-
3 abhängige Zelldifferenzierung nimmt jedoch die Expression von RhoH essentiell für die vermittelten 
Zellfunktionen ist.  
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2.  Introduction 
 
2.1  Interleukin-3 (IL-3) and the IL-3 receptor  
 
Interleukin-3 (IL-3) is an important cytokine for hematopoiesis, supporting the proliferation 
and survival of hematopoietic progenitors and promoting the differentiation of myeloid cells 
(e.g. basophils, erythrocytes, dendritic cells (DCs) and mast cells (MCs))1 from a common 
myeloid progenitor (CMP)2,3. IL-3 is a four helical cytokine serving as ligand for the IL-3 
specific type I cytokine receptor alpha (α) chain, CD123. The (human) IL-3 gene is located 
on chromosome 5q23-31 and is neighbored by the IL-3 family cytokine genes GM-CSF 
(Granulocyte macrophage colony-stimulating factor) and Interleukin-5 (IL-5)4. IL-3 is 
produced mainly by CD4+ T-helper (Th) cells and to a lesser extent by other cells, such as 
MCs, endothelial cells and monocytes.  
The IL-3 receptor belongs to the type I cytokine receptor family, which are mediating signal 
transduction by the formation of receptor heterooligomers. These receptors commonly 
comprise a shared beta (β) and a cytokine specific α-chain5;6. In humans it was found that 
GM-CSF and IL-5 can compete with IL-3 for receptor binding suggesting that these cytokines 
share a common β chain 7 (Fig.2.1). This observation does not occur in the murine system, 
since there is an additional IL-3 specific beta chain (βIL-3) present on murine cells. Ligand 
binding to the IL-3 receptor α chain (CD123) causes the formation of a high affinity 
heterodimeric receptor complex6,8. The IL-3 βc is quite unique within the type I cytokine 
receptor family, since the conserved WSXSW motif, usually found within the CHR stretches 
of type I cytokine receptors, is replaced by a distinctive LSXSW motif8,9. The membrane 
proximal intracellular part of the βc subunit of the IL-3 receptor includes a Box-1 domain 
which was found to be of importance for the induction of proliferation associated genes (c-
myc, pim-1 and oncostatinM) 10-12. Upon ligand binding, this region plays an important role in 
the interaction with different signal transducing proteins, such as Janus-Kinases (JAKs), 
STATs (Signal Transducers and Activators of Signal Transduction) , c-Scr (cellular-sarcoma)  
and PI-3K (phosphoinositid-3-kinase) 13. The membrane distal region is known to mediate 
survival signals and growth inhibiting signals induced by the cytokines of the IL3-family14. 
Moreover, the membrane distal region is reported to take part in the activation of Ras (rat 
sarcoma) as well as in the transcriptional activation of transcription factors14. Due to a lack of 
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intrinsic enzymatic activity, type I cytokine receptors, such as the IL-3 receptor use mainly 
the JAK–STAT signalling pathway to transmit incoming signals 15.  
2.1.1  The JAK-STAT pathway 
 
The investigation of cytokine signalling pathways led to the discovery of four types of JAK 
proteins containing seven JAK homology (JH) domains16. Members of the JAK family are 
JAK1, JAK2, JAK3 and Tyk2. Except for JAK3, JAKs are ubiquitously expressed. The C-
terminal JH domains inhabit the kinase and the pseudo-kinase region. Upon ligand binding to 
the receptor, receptor associated JAKs become activated through phosphorylation of critical 
tyrosines in their “activation loop” located within their kinase domain 17. The FERM (four-
point one, ezrin, radixin, moesin) domain is N-terminally located and is thought to mediate 
the association with the Box1 domain on cytokine receptors (type I and II)18. Upon activation 
JAKs initiate the phosphorylation of specific receptor tyrosine residues which serve as 
docking sites for the STAT proteins18. The seven discovered members of the STAT family 
STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 (90-100 kDa), inhabit a 
SH2 domain which is able to bind to phosphotyrosine residues, provided by JAKs. In resting 
cells, STATs are mostly located as inactive homodimers within the cytoplasm18. Once bound 
to the phosphorylated receptors sites, the STAT proteins become phosphorylated by JAKs and 
thereby activated. Activated STATs are released from the receptor and reorient into an anti-
parallel dimer. To achieve this conformation, the SH2 domain of one activated STAT has to 
bind to the phosphorylated tyrosine of another activated STAT. The resulting STAT dimers 
translocate to the nucleus, where they bind to specific DNA sequences and initiate gene 
transcription. The regulation of the JAK-STAT signalling pathway is tightly controled by 
different mechanisms. One important mechanism is mediated by phosphatises, such as Src 
homology region 2 domain-containing phosphatases (SHP)  which are able to 
dephosphorylate JAK proteins19. Members of the protein tyrosine phosphatase (PTP), family 
such as PTP1B are known to dephosphorylate STAT proteins. Only two of these 
phosphatases, TC-PTP and SHP-2, are able to dephosphorylate nuclear STATs, which plays 
an important role for the next regulatory mechanism, nuclear import and export of STATs. 
This process is driven by nuclear localisation and nuclear export signals in the sequence (NLS 
and NES) of STAT proteins19,20. Another important control function is initiated by members 
of the family of suppressors of cytokine signalling (SOCS) molecules. These molecules are 
STAT target genes which directly inhibit STAT activation resulting in a classical “feedback 
loop”. Once these inhibitory mechanisms fail to “turn-off” the cytokine induced reaction, a 
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hyperactivity of the cytokine receptor results, which is frequently found in diverse cancer 
types18. 
2.1.2  IL-3 mediated JAK-STAT signalling  
 
The major signalling pathway activated by IL-3 is the JAK-STAT pathway (Fig. 2.1)13. Upon 
receptor activation, the membrane proximal receptor associated JAK2 kinase (N-terminally) is 
activated and induces tyrosine (docking sites for STATs) and serine phosphorylation of βc 
residues. The α subunit of the IL-3 receptor (CD123), which is reported to be pivotal in IL-3 
mediated differentiation of hematopoietic stem cells, is also involved in JAK2 activation. 
Normally STAT5a and STAT5b can be activated by IL-3 treatment which leads to the 
transcription of pro-proliferative genes13,21,22. To a much lesser extent Tyk2, STAT1 and 
STAT3 phosphorylation, following IL-3 treatment, has been observed23.  
 
 
Fig. 2.1 The IL-3 receptor and its associated signalling 
molecules 
Schematic diagram of IL-3 bound to the type I cytokine 
receptor IL-3. IL-3 comprises an unique ligand binding 
subunit that is not shared by other members of the IL-3 
family receptors. The common β-chain is mostly 
responsible for cytokine mediated signal transduction and 
is shared by the IL-5 and GM-CSF receptors (modified 
from Reddy 2000) 
It needs to be highlighted that STAT1 and STAT5, despite both being targets of IL-3, have 
oppositional effects in cells. In inflammation, STAT1 mediates the recruitment and the 
activation of immune cells via control of gene transcription of cytokines, chemokines, 
adhesion factors and proinflammatory mediators24. The induction of apoptosis is controlled by 
STAT1 activation by initiating the transcription of caspases25 or death receptors and their 
ligands26-29. Also, the activation of STAT1 is known to have an inhibitory effect on the 
transcription of prosurvival genes such as members of the bcl-2 family30. Moreover, STAT1 is 
known to be an inhibitor of proliferation by the transcriptional repression of proteins involved 
in cell cycle progression, such as the cyclin c-myc31,32, or initiating the cell cycle dependent 
inhibitors (CDKIs) p21waf/cip1  and p27kip1  which can bind to the cell cycle dependent kinases 
(CDK2, 4/6) and by this causing cell cycle arrest in G1 phase31,33,34. By regulating cell 
survival and proliferation STAT1 is a major factor in the control of tumourigenesis24. 
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However, STAT5 a key regulator of hematopoiesis, is phosphorylated and activated to a much 
higher content by IL-3 than STAT1. STAT5 is reported to act “reverse” to different STAT1 
dependent processes by counter- regulating overlapping signalling pathways. By regulating 
genes such as c-myc, bcl-xl and genes of the bcl-2 family, STAT5 activity takes part in 
enhancing cell proliferation35,36. Proliferation and cell cycle progression is promoted by 
STAT5 through the initiation of the expression of cell cycle progressing cyclin protein, as it 
was demonstated for CyclinA237 and CyclinD138 or as recent studies suggest by the regulation 
of p21waf/cip1 and p27kip1 proteins39,40. Apoptosis is thought to be directly inhibited by STAT5 
through the regulation of the members of caspase proteins41,42. Aberrant STAT5 activation is 
also frequently found in a variety of malignancies and plays a key role in tumour development 
and oncogenic transformation and cancer progression36.  
2.1.3  The physiologic relevance of IL-3 and the IL-3 receptor 
 
2.1.3.1 Physiologic relevance of IL-3 for murine mast cells (MCs) 
Mast cells (MCs) are inflammatory tissue-based cells of myeloid origin, that function as 
major effectors of allergic reactions (e.g. anaphylaxis) and to a lesser extent as modulators of 
innate and adaptive immunity43. Different groups of mediators are produced by MCs: 
preformed mediators such as histamine, which effects the smooth muscle contraction and 
induces an increase of the vascular permeability; serine proteases and the cytokine Tumour 
Necrotizing Factor alpha (TNF-α). TNF-α is also  reported to be de novo synthesised like 
other cytokines (IL-6, IL-10, IL-4) by MCs upon antigen challenge 43-44. MCs are carriers of 
the high-affinity Immunoglobuline E (IgE) receptor (FcεRI)45. The release and secretion of 
MC mediators is triggered after antigen recognition or polyvalent allergen binding to the 
FcεRI bound IgE. Following antigen challenge the granules fuse to the plasma membrane and 
the granule contents are released44. The FcεRI β-chain inhabits immunoreceptor tyrosine-
based activation motifs (ITAMs)46, which are conserved sequences composed of tryrosine 
residues found throughout different types of immune-related proteins47. Upon IgE binding the 
crosslinkage of the FcεRI is induced and the ITAMs get phosphorylated and recruit the spleen 
tyrosine kinase (Syk) kinase. Syk initiates the downstream signalling cascades leading to the 
activation of the MC46. Also STAT5 was found to significantly contribute to the activation 
and to the maturation of MCs37, which differentiate to their mature form locally after 
precursor migration to the target tissue48. However, many factors in the micro-environment 
can dramatically influence the resulting mature MC phenotype in the tissue 49,50. In vitro 
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hematopoietic stem cells (HSCs) can be triggered to differentiate into MCs in the presence of 
only one of the required factors, which means either in the presence of SCF-1 or IL-3. 
However, the details of the influence of the environment and signal transduction leading to 
MC development are still unknown43. 
 
2.1.3.2 Physiologic relevance of CD123 in Acute Myeloid Leukemia (AML) 
Acute Myeloid Leukemia (AML) is a myeloid clonal stem cell disorder. Characteristic for this 
disease is the occurrence of clonal chromosomal defects and a low production of healthy cells. 
A few leukemic stem cells (LSC) are the origin of a vast amount of leukemic cells undergoing 
an aberrant and poorly regulated process of hematopoiesis51 52.Characteristic markers and 
features of AML is the elevated expression of the IL-3 receptor α chain on primitive AML 
cells, which is associated with an increased cell cycle activity and an increased resistance of 
these cells against apoptosis, when facing growth factor deprivation53. In addition CD123 
overexpressing AML blasts showed either spontaneous STAT5 activation or increased levels 
of STAT5 phosphorylation after IL-3 treatment. It is thought that the increased CD123 
surface expression in AML cells, as a result of the elevated expression of the STAT5 
dependent interferon regulatory factor-1 (IRF-1) surface53. Recent observations indicate that 
low expression levels of the atypical GTPase RhoH functions as an unfavourable prognostic 
marker for overall and disease free survival54. 
2.2  Rho GTPases member of the Ras superfamily of small 
GTPases 
 
There are over 150 highly conserved monomeric G- proteins belonging to the Ras 
Superfamily of small guanosine-triphosphatases (GTPases)55. Due to their sequence 
homologies and functional similarities, the members of the Ras Superfamily can be 
subdivided into six main branches: Ras, Rho, Rab, Ran, Arf and Miro. These small GTP-
binding proteins act as molecular “switches” in several cellular processes, working in a binary 
fashion. Stereotypic members of these subgroups cycle between a GTP bound “on” and a 
guanosinediphosphate (GDP) bound “off” conformation 56.  
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Fig. 2.2 Unrooted phylogentic tree of the 20 
members of the Rho GTPases Family 
Classification of the members of Rho GTPases 
based on their amino acid sequence similarities 
under specifications of the sequence homology 
(percentage) and indications of their GTPase 
activity (“classical” and “atypical”), (from 
Heasman and Ridley 2008) 
2.2.1  Structural features of Rho GTPases 
 
Rho GTPases are monomeric 20-30 kDa GTP binding proteins, found in all eukaryotic cells. 
22 mammalian genes encode for 25 Rho GTPases, which can be subdivided according to their 
functional and sequential homologies into 8 clusters (Fig 2.2): the “classical” GDP/GTP 
binding proteins including RhoA, Rac1 and Cdc42 57. These classical GTPases are cycling 
between an inactive GDP (inactive) and GTP (active) -bound conformation. The cycling is 
promoted by their intrinsic ability to hydrolyse GTP to GDP. They are thought to interact with 
their downstream targets and signalling mainly in their GTP-bound form. Besides the typical 
members there are the so called “atypical” Rho GTPases, which are comprised by the 
subbranches Wrch-1/Chp, Rnd, RhoBTB and RhoH/TTF (Fig. 2.2). The atypical Rho 
GTPases are in a constitutively GTP-bound “on” conformation58. 
 
   
 
Fig.2.3 Structure and “loaded spring 
mechanism” of Rho GTPases 
Schematic illustration of the universal 
loaded spring mechanism. Switch I and II 
domains are bound to the γ-phosphate via 
amino groups of conserved threonine and 
glycine residues. Switch region relaxes 
after release of γ-phosphate following 
GTPase hydrolysis (from Vetter and 
Wittinghofer 2001) 
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Characteristic for Rho family proteins is the Rho-type GTPase like domain, lined up within 
short N- and C- terminal extensions and inhabiting a Rho specific structural insert of 13 
amino acids (aa)56,59. In addition to the GTPase domain, GTP-binding molecules have 4 to 5 
other conserved sequence elements, of which the switch regions (I and II) and the β- and γ- 
phosphates located in the phosphate binding loop (P-loop) are of particular interest for 
nucleotide base binding. The “loaded spring mechanism” describes the conformational change 
of the GTPase, when the GDP is exchanged for GTP (Fig. 2.3)56,60. In the GTP-bound form, 
two hydrogen bonds from the γ-phosphate oxygens are formed to the invariant conserved 
threonine in the switch I region (37 in RhoA, 36 in RhoH) and to the glycine in the switch II 
region. The release of γ-phosphate after the GTP hydrolysis allows the switch to relax back to 
its “off”, GDP bound conformation56. 
2.2.2  Important regulation mechanisms of Rho GTPases 
 
2.2.2.1 Gene expression 
Rho GTPases are expressionally regulated. Most Rho GTPases are ubiquitously expressed, 
while other GTPases show tissue specific expression pattern59. In addition to the tissue 
specific gene expression, the control of transcription and translation are important regulatory 
mechanisms of Rho GTPases. The transcriptional control is of particular interest for the 
atypical, constitutive active members of Rho GTPases such as RhoH 59,61.  
 
2.2.2.2 Regulation through interactions with GEFs, GAPs and GDIs 
Guanine nucleotide exchange factors (GEFs), are proteins that promote the exchange of 
bound GDP to GTP of Rho GTPases. GTPase activating proteins, (GAPs) are accelerating the 
weak GTP hydrolysis activity of Rho proteins62-63. Guanine dissociation inhibitors, (GDIs) are 
interacting with the switch I and II region, as well as the C-terminal polybasic domain and 
CAAX motif of Rho GTPases 64. GDIs are able to: (1) inhibit the GDP dissociation, (2) 
inhibit the hydrolysis of GTP and blocking interactions with effector proteins, (3) mediate the 
cytosol sequestering of Rho GTPases, (4) provide the structural stability of Rho GTPases and 
facilitate the transport of RhoGTPases between different intracellular compartments 65,66. The 
GTPase RhoH was found to interact with GDIs61. However, the function and the mechanism 
of these interactions remain widely speculative. Competition between Rho GTPases for the 
interaction with overlapping effector and target proteins has been shown to contribute to the 
regulation of Rho GTPases and their mediated signalling pathways67.  
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2.2.2.3 Posttranslational protein modifications  
The activity and the mediated function of Rho GTPases also depend on their subcellular 
localisation. C-terminal CAAX motif determines GTPase localisation, and is known to be 
targeted for posttranslational lipid modifications. The CAAX motif can be prenylated, 
geranylated or methylated68, thereby the -AAX sequence is cleaved off and the free 
carboxylate anion of the cysteine residue is methylated 59,68. Rho GTPase activity can also be 
regulated by direct phosphorylation or ubiquitination69,70. The serine phosphorylation within 
the polybasic region of Rho GTPases was shown to modulate the binding affinity to their 
GDIs71. Ubiquitinylation of Rho GTPases in response to stimuli results in the 
posttranslational degradation of Rho GTPases70,72.  
2.2.3  Function and signalling of Rho GTPases 
 
Rho GTPases and their effector proteins are well described modulators of the cytoskeleton 
and related cell functions61,73,74. RhoA, Cdc42 and Rac1 are known to stimulate cell cycle 
progression either by promoting Cyclin D1 induced G1-S transition or by negative regulation 
of the cell cycle inhibitors p21waf/cip1 and p27kip1. The atypical GTPase Rnd3/RhoE however, 
blocks cell cycle progression via Cyclin D175. Rho GTPases are also known to control wide 
ranges of “nuclear factor kappa-light-chain-enhancer of activated B cells” (NFκB)-mediated 
processes such as cell survival76,77. Rho GTPases are also important for cytokine mediated 
JAK-STAT signalling. The phosporylation, as well as the nuclear translocation, of STAT5 
and STAT3 was demonstrated to be facilitated by activated Rac1 and the GAP molecule 
MgcRacGAP78,79. Also interferon-γ induced inflammatory response via STAT1/STAT3 
signalling strongly depends on Rac1 activity80. Rho GTPases are mediating numerous 
functions in hematopoiesis such as long-term engraftment, proliferation and migration of HSC 
or in the differentiation and development of MCs, B- and T- lymphocytes81. Apparently 
dysregulation of Rho GTPases is found to promote tumorigenesis and malignant disorders.  
2.3  The atypical GTPase RhoH 
 
RhoH, initially named Translocation Three Four (TTF), was discovered in 1995 by Dallery 
and co-workers as a fusion transcript from chromosome (3:4) translocation in Non-Hodgkin-
Lymphoma (NHL) with the transcriptional repressor B-cell lymphoma-6 (BCL6)/LAZ382. 
Sequence analysis assigned the sequence to the previously unknown small G like protein 
RhoH82. RhoH is localised on the short arm of chromosome 4, band p13 and has a length of 
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191 aa. RhoH shares a 27% H-RAS and a 45% relationship to other Rho family members and 
is GTPase deficient. Thereby RhoH activity is thought to be controlled through interactions 
with other GTPases, posttranslational modifications and transcription regulation83. RhoH 
expression is restricted on hematopoietic cells, with differential expression levels among the 
lineages81-84. The strongest expression of RhoH was detectable in lymphocytes, lower RhoH 
expression was also detectable in hematopoietic progenitor cells and myeloid lineages such as 
in vitro derived MCs61,85. 
2.3.1 Structural features of RhoH 
 
RhoH is GTPase deficient, due to absent residues critical to catalytic GTPase activity such as 
the conserved glycine 12 (RhoA), which is replaced in RhoH by a serine86 and glutamine 63 
(RhoA) that is asparagine in RhoH. The specific Rho family insert of 13 aa was found to be 
significantly shorter in RhoH with a length of only 7 aa83. The conserved CAAX motif on the 
C-terminus is present in RhoH as a CKIF-motif. The RhoH CKIF-motif was demonstrated to 
undergo farnesylation and to a lesser extent, geranylation83.  
2.3.2  RhoH in signal transduction 
 
2.3.2.1 RhoH and its inhibitory function on other GTPases 
RhoH was found to significantly retard the degradation of IκBα and thereby suppress the 
NFkB activation61. RhoH was also able to reduce the activation of NFκB, induced by the 
expression of constitutive active RhoA or Rac1. RhoH has an inhibitory effect on Rac1 and 
Cdc42 dependent TNF induced p38 activation independently of JNK or ERK activation61. 
Furthermore it was demonstrated that RhoH is able to inhibit stromal derived factor-1 (SDF-
1) induced, Rac1 mediated chemotaxis and polarisation of HPCs87. The inhibitory effect of 
RhoH on other GTPases is considered as a physiological function, although the exact 
mechanisms remain unknown. 
 
2.3.2.2 RhoH in T-cell signalling 
Studies of RhoH in lymphocytes showed that phorbol 12-myristate 13-acetate (PMA) 
treatment, which activates Protein Kinase C (PKC) and thereby mimics T-cell receptor (TCR) 
complex mediated signal transduction, results in the decrease of RhoH mRNA levels61. RhoH 
null mice exhibited substantial blocks at distinct developmental stages leading, to fewer 
mature T-cells and thereby indicating RhoHs` importance for pre-TCR signalling88. Mature T-
cells of RhoH-/- mice, despite normal amounts of TCR on their surface, failed to respond with 
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adequate proliferation in response to stimulation with anti-CD3 antigen. It was found that the 
spleen tyrosine kinase homolouge Zap70, binds to a putative ITAM in RhoH, which in turn 
sequesters its recruitment to the CD3ζ-chain following TCR activation leadinding to the 
initiation of proper downstream signalling89. Nevertheless, the interaction of RhoH and Zap70 
is contested since Brakebush and co-workers were unable to detect this interaction88. RhoH is 
subject to proteasomal degradation after TCR, but not after B-cell receptor activation, 
highlighting its distinct role for TCR signalling72.  
 
2.3.2.2.1 Anaplastic large T-cell lymphoma (ALCL) 
Anaplastic large T-cell lymphoma (ALCL) is a biologic and clinically heterogeneous subtype 
of peripheral T-cell lymphoma (non-Hodgkin lymphoma (NHL))90. 50-80 % of all ALCLs 
contain a chromosomal translocation which brings the orphan tyrosine kinase, anaplastic 
lymphoma kinase (ALK) under the promoter control of different genes (ALK+ ALCL)91. Most 
systemic ALK+ ALCL types inhabit the translocation t(2;5)(p23;35)92, which brings ALK 
under the promoter control of the nucleolar phosphoprotein nucleophosmin (NPM)93. One 
hallmark of ALCL subtypes is the aberrant immunophenotype, typicaly lacking the TCR and 
associated molecules such as CD3 and Zap70, as well as low or no expression of CD4/CD894. 
NPM-ALK+ ALCL show enhanced STAT5 phosphorylation correlating with higher cell cycle 
progression rates and cytokine independent growth95,96. Recent studies also reveal an 
important role of small GTPases (e.g. Rac1, Cdc42) contributing to the oncogenic attributes 
of NPM-ALK rearrangements in systemic ALCL97,98.  
2.3.3  RhoH, a negative modulator of hematopoetic proliferation and 
its function in cancer 
 
2.3.3.1 RhoH a negative modulator of hematopoietic cell proliferation and survival 
Hematopoietic progenitor cells with enhanced RhoH levels showed decreased proliferation 
rates in response to the cytokine SCF-1. Additionally, RhoH expression led to impaired 
colony formation in response to SCF-1. The susceptibility of RhoH overexpressing progenitor 
cells to undergo apoptosis was enhanced causing decreased cell counts. The explanation of 
the observed defects was due to an antagonistic effect of RhoH on the GTPase Rac1, which 
was previously described to have opposing consequences on the described processes in stem 
cells85.  
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2.3.3.2 RhoH involvement in cancer 
RhoH is a protooncogene since its coding region is juxtaposed to the immunoglobulin locus. 
BCL6/LAZ3 translocations with RhoH are frequently found during the process of indolent 
follicular lymphoma transformation to aggressive large B-cell lymphoma, which indicates a 
role of RhoH in pathogenesis and as a marker for transformation potential of follicular 
lymphoma83. RhoH involving translocations were also detectable in multiple myelomas, nodal 
marginal lymphomas and splenic lymphomas. RhoH is located on a hypermutable gene locus, 
and is thereby targeted by aberrant hypermutation at its non-coding region which indicates 
altered RhoH expression 61. Hypermutations in RhoH are considered as a tumor-associated 
event99. RhoH expression is downregulated in hairy cell leukemia (HCL) and AML. It was 
found that RhoH underexpression is a diagnostic marker for HCL associated with increased 
proliferation, adhesion and migration of HCL cells100. RhoH underexpression in AML 
supports Rac1 dependent protection from apoptosis and drug resistance and was thereby 
determined to be a poor prognostic factor for general and disease-free survival of AML 
patients4-54. Overexpression of RhoH also plays a role in leukaemia. Increased RhoH 
expression levels correlated with Zap70 expression in B-cell chronic lymphocytic leukemia 
(CLL) leading to enhanced Akt/Erk phosphorylation following B-cell receptor activation101. 
 
2.3.4  RhoH, inhibitor of IL-3 mediated proliferation and signalling: 
Preliminary data 
 
Previous work from our lab (Liu, H.) with parental and RhoH overexpressing BaF3 cells 
showed indications for RhoH as a negative modulator of IL-3 dependent proliferation. Further 
work suggested that RhoH might eventually modulate IL-3 induced STAT activity leading to 
the observed proliferation defects. Physiologic relevance of RhoH for IL-3 dependent 
differentiation and cell function was tested by Liu in initial experiments with RhoH deficient, 
IL-3 derived MCs. These experiments suggested defect IL-3 dependent MC development due 
to altered MC marker expression and altered MC functions based on decreased β-
hexosaminidase release measurements of RhoH deficient MCs102.   
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2.4  Aim of this study  
 
Based on the preliminary findings of Liu aim of the first part of this study was to gain an 
understanding of the role of RhoH IL-3 induced signalling and its relevance for hematologic 
malignancies. Subject of investigation was the potential of RhoH to modify specifically IL-3 
induced proliferation and cell survival by using the murine model proB cell line BaF3. Next it 
was attempted to understand how RhoH expression is able to alter IL-3 dependent 
proliferation by investigating IL-3 mediated JAK-STAT signalling in BaF3 cells with distinct 
RhoH levels. In this context it was further aimed to understand the alterations in gene 
expression induced by RhoH modulated JAK-STAT signal transduction with focus on the 
expression of STAT dependent CDKIs and CD123 surface expression. Complementary 
studies were assessed to outline a possible role of RhoH in the aberrant signal transduction of 
the myeloid malignancy AML, in which RhoH was reported to be underexpressed, 
transferring the previously gained knowledge from the BaF3 model system. Furthermore it 
was aimed to test RhoH expression in different lymphoma types with aberrant 
immunophenotypes and STAT signalling to gain insight into a potential role of RhoH in 
disease progression. To extend the knowledge about RhoH and the signalling networks 
involved in controlling IL3- mediated signal transduction it was planned to find novel 
interaction partners of RhoH by using mass spectrometry.  
The second part of this work addressed the role of RhoH for IL-3 dependent cell 
differentiation and function using in vitro derived murine MCs. It was sought to understand 
the consequences of RhoH deficiency on MC mediated functions using IL-3 derived bone 
marrow MCs from RhoH ko mice. Additionally, it was attempted to relate the previous 
findings of RhoH as a modulator of STAT activation in the BaF3 model system, to MCs 
differentiation and function.  
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3.  Materials and Methods 
3.1  Material 
 
3.1.1  Lab equipment 
 
Agarose Gel Elektrophoresis system  PerfectBlue TM Mini S, Pequlab, Erlangen 
Bacteria Shaker Incubator 1000, Unimax, 1010 Shaker, Heidolph Instruments GmbH Co. KG, 
Schwabach 
Bunsen burner Gasprofi 2scs,WLD-TEC GmbH, Göttingen 
Cell Counting Chamber Neubauer 0.0025 mm²/0.1 mm, Brand GmbH Schwerin 
Centrifuges 1. Biofuge fresco, Heraeus Instruments, Hanau 
2. Biofuge pico, Heraeus Instruments, Hanau 
3. Biofuge stratos, Heraeus Instruments, Hanau 
4. Sorvall RC 5B Plus, Thermo scientifc, Bonn 
Chemical Balance EW600-2M, Kern & Sohn GmbH, Balingen 
Extractor Hood Variolab Mobilien W90, Waldner-Laboreinrichtungen GmbH, Wangen 
FACS BD FACSCantoTM, BD Bioscience, Heidelberg 
Gel documentation system 1. Infinity Video ducumentation system 3000, Peqlab, Erlangen 
2. Chemi-Smart 5000, Peqlab, Erlangen 
Ice Flakes Device Scotsman® AF-30, ENODIS Germany GmbH, Herborn 
Incubators 1. BBD 6220, Heraeus Instruments, Hanau 
2. B5060 EK/CO2, Heraeus Instruments, Hanau 
Luminometer LUMIStar OPTIMA, BGM Labtech, Offenburg 
Magnetic agitator (with heating) IKA®
 
RCT basic, IKA®
 
RCT labtech, Staufen i.Br.
 
Microscopes 1. Invers-microscope, Axiovert 25 CFL, Carl Zeiss Jena GmbH, Jena 
2. Incident-light microscope, Leica DMLS, Leica Microsystems GmbH, 
Wetzlar 
3. Confocal Microscope, Leica TCS SMD FCS, Leica Microsystems 
GmbH, Wetzlar  
Microtiter-Plate reader SUNRISE Absorbance Reader, Tecan, Salzburg, Austria 
Microwave oven R-234, Sharp Electronics GmbH, Hamburg 
pH meter SevenEasy TM , Mettler Toleado GmbH, Gießen 
Pipettes Gilson, Middletown, Wisconsin, U.S 
Pipettor Pipetboy acu, Integra Bioscience AG, Chur, Switzerland 
Power supply Consort Power Supply E835, Pequlab, Erlangen 
Refrigerator 1. divers equipment, Liebherr home equipment Ochsenhausen GmbH, 
Ochsenhausen 
2. HERA Freeze®(-80°C), Heraeus Instruments, Hanau 
Safety cabinet HERAsafe classII, Heraeus Instruments, Hanau 
SDS PAGE System 1. SE400 Sturdier Vertical Electrophoresis Unit, Hoefer Inc., San Francisco, 
U.S 
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2. PowerEase 500 Pre-Cast Gel System, Invitrogen GmbH, Karlsruhe 
Semi-Dry Transfer Unit Standard Semi Dry Unit, Hoefer Inc., San Francisco, U.S  
Shaking devises 1. Vortexter, MS 1 Minishaker, IKA Works Inc., Wilmington, USA 
2. RS-24 (orbital shaker), Lab4You GmbH, Berlin 
Sonicator 1. Branson Sonifier B-R, Branson Sonic Power Company, Danbury, U.S. 
2. Sonoplus, Badelin electronic GmbH & Co. KG, Berlin 
Thermocycler 1. quantitative RT-PCR: 7900 HT Fast Real-Time PCR System, Applied 
Biosystems, Darmstadt 
2. Primus 96 advanced® Gradient, Pequlab, Erlangen 
Thermomixer Thermomixer Comfort, Eppendorf AG, Hamburg 
UV/Vis Spectrometer NanoDrop® ND-1000, Peqlab, Erlangen 
Vacuum pump Laboport® N811 KN, 18, KNF Neuberger GmbH, Freiburg 
Waterbath WB/OB 22, Memmert GmbHCo. KG, Schwabach 
 
3.1.2  Expandable material 
 
Blotting paper Whatman® GB003, GE Healthcare, Dassel 
Canula 27G, 0,4 mmx19 mm, BD Biosciences, Heidelberg 
Cover slides Round, Ø12mm, Carl Roth GmbH Co. KG, Karslruhe 
Cyro tubes CryotubesTM, Nunc GmbH Co.KG, Wiesbaden 
Disposable inoculation loop Looplast®, LP ITALIANA SPA, Milan, Italy 
FACS tubes BD Falcon TM 5 ml polystyrol tubes, BD Biosciences, Heidelberg 
Falcon tubes Cellstar, polypropylen, sterile, Greiner Bio-One GmbH, Frickenhausen 
Flat bottom 96 Well plate PS-Microplate, 96-well, non-sterile, Greiner Bio-One GmbH, Frickenhausen 
Luminometer plate CulturePlateTM, white, 96-well, non-sterile, Perkin Elmer, Rodgau-Jügesheim 
Nitrocellulose membrane  Whatman® Protan Nitrocellulose Membranes BA83(0,2 µm), GE Healthcare, 
Dassel 
Object plate Double smoothed, Süße GmbH, Gudensberg 
Parafilm American National CanTM, Chicago, US 
Pasteur pipettes  WU, Mainz 
PCR plate sealing foil Absolute QPCR Seal, ABgene House, Epsom, UK 
PCR-plates Thermo-Fast®, 96 Detection Plate, ABgene House, Epsom, UK 
Petri dishes Greiner Bio-One GmbH, Frickenhausen 
Pipette tips  1. TipOne® , Pippette Tips, Starlab, GmbH, Ahrensburg 
2. TipOne® , Filter Tips, Starlab, GmbH, Ahrensburg 
Precast gels 1. Anamed Elektrophorese GmbH, Gross-Bieberau 
2. Invitrogen GmbH, Darmstadt 
Reaction tubes 1. Safe Lock, Eppendorf AG, Hamburg 
2. PP-PCR tubes, Greiner Bio-One GmbH, Frickenhausen 
Sterile filter Millex®-GS 0,22 µm, Millipore, Billerica, U.S. 
Syringe BD Discardit II, BD Biosciences, Heidelberg 
Tissue flasks Cellstar, polystyrol, sterile, Greiner Bio-One GmbH, Frickenhausen 
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Tissue petri-dishes polystyrol, sterile, Nunc GmbH & Co. KG, Wiesbaden 
Tissue plates Cellstar, polystyrol, sterile, Greiner Bio-One GmbH, Frickenhausen 
 
3.1.3  Purchaseable kits and buffers 
 
AbsoluteTM QPCR SYBR Green 
ROX Mix 
Thermo Fisher Scientific Inc., Waltham, U.S. 
Annexin-V-FLUOS Staining Kit Roche, Penzberg 
BCATM Protein Assay Reagent Kit Pierce Biotechnology, Rockford, U.S. 
BD OptEIATM mouse IL-6 ELISA 
Kit 
BD Biosciences, Heidelberg 
BD OptEIATM mouse TNF ELISA 
Kit 
BD Biosciences, Heidelberg 
CellTiter-Glo Luminescent Cell 
Viability Assay System 
Promega, Madison, Wisconsin, U.S. 
Dual-Glo Luciferase System Assay 
System 
Promega, Madison, Wisconsin, U.S. 
FITC-BrdU-Flow Kit BD Biosciences, Heidelberg 
High Pure RNA Isolation Kit Roche Diagnostics, Penzberg 
High Speed maxi Kit Quiagen, Hilden 
High Speed mini Kit Quiagen, Hilden 
NEB 5-alpha New England Biolabs GmbH, Frankfurt/Main 
Platinum®Pfx DNA Polymerase Invitrogen GmbH, Darmstadt 
QIAquick Gel Extraction Kit Qiagen, Hilden 
QIAquick PCR Purification Kit Qiagen, Hilden 
Restore Western Blot Stripping 
Buffer 
Pierce Biotechnology, Rockford, U.S. 
RevertAidTM First Strand cDNA 
Synthesis Kit 
MBI Fermentas, St. Leon-Rot 
SuperSignal  West Pico 
Chemiluminescent Substrate 
Pierce Biotechnology, Rockford, U.S. 
Taq DNA Polymerase MBI Fermentas, St. Leon-Rot 
 
3.1.4  General chemicals 
 
If not stated otherwise, all chemicals and solvents were purchased from Merck (Darmstadt), 
Roth (Karlsruhe), Sigma-Aldrich (Taufkirchen) or AppliChem (Darmstadt). 
4',6-diamidino-2-phenylindole (DAPI) Molecular probes Inc. Eugene, U.S. 
A/G Agarose Santa Cruz Biotechnology, Santa Cruz, U.S 
Acetic Acid (100%) Merck, Darmstadt 
Acetone Roth, Karslruhe 
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Acrylamide rotiphenol  Roth, Karslruhe 
 Adenosine-5'-triphosphate (ATP) Sigma-Aldrich, Taufkirchen 
Agar bacteriological Agar No. 1, Oxoid GmbH, Wesel 
Agarose ultra pure Gibco BRL, Life technologiesTM, Eggenstein 
Ammonium Persulfate (APS) Sigma-Aldrich, Taufkirchen 
Ampicilin Kanamycine 
Aprotinin Sigma-Aldrich, Taufkirchen 
Aqua ad iniectabilia (10 ml) Braun, Melsungen 
Bovine serum albumine (BSA) AppliChem GmbH, Darmstadt 
Bromphenole Blue Sigma-Aldrich, Taufkirchen 
Complete Protease Inhibitor Cocktail  Roche, Penzberg 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Taufkirchen 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen 
Doxurobicine Sigma-Aldrich, Taufkirchen 
Dulbecco’s modified Eagle's medium (DMEM) Biochrom AG, Berlin 
Ethanol AppliChem GmbH, Darmstadt 
Ethidium bromide Merck, Darmstadt 
Ethylendiaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen 
FACSCleanTM BD Biosciences, Heidelberg 
FACSFlowTM BD Biosciences, Heidelberg 
Fetal calf serum (FCS) Biowest, Nuaillè, France 
Geneticin (G418, 50 mg/ml) PAA Laboratories, Pasching, Austria 
Glycerol Sigma-Aldrich, Taufkirchen 
Glycine Sigma-Aldrich, Taufkirchen 
Hydrogen chloride (37%) (HCl) Merck, Darmstadt 
Immersion oil Merck, Darmstadt 
Indole-3-acetitc acid (IAA) AppliChem GmbH, Darmstadt 
Isopropanol Roth, Karslruhe 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) AppliChem GmbH, Darmstadt 
Kanamycin AppliChem GmbH, Darmstadt 
Leupeptin (-hydrochloride) Sigma-Aldrich, Taufkirchen 
L-Glutamine, 200 mM (100x) Biochrom AG, Berlin 
Luria-Bertani- borth  AppliChem GmbH, Darmstadt 
Magnesium chloride-Hexahydrate (MgCl2x6H2O) Merck, Darmstadt 
Metafectene Biontex, Munich 
Methanol AppliChem GmbH, Darmstadt 
MOPS (3-(N-morpholino)propane sulfonic acid) Sigma-Aldrich, Taufkirchen 
Mounting medium  AF1, Citifluor Ltd., London, UK 
N,N,N`, N`-Tetramethylethylethyllendiamin (TEMED) Sigma-Aldrich, Taufkirchen 
Paraformaldehyde Merck, Darmstadt 
Penicilin/Strepromycin solution (100x) PAA Laboratories, Pasching, Austria 
Pepstatin A Sigma-Aldrich, Taufkirchen 
Phenylmethylsulfonylfluorid (PMSF) Sigma-Aldrich, Taufkirchen 
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Phosphate buffered saline (PBS) PAA Laboratories, Pasching, Austria 
Phosphatic acid (H3PO4) Merck, Darmstadt 
PhosSTOP Phosphatase Inhibitor Cocktail  Roche, Penzberg 
Polybrene Sigma-Aldrich, Taufkirchen 
Poly-D-Lysin Sigma-Aldrich, Taufkirchen 
Puromycine Sigma-Aldrich, Taufkirchen 
Roswell Park Memorial Institute  1640 medium (RPMI) Biochrom AG, Berlin 
Sequencing grade modified trypsine  Promega, Madison, Wisconsin, U.S. 
Serva Blue G Serva, Heidleberg 
Sodium chloride (NaCl) AppliChem GmbH, Darmstadt 
Sodium hydroxide (NaOH) Merck, Darmstadt 
Sodiumdeoxycholate Sigma-Aldrich, Taufkirchen 
Sodiumdodecysulfate (SDS) Roth, Karslruhe 
Sodiumfluoride (NaF) Sigma-Aldrich, Taufkirchen 
Sodiumorthovanadate (Na3VO4) Sigma-Aldrich, Taufkirchen 
Staurosporine Sigma-Aldrich, Taufkirchen 
Thioglycolate BD Pharmingen, Heidelberg 
Tris-Base Sigma-Aldrich, Taufkirchen 
Tris-HCL Sigma-Aldrich, Taufkirchen 
Triton-X-100 Sigma-Aldrich, Taufkirchen 
Trypan-Blue Sigma-Aldrich, Taufkirchen 
Trypsin/EDTA (10x) PAA Laboratories, Pasching, Austria 
Tween 20 Sigma-Aldrich, Taufkirchen 
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen 
 
3.1.5  DNA modifying enzymes 
 
BamHI New England Biolabs GmbH, Frankfurt/Main 
NotI New England Biolabs GmbH, Frankfurt/Main 
NotI New England Biolabs GmbH, Frankfurt/Main 
T4-DNA-Ligase Roche, Penzberg 
XhoI New England Biolabs GmbH, Frankfurt/Main 
 
3.1.6  Stimuli for cell culture 
 
Anti- Trinitrophenol(TNP)-ovalbumin(OVA) -IgE (x100) N.N. (University Freiburg) 
Lipopolysaccharide (LPS) Sigma-Aldrich, Taufkirchen 
Mouse IL-3 ImmunoTools, Oldenburg 
Mouse IL-4 ImmunoTools, Oldenburg 
Mouse INF-γ ImmunoTools, Oldenburg 
TNP-OVA (2µg/µg)  N.N. (University Freiburg) 
  Materials and Methods 
 
 
20 
 
3.1.7  Antibodies and isotypes 
 
Antibody Target 
species 
≈kDa Details 
(dilution, isotype) 
Company 
Anti-mouse IgG, HRP-
linked Antibody 
(heavy chain) 
Secondary 
 
 1:1000 Cell Signalling Technology, Danvers, 
U.S. 
Anti-rabbit IgG, HRP-
linked Antibody 
(heavy chain) 
Secondary  1:1000 Cell Signalling Technology, Danvers, 
U.S. 
APC-CD123 human 
 
as prescribed by 
Mouse IgG1 κ  
eBioscience, Frankfurt 
Cofilin-1 human, 
mouse 
20 Detection 1:1000 
IP 1µg 
Cell Signalling Technology, Danvers, 
U.S. 
FITC-CD4 human 
 
as prescribed by 
Mouse IgG1 κ 
BD Biosciences, Heidelberg 
FITC-FcεRI,  mouse  as prescribed by eBioscience, Frankfurt 
FITC-pSTAT1 (Y701) human, 
mouse 
 
as prescribed by  
Mouse IgG2a, κ 
BD Biosciences, Heidelberg 
FTIC-pSTAT5 (Y694) human, 
mouse 
 
as prescribed by 
Mouse IgG2a, κ 
BD Biosciences, Heidelberg 
Green Fluorescent  
Protein (GFP) 
tag 20 Detection 1:1000 
IP 1 µg 
Santa Cruz Biotechnology, Santa Cruz, 
U.S 
Hemaglutinin (HA) tag 5 1:1000 Santa Cruz Biotechnology, Santa Cruz, 
U.S 
N-DYKDDDDK-C 
(FITC-FLAG)  
tag 9 Detection 1:1000 
IP1:100 
Sigma-Aldrich, Taufkirchen 
p21cip1 mouse 20 1:1000 Cell Signalling Technology, Danvers, 
U.S. 
P27Kip1 mouse 30 1:1000 Santa Cruz Biotechnology, Santa Cruz, 
U.S 
PE-CD123 mouse 
 
as prescribed by 
Rat IgG2a κ 
eBioscience, Frankfurt 
PE-c-Kit, CD117 mouse  as prescribed by eBioscience, Frankfurt 
pSTAT1 (Y701) human, 
mouse 
90 1:1000 Cell Signalling Technology, Danvers, 
U.S. 
pSTAT5 (Y694) human, 
mouse 
90 1:1000 Cell Signalling Technology, Danvers, 
U.S. 
PTP-1B human, 
mouse 
50 1:1000 Abcam, Cambridge, UK 
RhoH-Serum murine 20 Detection 1:200 
IP N.N. 
Eurogentec, Seraing, Belgium 
STAT1 human, 
mouse 
90 Detection 1:5000 
IP: 1µg 
Santa Cruz Biotechnology, Santa Cruz, 
U.S. 
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STAT5 human, 
mouse 
90 Detection 1:5000 
IP: 1µg 
Santa Cruz Biotechnology, Santa Cruz, 
U.S 
β-Actin human, 
mouse 
45 1:1000 Cell Signalling Technology, Danvers, 
U.S. 
MCPt-1 mouse 36 1:1000 Abcam, Cambridge, UK 
 
*Isotypes for FACS Analysis 
Isotypes used in this work were purchased from the same company which provided the target antibody, labelled 
in the same fashion and were used in the same concentration as target antibody. 
 
3.1.8  Size markers 
 
 
3.1.8.1 Protein marker 
P7711S ColorPlus Prestained Protein Ladder, Broad Range (10-230 kDa) 
New England Biolabs GmbH, Frankfurt/Main 
161-0324 Kaleidoscope Prestained Standart, Bio-Rad Laboratories, Hercules, U.S. 
 
3.1.8.2 DNA marker 
Depending on the expected size of the analysed DNA fragements, different DNA marker 
ranges were used. If not otherwise stated, markers were purchased from New England Biolabs 
GmbH, Frankfurt/Main or MBI Fermentas, St. Leon-Rot. 
 
3.1.9  Vectors 
 
Plasmid name Basic vector Describtion Source 
 
pGEX-2T-GST-RhoH 
pGEX-2T-GST-T36A 
pGEX-2T-GST 
 
pGEX-2T 
 
bacterial expression vector, 
amp resistance, IPTG 
inducible promoter, GST-tag 
 
Institute for Experimental 
and Clinical Pharmacology 
and  Toxicology, 
University Freiburg 
 
pMX-IRES-GFP-HA-
hRhoH  
pMX-IRES-GFP-mRhoH-
flag) 
 
pMX-IRES-GFP (PIG) 
 
mammalian, retroviral, amp 
resistance 
 
Institute for Experimental 
and Clinical Pharmacology 
and  Toxicology, 
University Freiburg 
 
pMX-IRES-CD4-PURO-
mRhoH-flag 
 
pMX-IRES-CD4-PURO 
 
mammalian, retroviral, amp 
resistance, puromycin 
 
generated by D. M. 
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pMX-IRES-CD4-PURO selection gene 
 
p-EGFP-N1-Cofilin-1 
 
 
p-EGFP-N1 
 
CMV promoter, amp. 
resistance 
 
Institute for Immunology,  
University Heidelberg 
 
BSSK-ptp1b 
 
Blue-Scripe-KS+ 
 
Amp. resistance 
 
Addgene, Cambridge, U.S 
pSilencer-RhoH pSilencer-Retro 5.1 U6 Amp.Resistance, puromycin 
selection gene 
Ambion, Austin, USA 
 
3.1.10  Oligonucleotides 
 
All oligonucleotides were obtained from MWG Biotech, Eberberg or Apara Bioscience 
GmbH, Sexau/Freiamt. 
 
3.1.10.1 Primer sequences for quantitative real-time PCR (qPCR) 
To avoid amplification of genomic DNA primer for qPCR, primers were chosen according to 
their intron / exon boundaries.  
Gene species Sequence 5`→3` 
GAPDH human fw  ACGGATTTGGTCGTATTGGGC 
rv  TTGACGGTGCCATGGAATTTG 
GAPDH mouse fw  TTCACCACCATGGAGAAGGC 
rv   GGCATGGACTGGACTGTGGTCATGA 
Interleukin-2 human fw  AACTCACCAGGATGCTCACATTT 
rv  TTAGCACTTCCTCCAGAGGTTTG 
IRF-1 human fw  GCTGGACATCAACAAAGGAT 
rv  TGGTCTTTCACCTCCTCGAT 
IRF-1 mouse fw  GGAGATGTTAGCCGGACACT 
rv  TGCTGACGACACACGGTGA 
p21 mouse fw   GCAGACCAGCCTGACAGATT 
rv    GCAGGCAGCGTATATACAGGA 
p27 mouse fw  AGGGCCAACAGAACAGAAGA  
rv   CTCCTGGCAGGCAACTAATC 
RhoH human fw GACTTCGGCACAGGAACTTGCTT 
rv   GCA AGA GCT CGATATTTGGTTATTAT 
RhoH mouse fw  GCTACTCTGTGGCCAACCAT 
rv  AGGTCCCACCTCTCTCTGGT 
β-Actin human fw AGCTACGAGCTGCCTGAC 
rv  AGCACTGTGTTGGCGTACAG 
TCR beta human fw 1  CAGGAT AGG GCC AAACC 
fw 2  GTGTTTGAGCCATCAGAAGC 
rv    CACGAGGGCACTGACCAG 
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3.1.10.2 Primer sequences for genotyping 
Name Sequence 5`→3` 
Rh1 fw GTG TAC GAG AATACGGGTGT 
Rh2 rv GTGGCCACAACCAGCACC 
Rh4 fw CTTGTGTAGCGCCAAGTGC 
 
3.1.10.3 Primer sequences for gene mutation, sequencing and cloning 
plasmid / gene  primer Sequence 5`→3` 
PIG rv IRES-3 CCAACTTAATCGCCTTGCAGCA 
PIG-RhoH fw  BamHI-RhoH GATGCTGGATCCATGCTGAGCTCAA 
PIG rv IRES EcoRI-mRhoH CGAGGAATTCGTTAGAAGATCTTGCA 
RhoH fw RhoH-T36A GCCTACAAACCCGCGGTGTACGAGAAT 
RhoH rv RhoH-T36A ATTCTCGTACACCGCGGGTTTGTAGGC 
PIG-HA rv PIG-HA GAC CAC CCC ACC GCC CTC AAA GTA GAC GG 
PIG fw MX6 CGC CTC GAT CCT CCC TTT ATC 
PIG rv pMX HindIII TGT CTT CAA GAA GCT TCC AGA GGA 
 
3.1.11  Eukaryotic cells 
 
Cell lines were either obtained from DSMZ (German Resource Centre for Biological Material), ATCC 
(American Tissue Culture Collection), or were generously provided by the Megan Lim lab, (Ann Arbor, 
Michigan). 
Name  Origin Culture Medium 
BaF3 Murine pro-B cell line  RPMI/10%FCS (not heat inactivated)/1% PS/ 1-0,5% IL-3 
containing supernatant 
DEL human RPMI/1%PS/10% FCS 
FL-18 Human B-cell B-NHL  RPMI/1%PS/10% FCS 
FL-518 Human B-cell B-NHL  RPMI/1%PS/10% FCS 
Granta 519 Human B-cell Mantle cell  RPMI/1%PS/10% FCS 
HEK293 Human Embryonic Kidney DMEM/1%PS/10% FCS 
HH Human T-cell CTCL RPMI/1%PS/10% FCS 
HUT78 Human T-cell CTCL RPMI/1%PS/10% FCS 
Jurkat Human T-cell  RPMI/1%PS/10% FCS 
Karpas 299 Human T-cell ALCL RPMI/1%PS/10% FCS 
KG-1 Human AML RPMI/1%PS/10% FCS 
KG-1a Human AML RPMI/1%PS/10% FCS 
Mac2A Human T-cell ALCL RPMI/1%PS/10% FCS 
NCEB Human B-cell Mantle cell RPMI/1%PS/10% FCS 
OCI-LY1 Human B-cell B-NHL RPMI/1%PS/10% FCS 
Phoenix-Eco Human Embryonic Kidney 
(packaging cell line)  
DMEM/1%PS/10% FCS 
SKW-3 Human RPMI/1%PS/10% FCS 
SR-788 Human RPMI/1%PS/10% FCS 
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SUDHL-1 Human RPMI/1%PS/10% FCS 
SUDHL-4 Human B-cell B-NHL  RPMI/1%PS/10% FCS 
SUDHL-6 Human B-cell B-NHL  RPMI/1%PS/10% FCS 
SUPM2 Human RPMI/1%PS/10%  FCS 
THP-1 Human AML RPMI/1%PS/10%FCS 
X63Ag8-653 Murine myeloma cells RPMI/1%PS/10%FCS/ 2 mM L-Glutamin, 1x10-5M β-
Mercaptoethanol 
 
3.1.12  Special software & databases 
 
Name Application 
BioProfile Western-blot spot quantification 
Clustal W Gene search and Alignments 
Ingenuity Pathway Analysis Software 
Mascot Protein identification based on MS data 
Primer 3 Primer search 
Serial Cloner Molecular biology software 
Weasel FACS data analysis 
 
3.1.13  Buffers and working solutions 
 
10 x TNE Buffer 100 mM Tris, 2 M  NaCl, 10 mM EDTA, pH 7,4 
Bacteria Lysis Buffer 20 mM Tris-HCl (pH 7,4), 10 mM NaCl, 5 mM MgCl2,  1% 
Triton X-100 (not for MS), 5 mM DTT,  Protease Inhibitors 
Buffer  Contents 
Coomassie-Staining solution 1,25 g Coomassie Brilliant Blue R-2510, 227 ml methanol, 
46 ml acetic acid (96%), 
aqua bidest. ad 500 ml 
Destaining-Solution 150 ml acetic acid (96% v/v), 100 ml Methanol, aqua bidest. 
ad 2 l 
ELISA substrate 3,3’,5,5’-Tetramethylbenzidine (TMB)  
ELISA wash Buffer PBS, 0,05% Tween 20 
ELISA-Block-Buffer PBS/ 10%FCS 
ELISA-Coating-Buffer 0,1 M Na2CO3, pH 9,5 
ELISA-Stop Solution 1 M H3PO4, 1 mM H2SO4 
Ethidium Bromide Solution 10 mg/ml ethidium bromide in H2O 
FACS Washing/Blocking Buffer PBS / 2% FCS 
Freezing medium 10% (v/v) DMSO, 90% (v/v) FCS 
Gluthation Elution Buffer (10 ml) 1 M Tris (pH8), 5 M NaCl,, 0.001 % β-mercaptoethanol,  
0.0301 g Gluthatione , pH 7- pH 8 
GST-Fish Buffer 150 mM NaCl,  50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 1 
mM EDTA, Protease Inhibitors     
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HAA Lysis Buffer 0.5% (v/v) Triton X-100 
HAA-Stop-Solution 0.2 % (w/v) glycine, pH (10,7) 
HAA-Substrate Buffer 3.8 mM p-Nitrophenyl-glycNAc 4-Nitrophenyl N-acetyl-β-
D-glucosaminide, 0.05 M tri-sodiumcitrate-dihydrate,  
pH 4.5 
 
High Salt Buffer 240 mM NaCl, 20 mM HEPES (pH 7.9), 10 mM KCl, 1.0 
mM EDTA, 10 % Glycerol (v/v), 0.2% NP40 (v/v), Protease 
Inhibiotrs 
Hypotonic Buffer 20 mM HEPES (pH 7.9), 10 mM KCl, 1.0 mM EDTA, 10 % 
Glycerol (v/v), 0.2% NP40 (v/v), Protease Inhibiotrs 
Membrane-Blocking Buffer 3% (w/v) BSA, 0.1 % (v/v) Tween 20, solubilised in 1x TBS 
MS- Lysis Buffer (mammalian cells) 150 mM NaCl, 50 mM Tris-HCl (pH 7.4),5 mM MgCl2,  1 
mM EDTA, Protease Inhibitors 
NP-40 Lysis Buffer (2x) 2% NP-40, 300 mM NaCl, 40 mM Tris (pH 7.4), 20 mM 
NaF, 2 mM EDTAx2 H2O (pH 8), 2mM MgCl2x6 H2O, 
2mM Na3VO4, 20% Glycerin, Protease/Phosphatase 
Inhibitors 
PBS 8 g NaCl, 1.78 g KCl, 1.15 g Na2HPO4 × 2 H2O,  0.2 g 
KH2PO4 
aqua bidest ad 1000 ml, pH 7,5 
PonceauS-Solution 0.15 % (w/v) PonceauS, solubilised in 0.5 % (v/v) acetic 
acid 
Protein Sample Buffer (4x) 200 mM Tris-Hcl (pH 6,8) , 8% SDS (w/v), 40% Glycerol 
(v/v), 0,02% (w/v) Serva Blue G 2% (w/v), 20% (v/v) β-
Mercaptoethanol 
RIPA Lysis Buffer 50 mM Tris, HCl (pH 7,4), Igepal 1% (v/v), 
Sodiumdeoxycholate 0.25% (v/v), 150 mM NaCl, 1 mM 
EDTA, Protease/Phosphatase Inhibitors  
Running Buffer MOPS (Novex ) (20x) 1 M MOPS, 1 M Tris-Base, 69,3 mM SDS, 20,5 mM 
EDTA; pH 7,7 
SDS- Stacking-Buffer (2x) 250mM Tris-Hcl (pH 6.8), 0.2% (w/v) SDS  
SDS-Separation-Buffer (3x) 1.125 M Tris-Hcl pH (8.8), 0.3% (w/v) SDS  
TAE Buffer (50x) 2 M Tris-Acetate (pH 8.0), 100 mM EDTA 
Tail-Lysis-Buffer 100 mM Tris (pH 8), 5 mM EDTA, 0.2% SDS, 200 mM 
NaCl, 10 mg/ml Proteinase K 
TBS (Tris buffered saline) (10x) 100 mM Tris-HCl (pH 8.0), 1.5 M NaCl 
TBST (Membrane Wash Buffer) 0.1% (v/v) Tween 20 in 1x TBS 
TE(Tris-EDTA)- Buffer  10 mM Tris-HCl (pH 8.0), 1 mM EDTA 
Transfer Buffer 25 mM TRIS, 192 mM Glycin, 0.5 mM Na3VO4, 10% 
Methanol (v/v), 0,1 % SDS (10%) (v/v) 
Tris-Glycine Running Buffer (10x) 0.25 M Tris, 1.92 M Glycin, 1% SDS (w/v); pH 8.25 
Tyrode Buffer 137 mM NaCl, 2,7 mM KCl, 11.9 mM NaHCO3, 0.3 mM 
NaH2PO4, 5.6 mM D(+) Glucose, 1 mM MgCl2 x 6 H2O, 2 
mM CaCl2 x 6H2O, 2% FCS 
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3.2  Methods 
 
3.2.1  Eukaryotic cells  
 
3.2.1.1 Murine bone marrow preparation and mast cell differentiation 
Bone marrow cells (BMCs) were isolated from murine femurs of BL6 mice. The cells were 
rinsed from the bone using RPMI medium, washed once with PBS and then cultivated in 
RPMI medium containing 1-0.5 % IL-3 supernatant from X63Ag8-65, 20% heat inactivated 
fetal calf serum and 0,1 µM β-mercaptoethanol. Cells were obtained in culture for 3-4 weeks 
to allow differentiation into murine MCs. To avoid impurities and growth of adherent 
fibroblastic cells, growth surface was changed once a week during differentiation by carefully 
collecting cells containing supernatant. After differentiation MC maturation was controlled by 
analyzing FceRI and c-Kit expression, after activation of MCs with 1.0 % IgE stimulation 
(overnight or at least 6 hours).  
 
3.2.1.2 Cultivation of mammalian cells 
Mammalian cells were cultivated in incubators at 37°C, 5% CO2, in humidified atmosphere. 
Suitable centrifugation for tissue culture was at room temperature (RT), 3 min. at 1300 rpm. 
Mammalian cells were cultivated in media with appropriate supplements (as described in 
section 3.1.11) and passaged in ratios recommended by the cell line distributers, Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and/or American Type Culture 
Collection (ATCC). For cell passaging, supernatant covering adherent monolayer was 
removed. Cells were washed once with pre-warmed PBS (37°C) and covered with an 
appropriate amount of Trypsin-EDTA solution. The protease trypsin digests peptide bonds, 
leading to the loss of the adherent cell assembly. Ethylenediaminetetraacetic acid (EDTA) is 
supporting this process by binding metal ions, required for the formation of cell clusters. 
Trypsin digestion was stopped after 5 minutes (min) by addition and resuspension with fresh 
growth medium in a ratio 1:10 regarding trypsin amount. From this cell suspension cell 
seeding was performed.  
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3.2.1.2.1 IL-3 dependent cell lines 
The IL-3 dependent cell line BaF3 was cultivated in RPMI medium containing 10% FCS (not 
heat inactivated) and 1-0.5% IL3 containing supernatant from X63Ag8-653 cell line.  
 
3.2.1.3 IL-3 production with X63Ag8-653 cells 
As shown previously by Fritz Melcher`s lab, transformation with a bovine papilloma virus-
based expression vector pBV-IMTHA of X63Ag8-653 cells allows these cells to stably 
express copies of murine IL-3 and to secrete this in high amounts and quality 103. For this 
work X63Ag8-653 cells were cultivated in medium containing 0.3 mg/ml G418 to select for 
transfected cells. After confluent expansion of cells on approximately (approx.) 20 petri 
dishes, cells were washed with PBS to remove any remaining G418 and distributed for two 
daysin a ratio lower than 1:2 on 30 petri dishes. Cells were kept in culture for further 48 hours 
(h), then the supernatant was collected and aliquots of appropriate volumes were prepared. 
Aliquots were stored at -20°C until usage. 
 
3.2.1.4 Cell counting 
Cell counting was accomplished using a Neubauer-cell counting chamber. 10 µl cell 
suspension was mixed with 90 µl Trypan Blue which allowed exclusion of non-vital cells 
during count. 
 
3.2.1.5 Cryo-conservation of mammalian cells  
Approximately 1x106 cells were spun down; pellet was resuspended in 1 ml Freezing medium 
and transferred to a fresh cryo tube. The tube was immediately placed into a pre-cooled 
isopropanol containing “Mr. Frosty” freezing device and stored for 24 h at -80°C. After this 
time period, cryo tubes were transferred into liquid nitrogen containing cell storage container. 
 
3.2.1.5.1 Recultivation of mammalian cells 
Cells were thawed at 37°C and immediately transferred to 9 ml pre-warmed growth medium. 
After spinning down, supernatant was discarded and the cell pellet was resuspended in 10 ml 
fresh, warm growth medium and cultivated for 24 hours in a T25 tissue flask. The next day, 
growth medium again was changed to remove any toxic remains of the freezing medium.  
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3.2.1.6 Liposome-based transfection of mammalian cells 
To obtain altered target gene protein expression or in order to produce viral supernatants, cells 
need to be transfected with expression vectors.  
To transfect adherent human embryonic kidney (HEK) or Phoenix-eco cells, cells were 
seeded out at desirable scale 24 hours prior to tranfection and either Metafectene or 
Lipofectamin was used, according to the manufacturer’s instructions. To obtain optimal 
protein expression, cells were allowed to further incubate for 24-72 hours.  
THP-1 cells were transfected using Metafectene and an adapted form of the manufacturer’s 
transfection protocol. 1x106 cells/well (6-well) were seeded 24 h prior to transfection. A 
DNA: Metafectene ratio of 1:4 was used, cells were allowed to incubate 48 h post 
transfection. 
 
3.2.1.7 Retrovirus production 
To stably transduce BaF3 cells, it was required to use retroviral gentransfer in order to deliver 
target gene expression in the cell line. The Phoenix-eco packaging cell line is based on the 
293T cell line. Transfection of this cell line is highly efficient using liposome-based methods. 
The cell line was created by insertion into 293T cell constructs capable of producing gag 
(proteins of the virus nucleus) –pol (reverse transcriptase and integrase), and envelope (hill) 
protein for ecotropic (Phoenix-“eco”) viruses. This cell is capable of carrying episomes for 
long-term stable production of retrovirus. In order to produce virus particles, the cell line has 
to be transfected with retroviral vectors containing 5`and 3` the “packaging-signal” long-
terminal-repeat. This retroviral vector also contains the target gene which needs to be stably 
transferred into the BaF3 cell line. Transfection with a retroviral vector enables the Phoenix-
eco cell line to produce “safe” virons which are able to stably infect cells but which are not 
able to induce their own reproduction in the host-cell line. To obtain high virus titer, Phoenix-
eco cells are seeded 24 hours prior to transfection in a ratio 1:4 after trypsin proteolysis (as 
described above) 104 into a 6-well plate. 70-80% confluent cells were transfected using the 
appropriate retroviral vector containing the desirable target gene. 48-72 hours post 
transfection, virus-containing supernatant was collected and stored for at least two hours or 
until usage at -80°C. 
 
3.2.1.7.1 Retroviral infection and puromycine selection 
In order to retroviral transduction of BaF3 cells, the virus must enter the host-cell to be able to 
properly integrate viron information into the host genome.  
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5x105 BaF3 cells were resuspended in 850 µl of freshly thawed virus supernatant. After 
addition of 16 µg/ml polybrene, cells were spun for 2 h at 37°C. After this time period, cells 
were resuspended in fresh growing medium and transferred into a T25 flask and checked for 
protein expression after 48 h. For selection antibiotics (puromycin 1.5 ng/ml) were added after 
48 h and cells cultivated for 48 hours to ensure that only successfully transfected cells 
remained. 
 
3.2.1.8 Proliferation assays 
To investigate the time dependent proliferation rate changes in response to equal doses of 
cytokine over time, a proliferation assay was performed. 2.5x105 BaF3 cells were seeded out 
in 2 ml of growth medium containing equal amounts of cytokine. Cells were counted every 
day using a Neubauer-counting-chamber until cells reach saturation of proliferation (approx. 
after five days). For Cell Titer Glo (CTG) assay starved (3 h) cells were seeded out in 
appropriate numbers and stimulated with IL-3 (indicated time/concentration) ATP 
measurements were performed according to manufacturer`s instructions. 
 
3.2.1.9 Survival assay 
To check for changes in resistance to cytokine deprivation 5x105 BaF3 cells were washed 
three times with PBS and seeded out in 2 ml of RPMI Medium containing 10% bovine serum 
albumin (BSA). Cells were counted and stained with focus on declining viability rates. 
Immediately after reaching theoretical limit of viability (less than 1x104 vital cells), cells were 
spun and taken up in fresh growth medium containing IL-3. 
 
3.2.1.10 Cytospins 
Prelabeled glass slides were placed onto the rubber inlay of the metal holder. 200 µl of single 
cell solution (approx. 0.5x106 cells/ml) was loaded in a cytospin cuvette. By centrifugation at 
1300 rpm for 5 min, cells were absorbed onto the glass surface. Remaining liquid was 
carefully removed and the cells were washed once with 500 µl PBS. After centrifugation, the 
supernatant was removed. Cells on the glass surface were fixed for 20 minutes (min) with 0.4 
% paraformaldehyde (PFA) containing PBS at room temperature (RT). After two additional 
PBS wash steps, cells were stained according to manufacturer`s protocol. 
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3.2.2  Prokaryotic cells 
 
The gram negative bacterium Escherichia coli (E. coli) was used as host for the production of 
plasmid DNA and recombinant eukaryotic proteins. Bacterial growth was determined by 
photometric measurement of the optical density (OD) of bacterial cell suspension versus 
growth medium. Measurement was performed at a wavelength of 600 nm in a plastic cuvette 
(1cm).  
 
3.2.2.1 Cultivation and storage of E. coli 
Bacteria were either cultivated on solid growth Luria-Bertani broth (LB) medium (LB-Agar) 
or in liquid LB media (inoculated with a single colony), containing the appropriate antibiotics 
in sufficient amount. In the case of ampicilin resistance ampicilin concentration of 100µg/ml 
was used. For plasmid DNA, cells were then cultivated overnight between 14-16 h at 37°C. 
For protein expression, overnight culture was used for inoculation of (6 litre/RhoH, 6 
litre/RhoH-T36A, 1 litre/GST) growth medium in a ration of 1:10 and cultivated for approx. 3 
h until optical density (OD) of 0.9 was reached. Kryo-conservation of bacterial culture was 
obtained by mixing of 500 µl overnight cultured bacteria suspension with 500 µl of sterile 
glycerol (80%) and storage at -80°C.  
 
3.2.2.2 Preparation of competent E. coli cells 
In order to enable exogenous DNA uptake of bacterial cells, E. coli were chemically treated 
with calcium chloride solution. Bacterial cell membrane is permeable to chloride but non-
permeable to calcium ions. Water molecules accompany the charged chloride ions upon 
entrance into the cell, resulting in swelling. This uptake of water is necessary for the 
introduction of plasmid DNA. Competent cells were prepared by inoculation of 50 ml 
antibiotic free LB medium with a single colony of freshly grown E. coli from LB-agar plate. 
The bacteria suspension was incubated at 37°C until OD of approx. 0.5 was reached. The 
culture was centrifuged at 4000 rpm for 10 min at 4°C. After discarding the supernatant, the 
pellet was resuspended in 2 ml of 0.1 M calcium chloride solution. After adding 0.4 ml of 
Glyerol, 50 µl aliquots of competent cells were stored at -80°C until usage.  
 
3.2.2.3 Bacterial cell transformation 
Transformation represents an efficient method to introduce exogenous DNA molecules into 
competent bacterial cells. The calcium chloride solution in the aliquots of the previously 
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prepared competent bacteria cells along with an induced heat shock after DNA supplement 
supports the uptake of the plasmids. Competent cells were thawed on ice. 10 µl of ligation 
reaction or plasmid DNA between 50 ng and 1 µg was added to the bacteria with gentle 
mixing, and then incubated on ice for 10 min . Cells then were heat shocked for 2 min at 37°C 
and incubated for further 5 minutes on ice and transferred into preheated liquid LB medium 
(37°C, without antibiotics) and incubated for 20 min at 37°C. This step allows bacteria to 
recover from the treatment and leads to an increase in the number of clones carrying the 
antibiotics resistance. Bacteria were then pelleted by centrifugation (10000 rpm/ 30 sec). 
Supernatant was discarded and bacteria were resuspended in the remaining LB medium in the 
tube and streaked onto a LB-agar plate, containing appropriate antibiotics. 
 
3.2.2.4 Recombinant protein expression 
The E.coli strain BL-21 was used for protein expression. Bacterial cells were freshly 
transformed with the GST-2T expression vectors containing the appropriate gene variation of 
RhoH (wt RhoH, RhoH T36A) and streaked onto antibiotic containing agar plates. After 
overnight incubation at 37°C, a single colony was used for inoculation of an overnight liquid 
culture. The next day this overnight liquid culture was transferred in the ration 1:10 in new 
growth medium and was allowed to grow to an OD of approx. 0.9. Expression of recombinant 
proteins was induced by the addition of 0.2 to 1 mM isoprypylthio-β-D-galactoside (IPTG). 
Binding of IPTG inactivates the lac repressor which leads to the expression of downstream 
regions. Optimal expression temperature, time and IPTG concentration can vary depending on 
the expressed protein. In the case of wt RhoH and RhoH-T36A expression, 600 ml overnight 
culture was scaled up to 6 litres. The expression of the tag protein GST was scaled up 1:10 to 
1 litre volume. IPTG was added in a concentration of 1 mM and expression proceeded for 4 to 
5 hours at 37°C. Cells were pelleted by centrifugation (4°C, 4000 rpm, 15 min, GSA rotor, 
Sorvall). Bacterial pellets were washed one time with PBS and either used directly for lysis or 
were stored at -20°C. Bacteria pellets were resuspended with suitable bacteria lysis buffer 
containing protease inhibitors (Roche Protease Inhibitor Mix). Cells were then lysed by 
sonication on ice, for 3x pulses of 40 seconds (amplitude 42 %) with a break of 10 seconds 
after each pulse. The lysate was cleared by centrifugation for 30 minutes at 15,000 rpm (SS34 
rotor, Sorvall®) and the resulting supernatant was used for affinity chromatography.  
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3.2.3 Molecular biological techniques 
 
3.2.3.1 Genomic DNA extraction from mouse tail biopsy 
For genomic DNA extraction, (approx. 0.5 cm) tail biopsies of four to five week old mice 
were used. Each tail was incubated overnight in 710 µl of “Tail-Buffer” supplemented with 
10 mg/ml Proteinase K. After digestion, tubes were mixed for 5 min, after which 250 µl of 5 
M NaCl was added and the tubes were mixed again. Samples were centrifuged down at 
14,000 rpm/5 min/RT to remove tail debris. Supernatant was transferred to a new tube and 
DNA was precipitated using 550 µl Isopropanol. After vigorous shaking for 2 min, samples 
were again spun down for 5 min (14000 rpm at RT). The DNA pellet was washed with 70% 
Ethanol and centrifuged at same conditions. After discarding supernatant, pellet was air-dried 
for 10 minutes and finally resuspended in 100-200 µl 1x TE-Buffer or ddH2O and incubated 
for at least two hours at 37°C.  
 
3.2.3.2 Purification of plasmid DNA 
Methods and Kits for Plasmid purification were dependent upon the required amount of DNA 
for each respective experiment. Large and small amounts of Plasmid DNA were obtained by 
usage of Qiagen Plasmid Maxi- Kit and Mini-Kit (Quiagen, Hilden) and PureYield Plasmid 
Midiprep System (Promega, Mannheim) was used for intermediate amounts of plasmid DNA. 
Qiagen Gel Purifcation Kit (Quiagen, Hilden) was also used for preparative DNA purification 
from agarose gel slices. PCR products were purified with PCR-Purification Kit (Promega, 
Mannheim). The preparation was performed according the manufacturer`s instruction. The 
underlying principle for the plasmid purification is based on a modified alkaline lysis 
procedure, followed by binding of plasmid DNA to an anion exchange matrix under 
appropriate low-salt and pH conditions. Washing the matrix with a medium salt buffer 
removes RNA, protein, and other impurities. In the final step, nuclease-free water is used to 
elute bound DNA from the matrix. Long-Term storage of DNA was kept at -20 °C. 
 
3.2.3.3 DNA quantification 
DNA concentration was determined using the Nano-Drop Spectrometer by measuring the 
absorption maximum of double stranded DNA at 260 nm. Potential contaminants, such as 
proteins and single stranded DNA particles, have an absorption maximum of 280 nm, the ratio 
of OD at 260 nm and 280 nm is a parameter describing the purity of the DNA sample. Ratios 
between 1.8 and 2.0 indicate pure DNA.  
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3.2.3.4 Restriction enzyme digestion 
Restriction enzymes recognize and cut double stranded DNA at specific sites, also called 
restriction sites. Restriction sites are often composed of 4 to 8 palindromic nucleotides. 
Depending on the type of DNA processing enzyme, the resulting fragment can either have 
“sticky ends” which are overlapping ends that can be religated or “blunt ends” which result in 
a smooth cut that usually prevents religation of the DNA. According to manufacturer’s 
instructions, the DNA (5-10 µg preparative digestion, 0.5-2 µg analytic digestion) was 
incubated with the appropriate buffer system with or without BSA and the chosen restriction 
enzymes at the optimal concentration at 37°C for 1 to 2 hours. If double digestions were not 
possible, sequential digestion after the DNA precipitation step was performed.  
 
3.2.3.5 Polymerase chain reaction (PCR) 
Defined DNA fragments of a DNA template were amplified by using PCR with appropriate 
oligonucleotide primer pairs. These oligonucleotides are complementary to the DNA 
sequence and are defining the starting region of the region to be amplified. The 5` prime sites 
of oligonucleotides used for the replication of vector gene inserts normally contain restriction 
sites for further cloning of the PCR product. Thermostable polymerases were used to perform 
PCR reactions. The PCR reaction takes approx. 30 cycles comprised of a denaturation step 
performed at 95°C (30 sec) , a primer annealing and elongation step at 60° to 65°C (2 min) 
and the final elongation step (4-7 min at 72°C). The resulting PCR product was analysed with 
agarose gel electrophoresis. Depending on the following procedure the whole reaction was 
either directly purified using a PCR purification kit, or first separated with agarose gel 
electrophoresis and isolated from the gel matrix using a gel-purification kit. Isolated DNA 
fragments were either used for another PCR reaction or digestion to their included restriction 
sites.  
 
3.2.3.5.1 PCR based site directed mutagenesis 
A standard mutagenesis PCR was performed using the Pfx DNA polymerase kit (Invitrogen, 
Darmstadt) and performed according to manufacturer’s instructions. A template concentration 
between 10 pg and 200 ng was appropriate for optimal results. A standard program was used 
starting with a DNA denaturation step at 95°C (2 min) followed by 35 cycles of DNA 
amplification: 
94°C 30 sec 
60°C 2 min 
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72°C 4 min 
The reaction was finished with an elongation step of 10 min at 72°C. DNA was stored until 
usage at either 4°C or -20°C.  
 
3.2.3.5.2 Genotyping PCR 
Mice were genotyped using a touchdown PCR. This form of PCR is used to prevent the 
amplification of nonspecific products. For this type of PCR, a primer annealing temperature 
just below the optimum is used to allow binding of only highly specific primer sequences to 
the DNA. To distinguish RhoH genotypes of mice, two different PCRs were set up. The 
“wild-type (wt) detection” PCR reaction contained the primer Rh1 (located within the RhoH 
coding region) and Rh2 (located outside of RhoH coding region) which amplified a 240 base 
pair (bp) product. This product represented the wt allele. The “knockout (ko) detection” PCR 
contained primer Rh2 and Rh4 (located within the neomycin resistance cassette) and an 
amplification product of 325 bp resulted. The genotypes were analysed after agarose gel 
electrophoresis. Heterozygote and homozygote wt mice reacted positive for the Rh1+Rh2 
PCR, no product was detectable for homozygote KO mice. In the Rh2+Rh4 PCR, no product 
was detected for homozygote wt mice. For genotyping mice, the Fermentas (Fermentas, St. 
Leon-Rot) Taq DNA Polymerase kit was used. For the reaction, 2 µl of 10x PCR buffer was 
mixed with 50 mM MgCl2, 10 mM dNTPs, 100 pmol/µl primer and 5 U/µl Taq polymerase. 
Template DNA was added to a maximum concentration of 200 ng. Finally, the reaction 
mixture was diluted to a final volume of 20 µl with ddH2O. A touch down PCR program from 
65 to 55°C was used. The standard program started with a DNA denaturation step at 95°C (3 
min) followed by 9 cycles of DNA amplification: 
95 °C 30 sec 
54 °C 30 sec 
72 °C 30 sec 
Followed by a second amplification cycle with 35 repetitions: 
55 °C 30 sec 
72 °C 30 sec 
The reaction was finished using an elongation step of 10 min at 72°C. DNA was stored until 
usage at either 4°C or -20°C.  
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3.2.3.5.3 Quantitative real-time PCR 
To avoid contaminations with genomic DNA, DNases or RNases all preparative steps were 
performed with the usage of gloves, RNase and DNase free tips and tubes. To quantify target 
gene expression on mRNA levels, target gene-specific primers and the Absolute qPCR SYBR 
green ROX mix (Thermo-Fisher, Waltham, U.S.) was used to analyse template cDNA. The 2x 
PCR mixture contains a Thermo-Start DNA polymerase which prevents non-specifc 
amplification during the reaction. To activate this enzyme, an initiate PCR step of 95°C for 15 
min was required. The mixture contains the proper reaction buffer system including optimized 
MgCl2 concentrations and PCR enhancers to improve amplification rates, dNTPs, and the 
intercalating cyanid fluorescent SYBR Green I. This dye fluoresces after binding to the newly 
synthesised double stranded DNA .The detected overall fluorescence increases proportionally 
to the increasing concentration of double stranded DNA. The passive reference dye ROX was 
also supplied to the reaction mixture and was used by the PCR apparatus to normalise 
detected SYBR Green signals. The term real-time PCR refers to the measurement of the 
fluorescence signal after each PCR cycle which, in contrast to end-point measurements, 
allows the monitoring of gene amplification in real-time. The data is measured at the 
exponential phase of the PCR reaction, which is the optimal time point to analyze data. 2.5 ul 
of template cDNA, 12.5 pmol of forward and reverse primer, and 12.5 ul of SYBR Green Rox 
mixture were used for each 25 µl PCR reaction. PCR reaction and signal detection were 
performed in the 7900 HT Fast Real-Time PCR System (AB Applied Biosystems, Darmstadt) 
in a 96-well format (program: 95°C (15 min); 40x [95°C, 15s, 60°C; 1min]). Measurements 
were usually performed in duplicates. Automatic detection of baseline and threshold values 
was used and the determined Ct values were subtracted from the Ct values of an endogenous 
constitutively expressed reference gene (GAPDH) resulting in a ∆Ct for each target gene. 
Relative expression (rE) was calculated as rE=1/2 DCt and PCR reactions were verified for 
similar efficiencies. For reaction specificity, “no reverse transcriptase” and “no template” 
controls were performed with each reaction. Additionally, the dissociation curves of each 
target gene were determined. 
 
3.2.3.6 RNA isolation 
To isolate RNA for further procedures including cDNA synthesis, the High Pure RNA 
isolation kit (Roche, Penzberg) was used. The nucleic acid contents were absorbed by a Silica 
fleece located in the purification column in the presence of chaotrophic salt. Isolation of pure 
RNA was obtained by a digestion step with DNase. The isolation procedure was performed 
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using 1x106 cells. DNA was digested for 20 min at RT and RNA was eluted using 50 µl of the 
provided RNA elution buffer following to manufacturer’s instructions. RNA was either 
directly used for cDNA synthesis or stored until usage at -80°C. 
 
3.2.3.7 cDNA synthesis 
RevertAID first strand cDNA Sythesis kit (Fermentas, St. Leon-Rot) was used to generate 
cDNA from RNA templates. 11 µl of the RNA isolated as described above was mixed with 1 
µl of the provided oligo dT18 primer. This primer selectively binds to the poly(A) tail of the 
RNA and marks the starting point of the reverse transcription. Only 0.5 µl of the supplied 
RiboLock RNase Inhibitor and 0.5 µl of the reverse transcriptase were needed to get cDNA of 
appropriate yield and quality. Manufacturer’s recommended incubation steps for synthesis 
reaction were performed using a Thermo-cycler. For quantitative real-time PCR, cDNA was 
diluted in a ratio of 1:4 and stored until usage at -20°C. 
 
3.2.3.8 Agarose gel electrophoresis 
To analyze or purify digested DNA fragments, agarose gel electrophoresis was used. This 
method allows for the separation of DNA by size using an electric field. The phosphate-
containing sugar backbone of DNA strands is negatively charged and migrates once loaded on 
a gel matrix towards the positive charge. Depending on the mass of the migrating strand and 
the pore size of the DNA gel matrix, differing migration rates are observed resulting in the 
separation of the fragments. By co-loading a DNA ladder, which marks different DNA 
masses, the size of the migrated fragment can easily be determined. Depending on the 
expected DNA fragment size, gel concentrations between 0.3-2.0 % [w/v] agarose solubilised 
in 1x TAE buffer were used. 1-2 µg Ethidium bromide was added to the gel to make DNA 
visible under UV light (302 nm). DNA samples were mixed with 6x DNA loading buffer and 
loaded onto the gel which was placed in the electrophoresis unit containing the appropriate 
amount of 1xTAE buffer and run between 120 and 140 V. DNA bands migrating according to 
the expected mass were cut from the gel using a clean scalpel under ultraviolet (UV) light. 
DNA damage was avoided with short time periods of UV light exposure. 
 
3.2.3.8.1 DNA elution after gel electrophoresis 
DNA isolation of preparative agarose gel was performed using the QIAEX Agarose Gel 
extraction Kit (Quiagen, Hilden) according to manufacturer’s instructions. DNA was eluted 
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from ion exchange matrix by incubation with 50 µl of preheated nuclease-free water for 1-5 
minutes prior to a final centrifugation step. 
 
3.2.3.9 DNA ligation 
The enzyme T4-ligase catalyses the formation of covalent phosphodiester bonds between 
adjacent 3′hydroxyl ends of one nucleotide with the 5′ phosphate end of another via ATP turn 
over. This enzyme is used for introduction of DNA inserts into cloning vectors. Typically, 
100 ng of linearised vector was combined in a ratio of 1:5 with the DNA insert, 0.5 Units of 
T4-ligase and appropriate amount of 10x reaction buffer containing ATP. When required, 
ATP was also added to the reaction. The reaction was incubated between 1-2 h at 16°C. This 
reaction was used for transformation of competent E.coli. To check for background, clones 
resulting from self-ligation control reaction containing only vector (in the absence of insert 
DNA) were used for bacteria transformation.  
 
3.2.3.10 DNA sequencing 
Sequencing was performed commercially by GATC (Konstanz): 2-3 µg plasmid DNA was 
analysed with either standard or specifically designed primer. Results were analysed by 
alignments with the theoretical sequences using the alignment program CLUSTALW2 
(www.ebi.ac.uk/tool/clustalw2) 
3.2.4  Biochemical and immunological methods 
 
3.2.4.1 Enzyme-linked immunoabsorbent assay (ELISA) 
Enzyme-linked immunoabsorbent assay (ELISA) is one of the most commonly used 
quantitative immunoassays. In this method, a combination of an enzyme, namely 
streptavidine-horseradish-peroxidase conjugate and a biotinylated detection antibody is used 
as marker for determining antigen concentrations via substrate turn-over. Either an antigen or 
antibody is immobilised on a solid surface allowing for the rinsing and removal of unbound 
components. For sandwich ELISA based detection of IL-6 and TNF-α 1x106 cells/ml were 
seeded out in a volume of 200 µl into a 96-well plate and stimulated either for 6 hours or 
overnight with 1% anti-TNP-OVA-IgE. Antigen challenge triggers cytokine release of MCs. 
Therefore different concentrations of the Antigen TNP-OVA were used. Cells were incubated 
either overnight or at least for 5 hours with the antigen. Supernatant was then collected and 
  Materials and Methods 
 
 
38 
 
either frozen at -20°C or directly applied in different dilutions with PBS for ELISA. The assay 
was performed according to the manufacturer’s instructions. 
 
3.2.4.2 Hexosaminidase assay (HAA) 
To measure MC mediator release following antigen challenge, the β-hexosamindase assay 
(HAA) was performed105. When compound exocytosis is triggered, MC granule membranes 
fuse with the plasma membrane leading to the release of their components into the 
surrounding environment. The amount of the enzyme β-hexosaminidase released, directly 
correlates with those of histamine and chymase. By measuring the enzyme activity of this one 
component in the supernatant of MCs under high purity, one can quantify and determine the 
efficiency of MC degranulation. 2x106 cells/ ml were activated by incubation with 1% anti 
TNP-OVA-IgE (hen egg OVA) conditioned medium overnight or for at least six hours. Cells 
were then washed once with Tyrode buffer before resuspending in 100 µl Tyrode Buffer. 
Antigen challenge was performed with varying concentrations of TNP-OVA (10.0 ng/ml) 
solubilised in Tyrode buffer at 37°C for 1 hour. TNP-OVA as well as anti-TNP-OVA IgE 
were produced and generously provided by Prof. Aktories group (University Freiburg). To 
measure released mediators, supernatant was mixed 1:1 with HAA-substrate solution. To 
determine the remaining unreleased mediators, cells were lysed by addition of 10 µl of 
Tyrode-TritonX lysis Buffer and mixed in a ratio 1:2 with HAA-substrate solution. After 
incubation for 1 h at RT, the reaction was aborted by adding 100 µl of HAA-stop solution. 
Enzyme activity was measured by the turn over of the substrate 4-nitrophenyl-2-acetamido-2-
deoxy-β-D-glucopyranosid. The product of the colorimetric reaction is the yellowish p-
nitrophenol which can be measured photometrically at 405 nm.  
 
3.2.4.3 Fluorescence activated cell sorter (FACS) 
The underlying principle of the FACS is the laser-stimulated light emission of cells stained 
with different fluorescently labelled molecules. In this case, antibodies were used to mark 
certain cell population with specific properties such as activation, size and granularity. 
Different fluorescent dyes and labels require different laser types to acquire fluorescent 
spectra. The scattering of monochromatic laser light is dependent upon the properties of the 
samples. Forward diverted rays (Forwardscatter) correlate with the cell size while rays 
radiated at a 90° angle correlate with cell granularity (Sidwardsscatter). In the case of 
fluorescent labelled cells, additional absorption of the monochromic light is absorbed by the 
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dye and light of higher wave length is emitted by the fluorescent molecules. To guarantee 
specific results and avoid staining artefacts, one sample included antibody stained samples, 
unstained cells, as well as cells labelled with isotype control of the antibody with appropriate 
labelling into the measurements. In the case of double stained samples it was required to 
measure samples stained with only one of each dye to be able to identify problematic staining 
and wave length interferences. 
 
3.2.4.3.1 Extracellular FACS staining 
Approx. 1x106 cells per probe were harvested and pelleted by centrifugation (30 sec, 10,000 
rpm). Cells were washed once with PBS/2%FCS. Prior to staining, nonspecific antibody 
binding was avoided using a blocking step. Therefore, cells were resuspended in 100ul 
PBS/2%FCS and incubated on ice for 30 min. An appropriate amount of antibody was then 
added directly to the cell suspension and incubated in the dark and on ice for 45 min. To 
remove the remaining nonspecific staining, samples were washed twice with PBS/2%FCS 
prior to FACS analysis.  
 
CD123 staining: 
CD123 staining of murine primary or BaF3 cells was performed by the addition of 0.2 µg of 
murine CD123-APC antibody. CD123 staining of THP-1 cells was done using 10 µl of 
human-CD123-APC antibody. 
All experiments were performed using the appropriate isotype staining. 
 
c-Kit (CD117) / FcεRI: 
MCs were treated for at least 6 h with IgE prior to staining for maturation marker using 1 µl 
(0.2 µg) of PE-labelled anti-c-Kit antibody together with 1 µl (0.2 µg) of FITC-labelled anti-
FcεRI.  
 
3.2.4.3.2 Intracellular FACS staining 
Approximately 1x106 cells were pelleted by centrifugation (30 s, 10 000 rpm). Cells were 
washed once with PBS. For intracellular staining, cells were fixed 20 min at RT with 
PBS/4%PFA. Fixation is required to prolong stability of the intracellular proteins. After 
fixation, cells were washed twice with PBS/2%FCS and permeablised overnight with either 
incubation with 1 ml 90% methanol at -20°C overnight, or with 0.1% saponin detergent 
containing PBS at RT for 20 min. Following permeabilisation, cells were again washed twice 
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with PBS/2%FCS resuspended in 100 µl of the same buffer. Antibody in appropriate amounts 
was added to the sample and incubated 45 min at RT in the dark. 
 
Intracellular staining of phosphorylated STATs 
Cells were washed three times with PBS and cultured under IL-3 deprivation conditions for 
three hours prior to stimulation with 50 ng/ml IL-3 for different time points (5 min, 10 min, 
30 min) or left untreated. Stimulation was aborted by washing cells with cold PBS (30 s, 
10,000 rpm) followed by fixation using the procedure described above. 
All experiments were performed under the usage of the appropriate isotype staining. 
 
Propidium Iodide (PI) staining (Dye exlusion method) 
Propidium iodide is an intercalating, florescent dye commonly used for intracellular DNA 
staining as a parameter for cell viability. Necrotic cells with their porous membrane are 
strongly positive for PI while viable cells have an intact membrane which is inaccessible to 
PI. PI can not only be used for the detection of necrotic cells but also to exclude nonspecific 
staining of cells when probed with labelled antibodies. Necrotic cells would also 
nonspecifically take up fluorescence-tagged molecules. To exclude necrotic populations, 
double-positive cells were left out of the measurement by appropriate gating. For dye 
exclusion, appropriately antibody-stained cells were co-stained with 1 µl of PI (50 µg/ml) and 
analysed immediately by FACS. 
 
3.2.4.3.3 Annexin V- PI staining (Apoptose assay) 
Apoptosis was determined using the Roche Annexin-V-FLUOS-staining Kit. 
These proteins exhibit high binding affinity for negatively charged phospholipids in a calcium 
dependent manner. Annexin V, however, is a protein with high affinity for phosphatidylserine 
which is a phospholipid component normally localised at the inner leaflet of the cell 
membrane. Cells undergoing apoptosis, however, expose phosphatidylserine on the outer 
leaflet of their membrane. Using the provided FITC labelled Annexin V reagent, this PS can 
be stained. Since necrotic cells also have phosphatidylserine exposed on their cell membrane, 
it is required to co-stain with PI. Necrotic cells have a highly cavernous membrane leading to 
strong PI staining. This enables one to distinguish between highly PI and Annexin V positive 
necrotic cells and apoptotic cells highly positive for Annexin V and low for PI.  
For the measurement of RhoH-induced apoptosis, cells were starved in the absence of IL-3 for 
3 hours and 2.5x105 BaF3 cells/ml were seeded in a 6-well plate. Cells were either incubated 
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in RPMI medium (10% FCS) overnight or under other stress conditions (e.g.treatment with 1 
µM Doxurobucin or 1 µM Staurosporine). For analysis, cells were stained with Annexin-V 
and PI according to the Annexin-V-FLUOS kit protocol provided by the manufacturer. 
 
3.2.4.4. Toluidine Blue staining of MCs 
MC cytoplasm contains granules (metachromatic) composed of heparin and histamine. 
Toluidine blue should stain MCs red-purple (metachromatic staining of sulphated 
polysaccharides) and the background blue (orthochromatic staining of nucleic acids). For 
staining of MCs, previously prepared cytospins were incubated for two minutes in Toluidine 
Blue staining solution. Cytospins were then washed twice with PBS.  
 
3.2.4.5 Sodium dodecyl sulphate polyacrylamided gel electrophoresis (SDS-PAGE)  
SDS-PAGE seperates proteins according to their electrophoretic mobility. The migration of 
the proteins is not determined by their intrinsic electric charge of the polypeptides but by their 
molecular weight. The substance SDS is a strongly anionic detergent which denatures 
secondary and non-disulfate linked tertiary structures. This is achieved by wrapping the 
hydrophobic tail around the backbone of the polypeptide. SDS thereby confers a negative 
charge to each protein proportional to its mass. Specific molecular weight standard range 
markers allow for the estimation of the molecular weight. Complete unfolding of protein 
structure is achieved by the usage of disulfide-reducing agents such as β-mercaptoethanol. 
SDS-PAGE was performed by using discontinuous buffer systems with two layer gels 
containing a stacker and a resolving gel layer. The stacking gel layer containing 5% 
acrylamide and Tris-HCL (pH 6.8), was used to concentrate proteins in a thin starting zone 
before being resolving in the second Tris-Glycine gel layer. The acrylamide content of the 
resolving gel was specifically-chosen to accommodate the size of the target protein. 
Acrylamide concentrations in the resolution part can vary between 10-20%. Higher 
acrylamide concentrations are suitable for resolving proteins of lower sizes and vice versa. 
Continues gel systems containing an acrylamide concentration gradient (4-20%) were used to 
obtain optimal resolution for proteins of different or unknown sizes. 
 
3.2.4.5.1 Protein detection in SDS-gels with Coomassie Blue  
One method to visualize protein bands nonspecifically after SDS page is Coomassie Blue 
staining of the gel. The Coomassie mechanism for protein attachment is through ionic 
interactions and non-covalent bonds to non-polar regions via Van-der-Waals interactions as 
  Materials and Methods 
 
 
42 
 
the dye Coomassie is negatively charged and stable in the anionic form. The gel was washed 
twice for 5 min with water, then the proteins were fixed by incubating the gel for 1 h at RT 
with fixing/destaining buffer (40% methanol, 10% acetic acid, and 50% H2O). Gel was rinsed 
three times (5 min) with water and then covered with Coomassie Blue staining solution. After 
45 min of gentle shaking at RT, the gel was again rinsed several times with water. Destaining 
of the gel was performed to make individual bands visible by incubating the gel in 
fixing/destaining buffer 2 h or overnight. After this procedure, gel was stored in buffer 
containing 1% acetic acid. 
 
3.2.4.6 Eukaryotic cell lysates 
To obtain protein lysates for SDS Page from eukaryotic cells, different methods were used. 
All working steps for the preparation of cell lysates for protein analysis were performed on ice 
with cooled buffers (4°C) containing Roche Phosphatase Inhibitors and Protease Inhibitors 
(Roche, Penzberg), and cooled (4°C) centrifuges.  
 
PBS- lysates 
1x106-1x107 cells were collected and washed twice with PBS (30 s, 10,000 rpm). Cells then 
were resuspended in 250 µl PBS. To prevent high viscosity of the lysates via nucleic acids, 
samples were frozen at -80°C for at least two hours. After thawing, the cells were lysed 
through sonication with using 3x 10 sec pulses sepearated by five seconds each. Cell debris 
was pelletted by centrifugation and the supernatant was collected and either stored at -80°C or 
directly used for SDS-PAGE after determination of protein concentration.  
 
NP40-lysates 
Stimulated cells in solution were quickly lysed by the addition of an equal volume of 2xNP-
40 lysis buffer containg the appropriate amount of protease and phosphatase inhibitors. After 
resuspending the cells with lysis buffer, samples were spun for 45 min at 4°C. The lysates 
were then centrifuged at maximum speed for 30 min. Supernatant was then collected and 
either stored at -80°C until usage or directly used for determining protein concentration and 
SDS PAGE. 
 
RIPA-lysates 
At least 1x106 cells were washed three times with PBS and resuspended in 350 µl of RIPA 
Buffer. Cells were incubated while rotating upside down for 15-30 min at 4°C. Cell debris 
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was pelleted by maximum speed centrifugation for 20-30 min. Supernatant was then collected 
and either stored at -80°C until usage or directly used for determining protein concentration 
and SDS PAGE. 
 
3.2.4.7 Bicichinonic assay (BCA) 
For the measurement of protein concentrations of lysates and of GSH-matrix eluates, the BCA 
was used. The “biuret reaction” is the underlying principle of the BCA. Peptides containing 
more than two aa residues form a chelating complex with cupric ions (Cu2+) in an alkaline 
environment. One cupric ion forms a complex with 4 to 6 nearby peptides bonds which 
absorbs visible light. The blue color intensity, resulting from the reduction of cupric ion to 
cuprous ion, is proportional to the number of peptide bonds participating in the reaction. This 
reaction is combined with a second reaction in which the chelation of BCA with the cuprous 
ion of the former reaction yield an intense purple color. The reaction products are formed by 
the chelation of two molecules of bicichinon (BC) with one cuprous ion. The BC/copper 
complex is water soluble and exhibits a strong linear absorbance at 562 nm with increasing 
protein concentrations.  
 
3.2.4.8 Immunoprecipitation (IP) and Co-IP 
Immunoprecipitation (IP) is used to precipitate, and thereby concentrate and isolate, a single 
protein type out of a mixed solution by using immobilised antibodies. Cell lysates are 
prepared with suitable lysis buffer and are mixed with 30 µl of freshly resuspended Protein 
A/G Sepharose Beads (Santa Cruz, San Diego). 1-5 µg of the antibody is added to the 
reaction. After rotating incubation for at least 6 h at 4°C, beads are centrifuged at 13,000 rpm 
for 30 sec. Supernatant is either collected and stored at -80°C or discarded. Beads were 
washed twice with 350 µl lysate buffer and once with TNE-buffer to remove any remaining 
detergents. Beads were mixed with 30 µl of 2x sample buffer (Lämmli) and heated for 3-5 
min at 96°C. After centrifugation for 3 min at maximum speed, the supernatant was loaded 
onto a SDS page gel and proteins were detected via enhanced chemiluminescence. This 
method was also used to co-precipitate potential interaction partners of the target protein. 
 
3.2.4.8.1 Immunoprecipitation of STAT proteins 
1x107 starved (3 h) BaF3 cells in 250 µl RPMI medium were either stimulated with 50 ng/ml 
IL-3 or left untreated. Cells were lysed using 250 µl 2x NP40 lysis buffer. A/G Sepharose 
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beads as well as 5 µl of either STAT1 or STAT5 antibody were added to the reaction. 
Samples were run on 12% SDS-Page.  
 
3.2.4.8.2 Co-Immunoprecipitation of RhoH interaction partner 
100 µl of generated RhoH antibody serum (Eurogentec, Seraing, Belgium) was preincubated 
overnight with 30 µl of protein A/G sepharose per sample. Beads were collected after 
centrifugation and the serum supernatant was stored and reused up to three times. Lysates of 
1x107 BaF3 cells of 1x106 transfected HEK cells were incubated with the RhoH antibody-
coupled beads over night. Samples were run on an acrylamide concentration gradient (4-20%) 
gel (Anamed, Bad-Ems).  
 
3.2.4.9 Western-blot (semi-dry) 
After SDS–PAGE, the separated proteins were transferred onto a nitro cellulose membrane 
using a semi-dry blotting technique which allows for protein detection with antibodies. 
Nitrocellulose and filter paper (Whatman) were soaked with Transfer buffer. Four to eight 
soaked layers of Whatman paper were stacked between the positive and negative electrode of 
the blotting unit. Then the soaked membrane was placed on top of the staple of Whatman 
paper. The SDS gel was positioned onto the nitrocellulose membrane and was covered again 
with equal layers of Whatman paper. To avoid discrepancies during transfer, air bubbles were 
removed. Proteins were transferred vertically toward the anode for one hour under a current of 
approximately 0.8 mA per cm² gel. Transfer of proteins to the membrane was checked using 
Ponceau S. 
 
3.2.4.9.1 Antibody-mediated detection of immobilized proteins  
After protein transfer, the membrane was incubated with 3% lactose or 5% BSA containing 
TBST-buffer for 1 h/ RT to block nonspecific binding. The membrane was then probed with 
the antigen-specific antibody overnight at 4°C. The following day, the antigen-specific 
antibody was removed, washed three times with TBST (5 min, RT), and the membrane was 
incubated (1 h, RT) with horse radish peroxidase (HRP) coupled secondary antibody directed 
against the Fc portion of the primary antibody. After discarding the secondary antibody and 
three additional washing steps with TBST, detection of bound antibody was performed using 
luminol. Luminol serves as a substrate for HRP and during oxidation of the agent 
chemiluminescent molecules are formed. The luminescence signal is proportional to the 
amount of target protein and can be detected and visualised with the detection unit Chemi-
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Smart 5000 (Peqlab Erlangen). For analysis and quantification of resulting bands the software 
ChemiCapt (Peqlab, Erlangen) was used.  
 
3.2.4.9.2 Stripping  
Stripping was performed to remove primary and secondary antibodies from the membrane in 
order to re-probe chemiluminescent western-blots. The membrane was incubated for 1 h at 
37°C in the appropriate amount of Restore Western Blot Stripping Buffer (Pierce). After 
discarding Stripping buffer, membrane was washed with TBST several times to remove 
residual buffer. Finally, the membrane was blocked as described above and probed again with 
the primary antibody of interest.  
 
3.2.4.10 Nuclear extracts 
1x108 cells per sample were washed with 5 ml of cold PBS. Cells were transferred into falcon 
tubes and spun 5 min at 1000 rpm (4°C). The cell pellet was resuspended in 400 µl hypotonic 
buffer and allowed to swell on ice for 10 min. Again cells were centrifuged for 1 min at 
12,000 rpm and 4°C. Supernatant containing cytoplasmic extracts were either kept at -80°C or 
used directly for SDS-PAGE. Nuclear pellets were resuspended in 50 µl of high salt buffer 
and rocked or vortexed for 30 min at 4°C. Suspension was centrifuged for 10 min at 12,000 
rpm and 4°C. Protein content was quantified using BCA and either kept at -80°C until storage 
or 50 µl of the lysates were directly used for SDS PAGE. 
 
3.2.4.11 Affinity chromatography: GST-pulldown assay 
GST tagged proteins were purified using Glutathione Sepharose TM 4 fast flow (GE 
Healthcare). The gluthatione beads were conditioned to supernatant settings by three rinsing 
steps using appropriate bacteria lysis buffer. Equilibrated glutathione coupled beads were then 
incubated at 4°C for 2 h with bacteria supernatant. After this period beads, together with 
supernatant, were transferred to a column (Bio Rad). After five washing steps with bacteria 
lysis buffer, matrix bound proteins were eluted with 1 ml of reduced Gluthation-Buffer. For 
enhanced efficiency, this step was repeated three times. Next, the protein concentration of the 
eluate was determined colorimetrically using 10 µl of eluate which was mixed with 1 ml 
Coomassie Plus Bradford Protein reagent. Protein concentration dependent absorption was 
measured after 10 min at RT (595 nm) and the resulting protein concentration was from the 
pre-determined calibration curve.  
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3.2.4.12 Sample preparation for protein in-solution trypsin digestion 
In order to analyze and identify proteins by liquid chromatography (LC)-tandem mass 
spectrometry (MS/MS) methods, proteins are proteolyzed (e.g. digestion with trypsin) into 
their corresponding peptide fragments. For efficient digestion, the proteins should be 
denatured and solubilized in an aqueous solution buffered at an optimal pH (~ 7.5). The 
procedure for denaturing and digestion of the proteins was as follows: First, the proteins were 
precipitated overnight at -80°C by adding ice cold acetone in at a ratio 1:4. The next day, 
precipitated protein was pelleted by centrifugation (maximum speed, 45 min, 4°C). 
Supernatant was discarded and pellet was allowed to dry at RT for 15 to 20 minutes. Protein 
pellet was resuspended in 6M Urea containing Ammonium Bicarbonate Buffer (0.1 M).   This 
step denatures the protein structure. 5mM dithiothreitol (DTT) was added break disulfide 
bonds between different cysteinyl residues and this step, combined with denaturation, 
enhances the accessibility of proteolytic cleavage sites within the proteins. To prevent 
reforming of disulfide bonds, an alkylating agent, 15 mM iodoacetamide (IAA) was added to 
the mixture. After 30 min incubation at RT in the dark, DTT was added to the reaction to 
quench any excess IAA. In the final step, the mixture was diluted to a final concentration of 2 
M urea and trypsin (Promega) was added in a ratio of 1:20. Trypsin digestion was performed 
overnight at 37°C.  
 
3.2.4.13 Peptide fractionation and mass spectrometric analysis 
The peptides from each of the sample digestion mixtures were separated using two orthogonal 
fractionation techniques composed of strong cation exchange (SCX) followed by reversed-
phase HPLC of each fraction. Fractionation was performed on a polysulfoethyl aspartamide 
column (200 × 2.1 mm; 5 µm; 200 Ǻ) (PolyLC Inc., Columbia, MD) using a Paradigm MG4 
HPLC system (Michrom BioResources, Inc., Auburn, CA). Peptides were loaded onto the 
SCX column with mobile phase A (5 mM KH2PO4 (pH 2.7)/30% acetonitrile) and eluted with 
an increasing salt gradient from phase B (mobile phase A containing 500 mM KCl). The flow 
rate was set at 200 µl/min and elution was monitored with a UV-visible detector (214 nm). 
Fractions were collected at 2 min intervals (30 fractions) and then pooled (based on 
absorbance) for a total of twelve fractions for subsequent reversed-phase LC-MS/MS 
analysis.  Reversed-phase separations were performed on C18 media (5 µm particles; Applied 
Biosystems, Foster City, CA) packed in fused silica capillary tubing (8cm × 50 µm i.d.). An 
acetonitrile gradient was delivered by a binary nano-LC pump (nanoLC•2DTM; Eksigent).  
Buffer A was composed of 0.1% formic acid and buffer B was composed of 90% ACN/0.1% 
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formic acid. Peptides were delivered to the column at 3% buffer B and separated via a linear 
gradient of increasing buffer B to 60% at 45 minutes. It was held at 60% B for five minutes 
and then the composition was reset to 3% B for the duration (65 min/run). Eluates were 
analysed with an ion trap/Orbitrap hybrid mass spectrometer (LTQ Orbitrap, Thermo Fisher 
Scientific, San Jose, CA) equipped with a Nanomate nanospray ion source (Advion 
Biosciences, Ithaca, NY, USA). Settings included: spray voltage 1.3 kV; spray current 100 
µA; capillary voltage 35 V; ion transfer tube temperature 220°C. The mass spectrometer was 
operated in the data-dependent mode to automatically switch between Orbitrap-MS and ion 
trap-MS/MS acquisition. Survey full scan MS spectra (from m/z 400–2000) were acquired in 
the orbitrap at a resolution of 30,000 (based on m/z 400). The four most intense ions were 
isolated for fragmentation in linear ion trap using collision-induced dissociation with a 
normalised collision energy setting of 27.0.  
 
3.2.4.13.1 Data analysis and interpretation 
MS/MS peak lists from the raw files were extracted (.dta format) using Bioworks Browser 
version 3.3.1 SP1, ThermoFisher Scientific Inc. (San Jose, CA, USA).  The combined list of 
.dta files from each set of LC-MS/MS runs (from 12 SCX fractions each) were then converted 
to .mgf format (as one concatenated file) using a Perl script (merge.pl) available from Matrix 
Science Inc. (Boston, MA, USA). The .mgf peak lists were then analysed using the Mascot 
database searching software from Matrix Science Inc. (Boston, MA, USA) using the IPI 
mouse database.The following fixed settings and modifications were used in the searches: 
trypsin as the protease allowing for up to two missed cleavage sites; carbamidomethylation 
(C); precursor mass tolerance of 20 ppm (ion mass tolerance of 1 Da). The variable 
modifications included deamidation (N and Q) and oxidation (M). Peptide identifications and 
residue modifications were accepted if their scores were above the confidence threshold (95% 
confidence interval) as established by Mascot. The data from biological replicates were 
combined and sorted by IPI protein accession number in Microsoft Excel. Proteins identified 
by a single peptide hit were removed from the list and stored in a separate file. The data was 
then sorted by peptide aa sequence to identify redundant peptides. The total data from all of 
the 2D-LC-MS/MS experiments, including the duplicates wt RhoH ± IL3 and mutant T36A 
RhoH ±IL3 and the GST control, was then combined. The number of unique and/or redundant 
peptides were then entered into the appropriate sample column for each protein identified. 
Two unique peptides were required for a protein identification to be considered as a solid hit. 
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4.1.2  RhoH, an inhibitor of IL-3 induced proliferation 
 
To address the question of an inhibitory role of RhoH in IL-3 dependent, next BaF3 cells 
overexpressing RhoH (RhoH cells), BaF3 cells which were retrovirally transfected with a 
vector containing short hairpin shRNA directed against RhoH (siRhoH cells), and a control 
cell line of BaF3 cells, transduced with the corresponding empty vector (Mock) were 
generated. All vectors were containing a puromycin resistance gene for antibiotic selection. 
BaF3 cells were several times tested upon their IL-3 dependency to ensure solid and reliable 
results. To guarantee that only transduced cells were analysed, cells were kept continuously in 
puromycin containing medium. Due to a lack of a functional antibody against endogenous 
RhoH, the altered expression levels of RhoH in siRhoH, RhoH overexpressing and control 
cells were checked by quantitative real-time PCR and RhoH cDNA specific primers, that 
were suitable to detect endogenous and transduced RhoH expression (Fig. 4.2A). Short 
hairpin RNA mediated knock-down of RhoH reduced endogenous expression of RhoH up to 
90% of that of control cells while overexpression of RhoH enhanced RhoH mRNA expression 
approximately fivefold the mRNA levels detected in cells transduced with the control vector. 
It was previously reported that simultaneous expression of multiple genes in mammalian cells, 
transduced with IRES (internal ribosomal entry site) sequence containing vectors, are highly 
comparable107. Therefore CD4 was cloned into the IRES containing vector and was used for 
surrogate measurements to determine transduction efficiency. To demonstrate successful 
transduction, cells were analysed by FACS upon their CD4 surface expression. The CD4 
expression in both samples was about 80% compared to untransfected cells (Fig. 4.2B).  
(A) (B) 
 
 
Fig. 4.2 Generation of BaF3 cells with distinct RhoH expression levels  
(A) RhoH mRNA levels of BaF3 cells retrovirally tranduced with either empty vector (pMX-IRES-CD4-Puro) 
indicated here as Mock, with shRNA directed against RhoH containing vector, indicated as siRhoH or RhoH 
overexpression vector (pMX-IRES-CD4-Puro-RhoH) were analysed by quantitative SYBR Green Real-Time PCR 
using RhoH cDNA specific primer and GAPDH as reference gene. Statistical significance was determined using 
Student`s t-test (n=2, mean ± SD and *P≤0.05; **P≤0.01) (B) Human CD4 expression after puromycin selection 
of Mock or RhoH overexpression vector transduced BaF3 cell measured using FACS analysis. Parental BaF3 cells 
served as negative control. 
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To determine whether RhoH expression levels would impact IL-3 induced proliferation of 
cells, a proliferation assay was performed. The time-dependent proliferation rates of RhoH 
overexpressing cells, siRhoH and control cells with constant IL-3 concentration in the growth 
medium, when seeded out with equal cell counts were compared (Fig 4.3A). When observing 
the proliferation of cells with different RhoH levels over 5 days it became apparent that cells 
with shRNA mediated knock-down of RhoH showed an increased proliferation in response to 
IL-3, while cells overexpressing the protein showed a decrease of proliferation compared to 
empty vector transduced BaF3 cells. The differences became most prominent at day 5 when 
cell proliferation rate exit log phase. At day 5 both RhoH overexpressing and siRhoH cells 
differed from control cells in a cell count of about 4x105 cells. To clarify whether this 
observations correlated with a IL-3 dependent dose-response sensitivity caused by modified 
RhoH expression levels, a cell viability assay with varying IL-3 concentrations (0.001-1 
ng/ml) in the medium, was performed. In this assay the ATP levels of cells are measured. 
ATP levels are increasing with rising cell counts (Fig. 4.3B). ATP levels measured after 48 
hours of culture in different IL-3 concentrations confirmed and even clarified the observations 
which were made in the time-dependent proliferation assay. RhoH overexpressing cells 
showed 70% lower proliferation potential than control cells, while siRhoH cells proliferation 
showed an increase of 160% in proliferation compared to Mock transfected cells. The 
inhibitory effect RhoH had on proliferation was not able to be compensated with increasing 
IL-3 concentration. To address the question whether RhoH expression would have similar 
effects on proliferation rates when using a growth factor other than IL-3, BaF3 and RhoH 
overexpressing BaF3 cells were co-transduced with erythropoietin receptor (Epo-R) and were 
cultivated together with parental (untransduced) BaF3 cells in medium containing 
erythropoietin (Epo) as growth factor. In this experiment again ATP levels were determined 
(Fig. 4.3C). Parental cells, as expected showed no proliferation in response to Epo and 
interestingly RhoH overexpressing cells were growing with a proliferation rate, similar to that 
observed in EpoR tranduced cells with lower RhoH expression levels. These results supported 
the hypothesis that the RhoH modulated IL-3 dependent proliferation effects previously 
observed in cells with distinct RhoH levels were specifically in response to the cytokine IL-3.  
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(A) (B) 
 
 
 
(C)   
 
Fig. 4.3 RhoH modulates IL-3 stimulated proliferation  
(A) Time dependent proliferation of 0.25x105 cells over 5 days in 
of RhoH, Mock and siRhoH BaF3 cells, cultivated in 0.5% IL-3 
containing growth medium. Cell numbers were analysed using 
Neubauer`s cell counting chamber. Presented results from one 
represented experiment performed in dublicates ± SD (n=2) (B) 
IL-3 dose response curve of RhoH, Mock and siRhoH cells 
cultivated for 48 hours in medium with indicated IL-3 
concentrations. Viability of cells was determined in a CTG assay. 
Presented results from one representative experiment performed 
in triplicates ± SD (C) Epo dose response curve of parental BaF3 
cells (BaF3), BaF3 cells transduced with Epo-Receptor (EpoR) 
and RhoH overexpressing BaF3 cells co-tranduced with Epo-
receptor (RhoH-EpoR) cultivated for 24 hours in growth medium 
containing indicated concentrations of Epo. Viability of cells was 
determined in a CTG assay. Presented results from one 
representative experiment performed in triplicates ± SD (n=2).  
4.1.3  RhoH overexpression results in increased IL-3 dependent STAT1 
activation 
 
RhoH was previously reported to induce apoptosis in hematopoietic progenitor cells via an 
unknown signalling pathway85. IL-3 is known to induce not only factors important for 
survival but to a much lesser amount also growth inhibiting and proapoptotic transcription 
factor STAT123. To address whether RhoH levels can modulate STAT1 activation in 
response to IL-3, siRhoH, RhoH and control cells were starved prior to stimulation with IL-3 
and phosphorylated STAT1 levels were determined by FACS analysis (Fig. 4.4A). The 
treatment of control and siRhoH cells with IL-3 resulted in only slight or no phosphorylation 
of STAT1 compared to unstimulated cells, while the IL-3 treatment of RhoH cells resulted in 
a strong phosphorylation of STAT1. To confirm FACS analysis, STAT1 
immunoprecipitation (IP) was performed to detect tyrosine phosphorylated STAT1 (pSTAT) 
using western-blot analysis. Since no significant difference in phosphorylation has been 
detectable between Mock and siRhoH transfected cells using FACS analysis, only control 
and RhoH cells were starved and stimulated with IL-3 for IP (Fig. 4.4B). The results 
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confirmed that enhanced STAT1 activation can be observed in RhoH overexpressing cells 
after IL-3 treatment. The quantification of different experiments clarified that there is a 1.5 
fold increase of IL-3 induced STAT1 phosphorylation in RhoH overexpressing cells 
compared to the activation of STAT1 in control cells. These observations lead to the 
conclusion that RhoH expression causes enhanced IL-3 dependent phosphorylation of 
STAT1, which most likely causes the inhibition of IL-3 induced proliferation.  
(A) 
 
(B) 
 
 
Fig. 4.4 RhoH overexpressing cells show increased IL-3 induced STAT1 phosphorylation  
(A) Mock, siRhoH and RhoH BaF3 cells were starved for 3 h and then stimulated for 10 min with 50 ng/ml IL-3. FACS 
analysis of pSTAT1 was performed using a FITC labeled pSTAT1 antibody. Results from one representative experiment is 
shown (n=3). (B) (Left panel) Mock and RhoH cells were lysed for STAT1-IP, either directly after 3 h of cytokine 
withdrawal or after 10 min stimulation with 50 ng/ml IL-3 following 3 h starvation. For STAT1-IP STAT1 specific antibody 
was used, detection of pSTAT1 and total STAT1 was performed by enhanced chemiluminescence. (Right panel) 
Quantification of pSTAT1 levels was performed after normalisation to STAT1 levels in control cells and is presented as 
induction of phosphorylation compared to the unstimulated samples. Statistical significance was determined using Student`s 
t-test (n=3, mean ± SD; ***P≤ 0.005)  
 
4.1.4  RhoH modulated IL-3 dependent STAT1 activation correlates 
with expression of CDKIs 
 
To check the induction of STAT1 dependent apoptosis mediated through the activation of 
pro-apoptotic signalling pathways such as the activation of caspases 1 and 11 or through the 
inhibition of pro-survival signalling pathways29, apoptosis was induced in cells with different 
RhoH expression levels. To trigger distinct apoptotic mechanisms cells were kept under 
different stress conditions. RhoH, siRhoH and control cells were either kept under IL-3 
withdrawal, or treated with either doxorubicine (doxorub) or staurosporine (staurosp). As 
negative control for apoptosis, cells cultured in IL-3 containing medium were used (Fig. 4.5 
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A). Apoptosis was detected using FACS analysis. The results showed that cells with different 
RhoH levels did not differ in their ability to undergo apoptosis, indicating that the observed 
proliferation inhibition caused by RhoH overexpression is not the result of STAT1 induced 
apoptosis. STAT1 activation can result in growth inhibition by the induction of the CDKI 
p21waf/cip1 34. Investigations of p21cip1 mRNA levels in siRhoH, RhoH and control cells showed 
that indeed RhoH overexpression results in enhanced mRNA levels of p21waf/cip1 (Fig. 4.5B). 
Suprisingly the mRNA expression of the CDKI p21waf/cip1 measured in siRhoH cells seemed 
to be slightly elevated in comparison to control cells. Next it was confirmed that the enhanced 
mRNA levels of p21waf/cip1 also result in an accumulation of p21waf/cip1 on protein level (Fig. 
4.5B). To quantify the detected p21waf/cip1 protein amounts, the p21waf/cip1 signal intensity was 
corrected using β-actin loading control signal and normalised against the signal measured in 
control cells (100%). RhoH overexpressing cells showed 100 fold higher signal intensity of 
p21cip1. On protein level siRhoH levels showed insignificantly lower p21waf/cip1 expression 
than control cells. 
The CDKI p27kip1 is is known to be regulated by STAT131 and IL-3 treatment108. Therefore it 
was assumed that this protein could be also a potential target of RhoH mediated cell cycle 
inhibition. The mRNA expression levels of the p27kip1 gene were quantified in control, RhoH 
and siRhoH cells (Fig 4.5C). RhoH overexpression resulted in enhanced p27kip1 mRNA 
levels. Investigation of the p27kip1 protein levels in control, siRhoH and RhoH cells showed 
the same result. RhoH overexpression lead to an upregulation of p27kip1 protein expression, 
while control cells and siRhoH cells showed comparably low p27kip1 levels (Fig. 4.5C). 
Quantification of the results revealed an approximate increase of p27kip1 protein expression of 
30% compared to control cells. These results demonstrated that RhoH modulated enhanced 
IL-3 dependent STAT1 activation inhibits cell proliferation by upregulation of cell cycle 
inhibitors rather than by the induction of apoptosis. 
(A) 
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(B) 
 
 
(C) 
 
 
4.5 RhoH dependent STAT1 activation after IL-3 stimulation correlates rather with increased CDKI expression 
than with induction of apoptosis  
(A) Apoptosis was measured using FACS analysis of Annexin V/PI staining of Mock, siRhoH and RhoH cells. Apoptosis 
was measured after cultivation in normal growth medium, under IL-3 withdrawal (ON) or in growth medium containing 1 
µM doxorub. (12h) or 1 µM staurosp. (3h). (n=3, mean ± SD). (B)&(C) mRNA levels of p21waf/cip1 (B) and p27kip1(C) in 
control, RhoH and siRhoH cells was performed by quantitative SYBR Green Real-Time PCR and primers against p21waf/cip1 
(B) or p27kip1(C) and the reference gene GAPDH (n=3, mean±SD) statistical significance was determined using Student`s t-
test (*P≤0.05). Data is presented after normalization of p21cip1 (B) or p27kip1 (C) to mRNA levels detected in control cells. 
For western-blot analysis of p21waf/cip1 (B) or p27kip1(C) whole cell lysates of Mock, siRhoH and RhoH cells were prepared 
and separated by 4-20% gradient SDS-PAGE. Protein levels were detected using enhanced chemiluminescence. For 
quantification p21waf/cip1 (B) or p27kip1(C) levels were normalised to correlating β-actin levels (right panel). Data is 
presented as percentage of p21waf/cip1 (B) or p27kip1(C) levels detected in control cells. Statistical significance was 
determined using Student`s t-test (n=3, mean ± SD; *P≤0.05).  
4.1.5  RhoH expression modulates IL-3 induced STAT5 activity 
 
One of the major pro-proliferative signalling pathways activated by IL-3 treatment is the 
induction of the JAK2-STAT5 pathway22 resulting in the expression of cell cycle progression 
and survival supporting genes21. To address the question whether the enhanced proliferation 
of siRhoH cells could be connected to an increase of STAT5 activation, IPs of total STAT5 
(followed by the detection of the amount of phosphorylated STAT5) was performed. For this 
purpose control, RhoH and siRhoH cells were starved and restimulated with IL-3 (Fig 4.6A). 
After comparing IL-3 induced phosphorylation levels to the untreated sample a significant 
decrease in STAT5 phosphorylation of RhoH overexpressing cells (50% compared to control) 
was observed. The phosphorylation differences between Mock and siRhoH cells were hard to 
distinguish using IP, since total STAT5 levels seem to vary between samples. However the 
comparison of different, to the total STAT5 levels normalised experiments (Fig 4.6A), 
showed a slight enhancement of STAT5 phosphorylation in cells with RhoH knock-down. In 
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an effort to further characterise this slight difference in STAT5 activation, FACS experiments 
were performed using Mock and siRhoH cells (Fig 4.6B). Using FACS analysis made it 
possible to detect a stronger difference in phosphorylation between control cells and cells with 
lower RhoH expression (Fig. 4.6B). STAT5 activation is known to play a pivotal role in the 
mediation of cytokine independent proliferation and enhanced survival under cytokine 
deprivation conditions109.  
(A) 
 
 
(B) 
 
Fig 4.6 Low RhoH levels are correlating with enhanced STAT5 phosphorylation (A)Mock, siRhoH and RhoH BaF3 
cells were lysed for STAT5-IP, either directly after 3 h cytokine withdrawal or after 10 min stimulation with 50 ng/ml IL-3, 
following 3 h of cytokine starvation. For STAT5 IP STAT5 specific antibody was used, detection of pSTAT5 and total 
STAT5 was performed by enhanced chemiluminescence. Quantification of pSTAT5 levels was performed after 
normalization to detected STAT5 levels in control cells. Data is presented as induction of phosphorylation compared to 
unstimulated sample. Statistical significance was determined using Student`s t-test (n=2, mean ± SD; *P≤ 0.05) (B) FACS 
analysis of pSTAT5 in Mock and siRhoH cells after 10 min treatment with 50 ng/ml IL-3, following 3 h of cytokine 
starvation was performed using a FITC labeled pSTAT5 antibody. Presented data from one representative experiment is 
shown (n=3). 
 
It was tested whether the increased STAT5 activation in response to IL-3 would impact the 
survival of siRhoH cells. Parental cells and BaF3 cells with a shRNA mediated knock-down 
of RhoH were tested in a survival-assay (Fig. 4.7). After removal of any IL-3 from the growth 
medium, the decreasing cell viability and the correlating decreasing cell counts were 
documented. After day 3 no vital cells were detectable using Trypan Blue cell staining, 
indicating that less than 1x104 cells per ml medium were vital. At this time point IL-3 was re-
added to the growth medium and cells were allowed to recover from starvation period for 
several days before counting of vital proliferating cells started. The outcome of this 
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experiment showed that there is no increased survival of cells underexpressing RhoH after IL-
3 removal, highlighting that the increased levels of phosphoSTAT5 (pSTAT5) were a direct 
result of IL-3 treatment. Instead, siRhoH cells showed a more unfavourable reaction to the IL-
3 withdrawal than parental cells since cell counts of siRhoH cells declined with an increased 
rate in comparison to parental cells. However when IL-3 was re-added to the growth medium, 
cells with less RhoH expression exhibited the ability to recover from IL-3 starvation in 
contrast to parental BaF3 cells with higher RhoH expression.  
 
Fig. 4.7 Low RhoH expression correlates with 
increased recovery from IL-3 starvation 
Increased IL-3 sensibility of siRhoH cells was 
detected by daily counting of siRhoH cells and 
control cells using Trypan Blue and Neubauer`s 
cell counting chamber. Cells were kept 4 days in 
medium without IL-3 until reaching of theoretical 
viability limit then IL-3 was readded into medium 
and again cell number and viability was 
determined for further 12 days (n=2, ±SD).    
siRhoH cells seem to recover from starvation indicates that these cells may inhabit a stronger 
susceptibility to both IL-3 withdrawal and recovery. These experiments pointed out that RhoH 
overexpression not only inhibited the proliferation in these cells by the induction of IL-3 
dependent STAT1 activation but also by the inhibition of IL-3 induced pro-proliferative 
signals via decreased STAT5 activation. At the same time low expression of RhoH resulted in 
an enhancement of STAT5 phosphorylation and an increased sensitivity to IL-3 stimulation in 
response to IL-3 which explains the previously observed IL-3 dependent proliferation 
advantage of siRhoH cells. 
4.1.6  RhoH- a modulator of CD123 surface expression 
 
To explain the enhanced STAT5 phosphorylation and the observed increased sensitivity to IL-
3 in cells with low RhoH protein levels, the RhoH dependent surface expression of IL-3 
receptor α chain (CD123) was measured. It was assumed that altered IL-3 receptor 
expression, and thereby distinct levels of ligand binding to its receptor in cells with altered 
RhoH levels, would consequently led to differences in the activation and the outcomes of IL-3 
dependent downstream signalling, such as STAT5 activation and recover from starvation. To 
check this hypothesis Mock, siRhoH and RhoH cells were stained for the surface expression 
of CD123, and analysed via FACS (Fig. 4.8A). The analysis of the cells attested that 
expression of CD123 was altered depending on the amount of RhoH present in the cells. 
RhoH overexpressing cells showed only about 30% CD123 surface expression compared to 
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that measured on control cells. Controversially, CD123 expression on the surface of siRhoH 
cells was enhanced. Previous reports suggest that an enhanced expression of surface CD123, 
observed in AML cells can be initiated by a STAT5 dependent upregulation of the 
transcription factor IRF-1110. To analyse RhoH and siRhoH and Mock cells for their IRF-1 
expression levels, quantitative SYBR-green real-time PCR was performed (Fig. 4.8B).  
 
(A)  
 
 
(B)  
 
 
Fig. 4.8 RhoH levels modulate IRF-1 dependent CD123 surface expression in BaF3 cells  
(A) (Left panel) FACS analysis of CD123 surface expression on control, siRhoH and RhoH cells was performed using a 
CD123-PE antibody. Specifity of staining was controlled by the usage of correlating PE-labeled antibody isotype reagent.  
(Right panel) Quantification of CD123 surface expression was determined using mean fluorescence values, and is presented 
as percentage of detected CD123 mean fluoresecence signal in control cells (n=3, mean±SD, *P≤0.05). (B) IRF-1 mRNA in 
control, siRhoH and RhoH cells were determined using quantitative SYBR Green Real-Time PCR, IRF-1 specific primers 
and GAPDH as reference gene. Obtained data was normalised against GAPDH reference gene expression and presented as 
fold induction of IRF-1 gene expression detected in empty vector transduced cells induction of IRF-1 gene expression 
detected in control cells. Statistical relevance was determined using Student`s t-test (n=3, mean ± SD; *P≤0.05). 
Interestingly siRhoH cells exhibited increased mRNA levels of IRF-1 compared to control 
cells, although RhoH overexpressing cells showed a prominent upregulation of IRF-1 mRNA 
levels as well. The upregulation of IRF-1 in siRhoH cells lead to the conclusion that a lack of 
RhoH in the cells induces IL-3 dependent STAT5 activation, eventually resulting in enhanced 
IRF-1 expression and by this leading to an increased expression of CD123 on the cell surface. 
These findings were also in line with the previously observed increased sensitivity to IL-3, 
since the increased CD123 surface expression may allow these cells to react with higher 
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efficiency to the addition of IL-3, than cells with less CD123 on their surface. IRF-1 is a well 
known target of STAT1 activation and is reported to have tumour suppressor functions26. The 
elevated IRF-1 expression detected in RhoH cells could be a result of the enhanced STAT1 
activation caused by RhoH overexpression with other transcriptional consequences in the cells 
than the regulation of CD123 expression. 
4.1.7  RhoH reconstitution correlated with a downregulation of 
prognostic AML markers in THP-1 cells 
 
As mentioned above overexpression of the IL-3 receptor is a characteristic prognostic marker 
of AML cells111,112. Additional studies showed that there might be a correlation of constitutive 
STAT5 activation on the expression of the transcription factor IRF-1 finally resulting in the 
overexpression of CD123110. Moreover, recent publications highlighted the fact that AML 
cells also show decreased RhoH expression levels, which is associated with bad prognosis for 
patients54. To check whether the phenotype observed in AML cells could be caused by a lack 
of RhoH- and thereby be compensated through the reconstitution of RhoH, experiments with 
the AML cell line THP-1 were performed.  
(A) 
 
Fig. 4.9 AML cell line THP-1 mimics siRhoH phenotype  
(A) THP-1 cells transfected with either pMX-IRES-HA-RhoH or pMX-
IRES empty vector (Mock) were lysed 48 h post transfection. Samples were 
separated using 4-20% gradient SDS-PAGE. HA-expression and β-actin 
loading control were detected using enhanced chemiluminescence. (B) 
FACS analysis of CD123 in Mock and RhoH transfected THP-1 cells was 
performed using a CD123-APC antibody, specifity was determined with 
APC-labeled isotype control. Quantification of CD123 expression was 
determined using mean fluorescence values. Presented as percentage of 
detected CD123 mean fluorescence signal in control cells (n=3, mean ± SD, 
*P≤0.05). (B) IRF-1 mRNA levels in Mock and RhoH overexpressing THP-
1 cells, determined using quantitative SYBR Green Real-Time PCR, IRF-1 
specific primers and GAPDH as reference gene. Data was normalised 
against reference gene expression and presented as fold induction of IRF-1 
gene expression detected in control cells. Statistical relevance was 
determined using Student`s t-test (n=3, mean ± SD; ***P≤0.005). 
(B) 
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(C) 
 
The monocytic THP-1 lineage is generated from a patient suffering from AML. First, human 
HA-tagged RhoH and the corresponding empty vector were transduced into THP-1 cells and 
expression was proved via western-blot (Fig. 4.9A). Next, cells were FACS analysed for 
CD123 expression (Fig 4.9B). Comparing control cell with HA-RhoH transfected cells it 
became apparent that the overexpression of RhoH, led to an approximate decrease of 60% in 
CD123 surface expression (Fig. 4.9B). To prove that the RhoH induced reduction of STAT5 
activity would consequently lead to a decrease of IRF-1 expression in these cells, control and 
RhoH transfected cells were analysed for IRF-1 expression on mRNA levels (Fig 4.9C). The 
observed IRF-1 levels in RhoH transfected versus control cells confirmed that through the 
reconstitution of RhoH into the AML cells, the THP-1 characteristic prognostic markers, 
CD123 and IRF-1 expression were downregulated, most likely through the RhoH induced 
inhibition of STAT5, and thus it was able to link the prognostic CD123 expression in AML 
cells to RhoH expression levels. 
 
4.1.8  RhoH expression pattern in lymphoma derived cell lines  
 
CD123 overexpression53 as well as low RhoH expression levels54 were independently from 
each other described as two negative prognostic markers for acute myeloid leukaemia. In an 
attempt to analyse other hematopoetic cell lines derived lymphoma for a yet unknown 
correlation with RhoH expression patterns, different leukaemia cell lines were subject to 
investigations. 40 to 60% of diagnosed ALCL inhabit a chromosomal rearrangement leading 
to the formation of the fusion protein NPM-ALK. Patient prognoses of NPM-ALK+ (positive 
for NPM-ALK) lymphoma are generally considered worse than that of patients negative (-) 
for this specific rearrangement. This is due to the fact that the rearrangement results in the 
formation of a constitutively active version of the anaplastic lymphoma kinase, which seem to 
be involved in the activation of various tumorigenic signalling pathways113. In regard to the 
previous observations made in RhoH underexpressing BaF3 cells and AML cells, it was of 
particular interest to determine whether an underexpression of RhoH would be detectable in 
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different ALCL subtypes and if these findings would correlate with the expression pattern of 
the NPM-ALK fusion protein. To further specificy the observed phenomena on their lineage 
specifity, not only NPM-ALK positive and negative lineages were tested for their RhoH 
expression, but also other lymphoma derived lineages, such as B-cell Non-Hodgkin 
Lymphoma subtypes and mantle cell lymphoma types. As a positive control for RhoH 
expression, the human T-cell line Jurkat, with known expression, of RhoH61, and as a 
negative control for RhoH expression the breast cancer cell cline MCF-7 was analysed on 
mRNA level. Data were first normalised against the expression of the reference gene HPRT 
and than normalised against the RhoH levels detected in Jurkat cells (Fig. 4.10).  
 (A)  
 
 
  
(B) 
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(C) 
 
 
  
(D) 
 
 
 
 
Fig. 4.10 RhoH underexpression in lymphoma derived cell lines  
RhoH mRNA was analysed from indicated cell lines, using quantitative SYBR green PCR and primers directed 
against human RhoH and the reference gene HPRT.The human breast cancer cell line MCF-7 served as negative 
control, while RhoH mRNA levels detected in Jurkat cells marked base line of RhoH expression. RhoH expression 
was normalised against HPRT and compared to expression levels detected in Jurkat cells. Statistical relevance was 
determined using Student`s t-test (n=3, mean± SD; *P≤0.05, **P≤0.01, ***P≤0.005) 
 
Interestingly, almost all ALCL types showed a significant downregulation of RhoH 
expression, compared to that of Jurkat cells, indicated by the baseline. The most prominent 
downregulation could be detected in NPM-ALK- Mac2A cells, while the lowest regulation of 
RhoH was observed in the NPM-ALK+ DEL cell line. However, a direct correlation between 
NPM-ALK fusion gene expression in ALCL cells and a certain RhoH expression pattern was 
not found. When comparing the results of RhoH expression in B-cell NHL, ALCL and B-cell 
mantle lymphomas there was a clear downregulation of RhoH detectable in ALCL and B-cell 
NHL cell lines. The two analysed B-cell mantle cell lymphomas, as well as the B-cell NHL 
cell line NCEB, showed an enhanced or almost equal level of RhoH expression in comparison 
to Jurkat cells. 
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4.1.9  Proteomics of RhoH in IL-3 dependent cell lines 
 
To gain insight into how RhoH in detail interferes with IL-3 dependent signalling, GST-
pulldown assays with recombinant GST-RhoH and lysates of BaF3 cells treated and untreated 
with IL-3 were performed. Resulting eluates were subject to mass spectrometric analysis with 
the aim to identify new interaction partners of RhoH, with special relevance for IL-3 
dependent signalling events. To exclude unspecific binding two negative controls were used 
for pulldown assay. GST-only protein (25 kDa) was produced with E. coli transformed with 
GST-2T empty vector and additionally a T36A mutant variant of RhoH (resulting in an 
constitutive inactive variation of RhoH85) was cloned into GST-2T vector and the correlating 
recombinant protein was produced and used as an additional negative control (Fig 4.11). 
 
Fig. 4.11 Work-Flow Proteomics of RhoH 
Produced GST fusion proteins were coupled to GSH Beads and incubated with lysates of BaF3 cells which were previously 
kept in IL-3 containing medium or were cultured 10-15 hours under IL-3 withdrawal in RMPI medium with 0.1 % BSA. 
Beads were washed and GST-fusion proteins were eluated from beads. After eluation samples were prepared for LC/MSMS 
and peptide fragments of interacting proteins were then identified using Mascot IPI software. Previously published or 
interaction partner of RhoH (Syk, Rho GDI 1 and 2), or expected hits (GST, RhoH) were identified and sorted out from hit-
list.  
 
The resulting recombinant GST-fusion proteins (45 kDa) were purified using columns packed 
with GSH-beads. SDS Page and Coomassie Blue staining of the purified proteins from the 
columns showed that there was indeed production of recombinant GST-fusion proteins of the 
expected size, as well as stable expression of GST-only protein detectable (Fig. 4.12A). 
However it should be mentioned that recombinant RhoH expression in E.coli is difficult to 
perform and requires six times the volume that is required, for instance for the production of 
GST-only protein (1 litre), since the induction of RhoH protein expression seems to be toxic 
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for bacteria. Additionally there was fragmentation of the final GST-RhoH-fusion protein (Fig 
4.12B). The recombinant production of RhoH required stepwise substantial process 
improvement by careful selection of optimal production temperature, volume as well as the 
time frame of protein expression. Samples for mass spectrometric analysis were prepared 
from eluates collected from columns containing fusion-protein coupled beads which were 
incubated with lysates generated from either IL-3 treated or untreated cells. 
 
(A) (B) 
 
 
Fig. 4.12 Recombinantly produced GST-fusion proteins 
(A) BL21 bacteria were transformed with GST-only, GST-RhoH and GST-RhoH-T36A, expression was induced and lysates 
prepared. After coupling to GSH beads, samples were run on gradient SDS-PAGE (4-20 %) (B) Western-blot analysis of 
GST-RhoH fusion protein production after induction of expression with different IPTG concentration, expression was 
allowed for 3 hours prior to lysis of BL21cells. Proteins were separated using 4-20% gradient SDS-PAGE. 
 
4.1.9.1 Statistical evaluation of MS protein hits - Cytokine dependent binding events 
Mass spectrometric data was analysed and related to proteins using the IPI-mouse databank. 
The results of two technical and two biological experiments, were combined and processed as 
follows: one peptide hits were considered as insolid hits and thereby removed, also proteins 
simultaneously occurring in GST-only, as well as in the RhoH and T36A samples, were 
removed. Known interaction partners (Zap7089, Syk114, GDI´s61) and GST, and RhoH itself 
were also considered as control proteins, and their identification was interpreted as indication 
for proper work-flow and experimental integrity. Next, redundant protein hits were combined 
and finally, to exclude further unspecific hits, results were checked for E. coli sequence 
homologues. Processed data was than manually sorted according to their “binding pattern” 
(Appendix Tab. 6.1.1). For instance, some proteins were found to bind only to wt-RhoH and 
only when cells were treated with IL-3, others were binding exclusively to the T36A-RhoH 
protein and this again only when cells were treated with IL-3.  
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Tab. 4.1 Binding “pattern” of RhoH interaction partners 
 
Tab. 4.1 Binding patthern of RhoH 
interaction partners Listing of resulting 
groups of interaction partners when hits 
were sorted according to their binding 
behaviour to either wt-RhoH (RhoH) or 
T36A-RhoH indicated as T36 in regard of 
cytokine treatment (+/- IL-3) 
 
From this interaction behaviour a chart with different binding conditions was postulated 
(Tab.4.1). Surprisingly, when protein interaction partners of wt RhoH and RhoH T36A were 
combined and statistically evaluated in a cytokine treatment dependent manner (Fig 4.13) it 
became clear that 115 proteins can bind to RhoH when cells were cultivated in IL-3 prior to 
their lysis, in addition, 133 proteins can bind to T36A under the same conditions. From these 
hits 31 were specific binding partners of wt-RhoH and 49 seem to be specific for T36A. 
Interestingly there was an overlap of 84 proteins being able to bind both the wt, and therefore 
active, GTP bound RhoH as well as the negative and conformational inactive variant T36A in 
a strictly IL-3 dependent manner (Fig. 4.13A). Numbers of interacting proteins in IL-3 
untreated samples were comparable between wt-RhoH (61), and T36A variant. Again there 
was an intersection of 38 proteins being able to bind to wt-RhoH and T36A variant (Fig 
4.13B). The examination of the numbers of the binding proteins in dependency of the 
cytokine treatment from these evaluations already suggested a strong relevance of IL-3 
treatment. The numbers of the interacting proteins seem to decrease by 50% when 
recombinant proteins were incubated with lysates of cells cultured under IL-3 withdrawal 
(Fig. 4.13 A, 4.13 B). This phenomenon becomes even more apparent when binding partners 
of the same recombinant sample are sorted according to their cytokine dependency (Fig. 
4.13C, 4.13D). From the total of 116 RhoH wt specific binding candidates, 83 are specifically 
occurring when cells are maintained in IL-3 prior to their lysis, only 28 proteins seem to bind 
only when cells were kept under starvation conditions and the binding of an intersection of 33 
proteins remains to be unaffected by the cytokine treatment of the cells (Fig. 4.13C). In the 
case of T36A a similar effect was observed (Fig. 4.13D), from a total of 133 interaction 
partners for the T36A mutant of RhoH, 91 only bound when beads were incubated with IL-3 
treated lysates, 24 were binding only when cells are not treated with IL-3 and an intersection 
of 42 proteins seemed to bind generally and independent of the IL-3 treatment (Fig. 4.13D). 
These findings on the one hand indicated that there is a surprisingly high number of 
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interacting proteins which seem to be “blind” for the conformational changes of RhoH, 
induced by the T36A mutation. On the other hand, in line with the previous findings of this 
study, it was found that the binding of proteins interacting with RhoH seem to be strongly 
influenced by the IL-3 treatment of the cells, suggesting a specific IL-3 dependent role for 
RhoH in BaF3 cells. As aim of this work is to elucidate the role of RhoH in IL-3 dependent 
signalling the focus of further studies was directed towards hits occurring in wt-RhoH. For 
further studies in this work T36A specific hits were neglected. 
 
(A) (B) 
 
 
Fig. 4.13 Statistical evaluation of RhoH interaction partners: Venn diagrams  
(A) Comparison of interaction partner, wt-RhoH (RhoH) versus T36A-RhoH (T36A) variant found in lysates of IL-3 treated 
BaF3 cells samples (upper panel), lower panel comparison of interaction RhoH versus RhoH T36A variant found in lysates 
of BaF3 cells after IL-3 withdrawal. (B) Comparison of detected interaction partner, form lysates of IL-3 treated BaF3 cells 
versus IL-3 untreated BaF3 cells, upper panel wt-RhoH lower panel T36A-RhoH variant. 
 
To gain insight into the function of the RhoH wt binding proteins under different cytokine 
conditions a function dependent segmentation of the interacting protein hits was performed 
(Fig 4.14). It was found that under IL-3 containing conditions, RhoH apppeared to bind 
preferentially to proteins, involved into metabolic processes in the cell (Fig. 4.14A), these 
interactions occured to lesser extent when cells were kept under IL-3 withdrawal. This 
supported the previous findings in which RhoH inhibited cytokine induced proliferation. 
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Fig. 4.14 Statistical evaluation of according to gene ontology of RhoH interacting proteins 
(A) Gene ontology of RhoH interacting proteins binding exclusively when BaF3 cells were treated with IL-3 prior to lysis 
(B) Gene ontology of RhoH interacting proteins binding independently of previous cytokine treatment of lysed cells.  
(C) Gene ontology of RhoH interacting proteins found exclusively when cells were lysed after IL-3 deprivation -3. 
 
4.1.9.2 Subcellular distribution of RhoH and T36A interacting proteins depends on IL-3  
There are several publications in which RhoH is shown to be incorporated after 
posttranslational modifications on its CKIF motif into the lipid rafts of cells68,87,89,115. 
Cytokine stimulation is reported to induce protein trafficking and recruitment in the cell116 
which is important for various ongoing signal transducing mechanisms, such as cell 
proliferation. Cytokine induced posttranslational modifications of proteins can influence their 
ability to bind to certain adaptor proteins, which results in the accumulation of proteins into 
different cell compartments117,118. To clarify whether the capability of proteins to interact with 
RhoH changes with IL-3 treatment and to gain insight into possible consequences on 
functional and signal transduction of IL-3 withdrawal on RhoH mediated signalling, the 
interaction partners of RhoH, were sorted according to their localisation within the cell and in 
dependency of cytokine treatment.  
 
By this, the importance of cytokine induced posttranslational modifications of cellular 
proteins leading to an enhanced binding capacity to RhoH would be clarified. Also the 
validation would address the question of whether there is a cytokine dependent influence of 
preferred RhoH binding to specific groups of proteins. Additionally, the data generated from 
the T36A mutant was also reviewed and checked for similarities in the subcellular distribution 
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between wt RhoH and T36A binding interaction partners since this mutant still inhabits a 
functional CAAX-box, which was reported to play an important role in protein-protein 
interaction64.  
 
First hits were sorted in different interaction patterns depending on the cytokine treatment 
(Tab. 4.1). The majority of protein hits showed a clear affiliation to one of the resulting 
groups but there was also a cluster of proteins of randomly occurring hits. Assuming that 
these proteins are most likely unspecific interactions, the focus was set on the proteins of the 
remaining groups with clear affiliation patterns. Comparison of the statistical distribution of 
the hits detected in RhoH wt samples incubated with IL-3 treated cell lysates (Fig. 4.15) with 
the distribution pattern of interaction partners found in samples without IL-3 treatment or with 
samples of the T36A mutant, regardless of the cytokine treatment, it showed that 14% of 
interacting proteins were related to the cytoskeleton (Fig. 4.15A). This was not present in all 
other samples (Fig. 4.15B, C, D). Another remarkable observation was made when the 
section of “nuclear” located hits of the cytokine treated wt RhoH sample (Fig. 4.15A) was 
compared to the hits occurring in the other samples. The contingent of nuclear located 
proteins increased from 5% in RhoH wt samples with IL-3 treatment as high as 30% in the 
other samples (Fig. 4.15B, C, D). The subcellular evaluation of the interaction partner 
indicated that RhoH seemed to be able to interact with differently localised proteins in the cell 
upon IL-3 treatment, most likely depending on their cytokine induced altered posttranslational 
conformation. Also this statistical read-out was interpreted as indication that RhoH might 
shuttle, depending on IL-3 treatment, between the nucleus and the cytoplasmic compartments 
of the cell. Furthermore it was clarified that although the T36A mutation of RhoH does not 
seem to directly influence the binding capacity of the GTPase, it did however decrease the 
ability of the protein to efficiently interact with proteins located in the cytoskeleton.   
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Fig. 4.15 Statistical evaluations of RhoH /RhoH T36A interacting proteins according to their subcellular localisation 
in dependency of IL-3 treatment 
(A) Subcellular localisation of RhoH (wt) interacting proteins when recombinant GST-fusion proteins were incubated with 
lysates of IL-3 treated cells. (B) Subcellular localisation of RhoH (wt) interacting proteins when recombinant GST-fusion 
proteins were incubated with lysates of cells cultivated under IL-3 withdrawal. (C) Subcellular localisation of RhoH-T36A 
interacting proteins when recombinant GST-fusion proteins were incubated with lysates of IL-3 treated cells. (D) 
Subcellular localisation of RhoH-T36A interacting proteins when recombinant GST-fusion proteins were incubated with 
lysates of cells cultivated under IL-3 withdrawal. 
 
4.1.9.2.1 IL-3 dependent localisation of RhoH  
To address the question of whether there is an IL-3 depending “shuttling” of RhoH, as 
indicated by the mass spectrometry data, BaF3 cells were retrovirally infected with flag-
tagged RhoH (Fig. 4.16A). Transduced cells were either kept under IL-3 starvation conditions 
or were starved and restimulated with IL-3. They were then intracellularly stained with a 
FITC labelled flag-tag antibody. First microscopic analysis suggested that there might be an 
IL-3 dependent shuttling of RhoH, partly explaining the generated mass spectrometry analysis 
(Fig. 4.16A). After IL-3 treatment however RhoH still is located in the nucleus but is also 
clearly to a higher percentage present in the cytoplasmic region of the cells. At the same time 
it seemed that starvation of IL-3 induces RhoH protein degradation (Fig. 4.16A). Lysosomal 
processing of RhoH, and thereby regulation of RhoH, is already known to be an early event 
after proximal TCR activation72. Another initial experiment was performed to provide further 
insight to the intracellular distribution of RhoH on protein level (Fig. 4.16B). IL-3 treated and 
untreated BaF3 cells were lysed to obtain nuclear and cytoplasmic fractions. Western-blot 
analysis of RhoH protein and β-Actin as an indicator for the cytoplasmic fraction, appeared to 
confirm the preliminary microscopy. In this experiment RhoH was detected in the 
cytoplasmic fraction of IL-3 treated cells, while in cells cultured without IL-3 no RhoH 
protein was detectable. 
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(A) 
 
(B) 
 
Fig.4.16 IL-3 dependent subcellular localisation of 
RhoH  
(A) Confocal microscopy of IL-3 treated (upper panel) or 
starved (lower panel) BaF3 cells transduced with Flag-
RhoH overexpressing vector. First row shows nuclear 
staining with Höchst, second row shows staining of Flag 
tagged RhoH with FITC labeled flag antibody, third row 
show overlay of Höchst and FITC staining (B) Following 
IL-3 cultivation or three hours of starvation BaF3 cells 
cell proteins were separated into nuclear and cytoplasmic 
fraction. Lysates were separated using 4-20 % gradient 
SDS-PAGE. Cytoplasmic contents were indicated by 
detection of β-actin.  
 
In both conditions RhoH was detectable in the nuclear fraction. However, to make final 
conlusions the experiment needs to be repeated with more appropriate loading controls for the 
cytoplasmic (e.g Tubulin) instead of β-Actin, as well as for the nuclear fraction (e.g Lamin). 
 
4.1.9.3 Verifying RhoH protein interactions – Cofilin-1 (Cof-1) 
The mass spectrometry analysis revealed Cofilin-1 (Cof-1), a 19 kDa sized, ubiquitous protein 
as a RhoH interacting candidate in IL-3 treated samples. Cof-1 is a promoter of actin 
polymerisation and filament elongation119. As a downstream effector of  the GTPases Rac1 
and Cdc42 it is known as a key molecule of cytoskeleton rearrangement74. To verify the data 
obtained from the mass spectrometry experiments, the binding of RhoH to Cof-1 was tested in 
HEK cells. HEK cells were cotransfected with HA tagged RhoH and GFP-Cof-1. HEK cells 
lack IL-3 receptor surface expression, as such, HEK cells required treatment with sodium 
ortho vanadate (Na3VO4), which inactivates phosphatases and thereby mimics an IL-3 treated 
activation state. It was found that in HEK cells the interaction of Cof-1 and RhoH only 
occurred when cells were activated by Na3VO4 prior to lysis (Fig. 4.17).  
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Fig. 4.17 Verification of RhoH interacting protein 
Cofilin-1 in HEK cells HEK cells were cotransfected with 
GFP-Cofilin-1 overexpression and HA-RhoH overexpression 
vectors or with empty vector only (control) for 48 hours. 
HEKcells were treated with 1mM Na3VO4 or left untreated, 
lysed and IP was performed using either antibody against 
Cofilin-1. Samples were separated using gradient (4-20%) 
SDS PAGE. Precipitated proteins were targeted using 
antibodies against RhoH (lower panel) and Cofilin-1 (upper 
panel) and were detected with enhanced chemiluminescence. 
This binding of RhoH and Cof-1 confirms the results of the mass spectrometry analysis and 
also suggests that also in BaF3 cells the interaction of RhoH and Cof-1 would occur only after 
IL-3 treatment of the cells. This interaction partner of RhoH could contribute to future 
understanding of how RhoH takes part in cytoskeleton related processes such as migration of 
hematopoietic cells by a mechanism other than the previously reported inhibition of other 
GTPases85,87.  
 
4.1.9.4 Verifying RhoH protein interactions- Protein tyrosine phosphatase 1B (PTP1B) 
The mass spectrometry analysis revealed the ubiquitously expressed phosphatase PTP1B, a 50 
kDa sized protein, as a RhoH interacting candidate in IL-3 treated samples. Different 
publications show that PTP1B is able to target the JAK-STAT signalling pathway20,120-122 and 
IL-3 dependent proliferation 123. Therefore the potential interaction of RhoH with PTP1B may 
have contributed to the observed RhoH modulated IL-3 dependent effects. To verify the 
specificity of the binding of RhoH to PTB1B, HEK cells were cotransfected with flag-tagged 
RhoH and PTP1B. Again, because of the lack of IL-3 receptor on HEK cells, treatment with 
Na3VO4 was required. The results showed that in HEK cells the interaction of PTP1B and 
RhoH is only formed when cells were set in a state of activation, and is not detectable when 
cells remain in an inactivated state (Fig. 4. 18). 
 
Fig. 4.18 Verification of RhoH interacting 
protein PTP1B in HEK cells  
HEK cells were cotransfected with PTP1B 
overexpression and HA-RhoH overexpression 
vectors or with empty vector only (control), for 48 
hours. HEK cells were treated with 1mM Na3VO4 
or left untreated, lysed and IP was performed using 
antibody against PTP1B. Samples were separated 
using gradient (4-20%) SDS page. Precipitated 
proteins were targeted using antibodies against 
RhoH (lower panel) and PTP1B (upper panel) and 
were detected with enhanced chemiluminescence.  
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4.2  RhoH in IL-3 derived bone marrow MCs 
 
The aim of this work included investigations of the physiological role of RhoH on IL-3 
dependent processes in murine MC. In early studies supernatant derived from mitogen-
activated T-cells was used to induce MC differentiation124,125.IL-3 was identified to be the 
cytokine which directed the differentiation of CD34+/c-Kit+ cells into functional MCs126,127. 
However, the details of the signalling cascade that triggers the differentiation to MCs remains 
fairly unknown. RhoH has been reported to be of importance for the development, survival 
and the differentiation of hematopoietic progenitor cells85. Together with the previous 
findings of this study regarding its relevance for IL-3 mediated signal transduction and its 
effect on CDKI expression it was decided to elaborate the impact of a lack of RhoH for IL-3 
mediated differentiation and of murine hematopoietic progenitor cells to functional MCs in 
more detail. 
4.2.1  RhoH mRNA expression in IL-3 derived murine MCs  
 
The relevance of RhoH for IL-3 mediated MC development from HPC was investigated. It 
was assumed that unregulated or extremely low expression levels of RhoH would suggest a 
minor role for the atypical GTPase in the differentiation and function of murine MCs. Bone 
marrow cells (BMCs) isolated from C57BL/6 wt mice femurs were cultivated for 27-30 days 
in IL-3 containing medium. mRNA samples isolated from these progenitor cells at different 
time points and RhoH expression was measured using quantitative real-time PCR and 
GAPDH as reference gene (Fig. 4.19). The results of the quantification of RhoH mRNA 
levels show a decrease of approx. 40% of RhoH mRNA on day 5 (compared to day 0), 
followed by an upregulation of RhoH mRNA and remains stably expressed at this level 
during the period of cultivation. From these results it was assumed that RhoH plays a defined 
role in the process of IL-3 dependent murine MC signalling. 
 
Fig. 4.19 RhoH mRNA expression in 
murine HPCs differentiating to mast 
cells over 27 days (4-weeks) wt mice 
BMCs were isolated (day 0) and cultivated 
in IL-3 containing medium for 4 weeks. At 
indicated time points, mRNA was prepared 
and RhoH expression was detected using 
RhoH specific primers, GAPDH served as 
reference. RhoH expression was 
normalised against GAPDH and are shown 
fold induction in comparison to day O. 
Presented results from one representative 
experiment performed in duplicates ± SD 
(n=3) 
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4.2.2  RhoH null HPCs show elevated IL-3 induced proliferation 
 
It was tested whether the findings made in the BaF3 model system were transferable to the 
more physiologic system of MCs. Therefore the IL-3 dependent proliferation behaviour of yet 
undifferentiated hematopoietic progenitors from RhoH null mice in comparison to wt mice 
progenitor cells was observed. The proliferation assay was performed early after isolation of 
BMCs, which was posted between day three and day five after isolation of cells from the bone 
marrow. A Cell Titer Glo assay was performed to measure ATP levels after cells were 
cultivated for 24 hours at distinct IL-3 concentrations (Fig. 4.20A). The read out of this assay 
showed that IL-3 concentrations higher than 0.01 ng/ml were able to induce proliferation of 
cells both, from RhoH null and wt mice origin. While wt progenitor cells reached a plateau of 
proliferation at 0.1 ng/ml, RhoH null progenitor cells showed a remarkable ongoing increase 
in proliferation (Fig. 4.20A).  
(A) 
 
(B) (C) 
 
 
Fig. 4.20 IL-3 induced proliferation, IRF-1 expression and CD123 surface expression in progenitors from RhoH 
deficient are similar to that observed in siRhoH BaF3 cells  
(A) IL-3 dose response curve of RhoH null and wt progenitor cells (day 3-5 after preparation) cultivated for 48 h in medium 
with indicated IL-3 concentrations. Viability of cells was analysed by ATP determination in a Cell Titer Glo assay. 
Presented results from one representative experiment performed in triplicates ± SD (n=2). (B) FACS analysis of CD123 
surface expression on wt and RhoH null progenitor cells in IL-3 containing medium, was performed using a murine CD123-
PE antibody. Antibody specifity was controlled by the usage of correlating PE-labeled antibody isotype reagent. Presented 
results from one representative experiment (n=3). (C) Normalised IRF-1 mRNA levels detected in progenitor cells 
cultivated 3-5 days in IL-3 containing medium using quantitative SYBR green Real-Time PCR with IRF-1 specific primers 
and GAPDH as a reference gene. Presented results from one representative experiment performed in duplicates (n=2). 
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The impressive observation of RhoH null proliferation response to cultivation in IL-3 
containing medium confirmed that RhoH indeed functions as a negative regulator of IL-3 
dependent proliferation not only in the BaF3 model system, but also in progenitor cells. From 
this experiment it was concluded that RhoH deficient progenitor cells show, similar to siRhoH 
cells, an increase in IL-3 induced proliferation. To clarify whether these increased 
proliferation rates were due to an increased sensitivity to IL-3 and thereby enhanced pro-
proliferative signal delivery to the progenitor cells lacking RhoH expression, the surface 
expression of CD123 was determined using FACS analysis (Fig. 4.20B). Here again the 
previous results obtained from the model system BaF3 cells with knock-down of RhoH were 
able to be reproduced in RhoH null mice progenitor cells. Indeed RhoH deficient progenitor 
cells showed a substantially higher surface expression of CD123 than wt progenitors. This 
enhanced CD123 expression was detectable over the period of differentiation and mast-cell in 
vitro cultivation. Since the elevated CD123 levels in siRhoH cells were a result of enhanced 
expression of the STAT5 dependent trabscription factor IRF-1, IRF-1 mRNA levels of 
progenitor cells lacking RhoH in comparison to that found in wt mice were analysed using 
quantitative PCR to clarify whether the observed effects in MCs were related to that observed 
in siRhoH cells (Fig. 4.20C). The results of the IRF-1 mRNA quantification suggested that 
there may be the same correlation between enhanced STAT5 dependent IRF-1 expressions 
which ended up in elevated CD123 surface expression in IL-3 cultivated progenitor cells.  
4.2.3.  RhoH null HPCs show lower p21waf/cip1 and p27kip1 mRNA 
expression only in early phase of IL-3 cultivation 
 
It was hypothesised that the increased proliferation observed in RhoH null progenitors could 
be indicative of a defective ability to differentiate in response to IL-3 into MCs, due to a 
shorter duration phase of cells in the G1-phase. Studies made with pluripotent cells showed 
that upon decreased entry of cells into G1-phase, the differentiation and cell-fate-decision 
processes are introduced128. In turn, cells that show high rates of cell division seem to be more 
resistant to these processes129. The mRNA levels of the cell cycle inhibitors p21waf/cip1 and 
p27kip1 were measured in freshly isolated and in IL-3 cultivated bone marrow progenitor cells 
from RhoH null mice and wt mice (Fig. 4.21A). The detected CDKI levels were normalised 
against GAPDH and were compared (fold induction). The results showed that p21waf/cip1 and 
especially p27kip1 show an increased expression than measured in hematopoietic progenitors 
from wt mice in the early stage of cultivation with IL-3. P21waf/cip1 34 showed a 4-fold higher 
mRNA expression in normal progenitor cells and p27kip1 mRNA levels, were found to be 14-
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fold higher in progenitor cells expressing RhoH in the early cultivation state. To check 
whether the decreased expression of p21waf/cip1 and p27kip1are stable during the differentiation 
of the RhoH null progenitor cells to MCs, p21waf/cip1 and p27kip1expression was tested in 
different stages of differentiation (Fig. 4.21B). Interestingly, expression differences in 
p21waf/cip1 and p27kip1 were found to diminish after the early state of cultivation in IL-3 (day 3-
5), and p27kip1seem even to be slightly, increased in RhoH-/- cells. This dynamic recovery of 
p21waf/cip1 and p27kip1mRNA expression levels of RhoH ko mice indicated that RhoH deficient 
progenitors may proliferate with increased rates and show less duration in G1-phase in the 
very early state of in vitro culture in IL-3. Although there were clear differences in the early 
expression of p21waf/cip1 and p27kip1the proceeding efficient upregulation of CDKI expression 
levels indicated that proliferation rate of RhoH null progenitor cells will decrease during the 
course of MC differtentiation in IL-3 containing medium.  
(A)  (B) 
 
 
Fig. 4.21 RhoH null progenitor cells dynamically upregulate CDKIs during mast cell differentiation  
(A) mRNA from BMC of wt and RhoH null mice, day 3-5 after preparation (cultivated in IL-3 containing medium)was 
prepared and analysed for CDKI p21waf/cip1 and p27kip1 expression with quantitative SYBR green real-time PCR. P21waf/cip1 
and p27kip1 levels were normalised against the reference gene GAPDH and presented as fold induction compared to levels 
detected in wt mice. Presented results from one representative experiment performed in duplicates (n=2). (B) mRNA from 
progenitor cells of wt and RhoH null mice, after day 5 were cultivated in IL-3 containing medium was prepared and CDKI 
p21waf/cip1 and p27kip1 expression was quantified SYBR green real-time PCR and p21waf/cip1/p27kip1 specific primer. P21waf/cip1 
and p27kip1 levels were normalised against the reference gene GAPDH and presented as fold induction compared to levels 
detected in wt mice. Presented results from one representative experiment performed in duplicates (n=3) and presented as 
fold induction compared to wt mice.   
4.2.4.  RhoH null progenitors show no differences in the 
differentiation to MCs  
 
The IL-3 induced differentiation capability of HPC of RhoH null mice to develop into MCs 
was tested by analysing the MC specific markers c-Kit and FcεRI during MC differentiation. 
For this purpose RhoH null and wt progenitors were cultivated 4 weeks in IL-3 containing 
medium. Each week the expression pattern of FcεRI and c-Kit receptor were analysed after 
IgE mediated activation of the cells. The FACS analysis of c-Kit and FcεRI expression of 
RhoH null MCs in comparison to RhoH wt MCs indicated no differences in MC 
development(Fig. 4.22A), the same was true for all time points (data not shown). To address 
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the question of morphologic differences between RhoH deficient and wt MCs, which could 
occur independently of the expression of MC specific surface markers MC specific 
histological Touluidine Blue staining of MCs was also performed. The metachromatic 
staining of MCs derived from RhoH null and wt mice indicated no obvious morphologic 
abnormalities between RhoH null and wt MCs (Fig. 4.22B). Additional western-blot analysis 
of MC specific proteases confirmed that RhoH null progenitors can differentiate to MCs (Fig. 
4.22C).However, these in vitro experiments do not clarify the in vivo situation regarding MC 
development, number and distribution in RhoH KO mice. 
(A) 
 
(B) 
 
(C) 
 
Fig. 4.22 RhoH-/- progenitor cells differentiate to morphological typical 
mast cells  
(A)FACS analysis of mature MCs (right panel: wt, left panel: RhoH null) MCs 
were activated with 1% IgE overnight and co-stained with PE-c-KIT and 
FTIC-FcεRI antibody. Presented results from one representative experiment 
(n=3). (B) Cytopspins from bone marrow derived MCs (week 4) were prepared 
and stained with Touluidine Blue (n=2)(C) Lysates of MCs from RhoH ko and 
wt mice as well as dendritic cells (DCs) from control mice were prepared and 
separated using 12% SDS PAGE. Proteins were detected using enhanced 
chemicluminescence. Presented result from one representative experiment 
(n=2). 
4.2.5.  RhoH is important for FcεRI mediated degranulation of MCs 
There were no obvious morphologic differences reported for neutrophils generated from 
RhoH ko mice. However, the GM-CSF induced neutrophil specific release of leucotriene, and 
thereby the function of neutrophils, was found to be impaired in RhoH ko mice106. To check 
whether the same would be true for MC specific functions of IL-3 derived RhoH ko MCs, 
showing previously no obvious morphologic or developmental defects, the antigen triggered 
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release of the major mediator of anaphylaxis, histamine, was measured. β-hexsosaminidase 
assays were performed using fully differentiated IL-3 derived MCs from RhoH ko and wt 
mice. Degranulation of MCs was triggered after the antigen, trinitrophenol (TNP)-haptenised 
ovalbumin (OVA), induced aggregation of the IgE bound FcεRI, therefore MCs were first 
incubated with 1% anti-TNP-OVA-IgE conditioned medium and then challenged with distinct 
concentrations of TNP-OVA (0-10 ng/ml). The released as well as the remaining intracellular 
MC mediators were measured. The measurement of this enzyme is a parameter allowing 
inferences on the release of MC specific mediators, including histamine. Interestingly, the 
results of the colourimetric reaction indicated defective MC antigen mediated degranulation 
of RhoH deficient MCs. At each TNP-OVA concentration RhoH deficient MCs were found to 
degranulate to a lesser extent than wt MCs. Most remarkably at the lowest TNP-OVA 
concentration of 0.0001 ng/ml RhoH ko MCs were found to degranulate to less than 25% of 
the degranulation potential detected in wt MCs (Fig. 4.23). Even at the highest TNP-OVA 
concentration of 10 ng/ml the MCs lacking RhoH show degranulation decreased to 60% of 
the amount measured in wt MCs (Fig. 4.23). These experiments suggest that even though 
RhoH does not play a role in the IL-3 dependent differentiation of MCs, the antigen mediated 
function of MCs, such as degranulation, seem to suffer from the lack of RhoH and that there 
may be defects in FcεRI mediated signal transduction. 
 
 
Fig. 4.23 Defective histamine release of 
RhoH null mast cells  
Histamine release of MCs derived from 
RhoH null and wt mice BMCs, previously 
activated with 1% anti-TNP-OVA-IgE 
overnight and incubated with indicated 
concentrations of antigen TNP-OVA for 1h. 
Degranulation was determined by β-
hexosaminidase release. Presented results 
from one representative experiment 
performed in triplicates (mean ± SD); n=2.  
4.2.6.  RhoH-/- MCs show impaired release of IL-6 and TNF-α  
 
To address the question of functional defects caused by a lack of RhoH in MCs, cytokine 
release was determined. MCs are known to release pro-inflammatory cytokines in response to 
antigen challenge and thereby induce and promote immune responses in the organism130. 
Degranulation of MCs was again triggered by TNP-haptenised OVA induced aggregation of 
the IgE bound FcεRI. From previous hexsosaminidase experiment it was concluded that an 
antigen concentration of 0.1 ng/ml would be sufficient to trigger efficient MC cytokine 
release. The comparing the released cytokine concentrations showed that there were again 
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strong differences between MCs of wt and RhoH ko animals (Fig. 4.24). The release of the 
pro-inflammatory cytokine IL-6, which is known to target immune cells such as T-cells and 
other cell types131,132, was remarkably decreased in MCs of RhoH deficient mice (Fig. 4.24A). 
In comparison to wt MCs, which released about 420 ng/ml of IL-6, RhoH deficient MCs were 
only capable of releasing less than the half this amount of IL-6, with a concentration of 
approx. 200 ng/ml. The decrease in TNF-α release, also playing a major role in host immune 
defence and inflammatory reactions133 was even more impressive (Fig. 4.24B). While antigen 
challenged wt MCs released about 380 ng/ml, of TNF-α the release from RhoH deficient 
MCs was negligible. Again this observed defect in antigen induced cytokine release indicated 
that downstream signalling of FcεRI mediated signals are impaired due to the lack of RhoH. 
(A) (B) 
 
 
Fig. 4.24 Defective cytokine release of RhoH null mast cells  
(A)IL-6 release of MCs derived from RhoH null and wt mice BMCs, previously activated with 1% anti-TNP-OVA-IgE 
overnight and either treated with 10 ng/ml TNP-OVA or left untreated for 5 h. Release was determined by IL-6 specific 
ELISA. Presented results from one representative experiment performed in triplicates (mean ± SD) n=2. (B) TNF-α release 
of MCs derived from RhoH null and wt mice BMCs, previously activated with 1% anti-TNP-OVA-IgE overnight and either 
treated with 10 ng/ml TNP-OVA or left untreated for 5 h. Release was determined by TNF-α specific ELISA. Presented 
results from one representative experiment performed in triplicates (mean ± SD) n=2.  
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5.  Discussion 
5.1  RhoH expression is regulated by IL-3 and modulates IL-3 
induced proliferation 
 
The results of this study have demonstrated that RhoH functions as an inhibitor of IL-3 
dependent cell proliferation. Neither the starvation nor the long-term cultivation of IL-3 
dependent BaF3 cells was shown to have an effect on the regulation of RhoH expression 
levels. Only treatment of starved cells with IL-3 caused a downregulation of RhoH mRNA 
levels within 5 hours (Fig. 4.1). The results confirmed a transcriptional regulation of RhoH in 
IL-3 mediated signal transduction. Transcriptional regulation of RhoH was already shown by 
pervious studies to to be crucial for proper signalling in T-lymphocytes and neutrophils61,106. 
In contrast to this study the treatment of T-lymphocytes and neutrophils with PMA or GM-
CSF led to an increase of RhoH expression and thereby the transcriptional upregulation of 
RhoH was interpreted as indication for a functional role of RhoH in the defined cell subsets 
by the investigators61,106. However, since RhoH is known to be a negative regulator of 
hematopoietic cell proliferation85 it was assumed that IL-3 dependent induction of 
proliferation would most probably cause a decrease of endogenous RhoH levels to allow 
proproliferative signalling. The considerably high levels of RhoH, when cells are kept 
continuously in IL-3 containing medium and after IL-3 starvation (Fig. 4.1), suggests that 
RhoH levels are dynamically upregulated and remain enhanced to control events involved in 
IL-3 mediated signalling. Analysis of IL-3 dependent cell proliferation with altered RhoH 
levels confirmed previous work of Liu in which high RhoH levels had a specific inhibitory 
effect on IL-3 dependent proliferation regardless of the IL-3 concentration102 in comparison to 
parental BaF3 cells (Fig. 4.3). In this study an additional control (Mock), as well as RhoH 
underexpressing cells were included into CTG proliferation analysis, proofing the reliability 
of the previous results102. While the proliferation assay with constant IL-3 concentrations 
shows rather small differences between the proliferation rates of the distinct cell lines (Fig. 
4.3A), the CTG assays clarify the inhibitory effect of RhoH on IL-3 mediated proliferation 
(Fig. 4.3B). Assays were carried out with empty vector transduced cells as control. Since 
shRNA was used for knock-down of RhoH it should be considered to use BaF3 cell 
transduced with control shRNA containing vector as additional control for proliferation as 
well as signalling experiments to disclude shRNA mediated off-target effects.  
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However, since RhoH underexpressing cells seem to reach inhibitory levels of proliferation at 
latter time points, future experiments could include the investigation of proteins which are 
involved in contact inhibition of proliferation, which might be deregulated by a lack of RhoH 
134,135
. RhoH is a known negative regulator of the adhesion protein LFA-1136 and also of 
Rac161,87, several reports show that adhesion molecules, as well as the GTPase Rac1, are 
taking a substantial part in mediating growth inhibiton134,135. The results also highlighted that 
the inhibitory effects that RhoH had on proliferation were specific for IL-3 induced 
proliferation and are not detectable when the cytokine IL-3 is replaced by the growth factor 
Epo (Fig 4.3C). Although, Epo does not belong to the IL-3 family of cytokines15. To check 
whether some of the observed effects may result from a RhoH dependent deregulated 
signalling of the common β chain of the IL-3 receptor further proliferation experiments with 
IL-5 and GM-CSF should be considered since JAK-STAT mediated signaltransduction, for 
example, is reported to depended partly on the on the common β chain of the IL-3 receptor13. 
Finally it would be interesting to investigate the consequences on IL-3 dependent proliferation 
of the T36A mutant variant of RhoH, since it is reported that SCF-1 mediated proliferation in 
HPCs remains unaffected when the T36A variant instead of wt RhoH is transduced into the 
cells.  
5.2  RhoH: Fine-tuning of IL-3 dependent JAK-STAT signalling 
 
The JAK-STAT pathway is one of the major signalling cascades in hematopoietic cells, 
controlling cell survival, proliferation and differentation137,138. STAT1 is known to initiate the 
transcription of genes leading to cell cycle arrest or apoptosis in cells30. RhoH expression was 
reported to induce apoptosis in HPCs, explaining the observed decreased cell counts85. 
Preliminary data from Lius` work suggest that increased RhoH levels modulate 
STAT1/STAT5 activity102. However, these experiments were performed with parental BaF3 
cells as control cell line and did not include the investigation of RhoH underexpressing cells. 
In this study it was confirmed that increased RhoH expression amplified IL-3 induced STAT1 
phosphorylation (Fig. 4.4) in comparison to empty vector transduced cell line. The FACS 
experiments imply slightly less IL-3 induced STAT1 phosphorylation in siRhoH cells 
compared to control cells. The significance of this difference however was not determined 
during this study and can be subject for future experiments. The STAT1 activation did not 
lead to enhanced apoptosis, instead it resulted in enhanced expression of the STAT1 
dependent CDKIs p21waf/cip1  and p27kip1 34, 30(Fig 4.5). However, as well as being regulated by 
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STAT1, p27kip1 has also been described to be modulated following IL-3 treatment of cells108. 
The enhanced expression of CDKIs was a result of RhoH overexpression, suggesting an 
increasead G1 cell cycle arrest in RhoH cells. The induction of a cell cycle arrest however 
remains to be carried out in further experiments and would support the hypothesis that there is 
a different mechanism in the IL-3 dependent system by which RhoH can inhibit cell counts 
other than its known role in inducing apoptosis in HPCs85.  
 
While the induction of STAT1 by IL-3 is poorly described, IL-3 is well known as a potent 
inducer of STAT5 phosphorylation, which initiates the transcription of genes required for 
proliferation and survival 22. Previously generated data from Liu suggested that RhoH 
overexpression results in decreased IL-3 induced STAT5 phosphorylation102. However, these 
studies used parental cells as control cell line instead of empty vector transfected cells. 
Analysis of empty vector transfected cells is of special importance since virus particle based 
transduction of cells may target immunestimulatory pathways139 and thereby modulate STAT 
activity. Furthermore, the previous data did not provide solid information about the 
phosphorylation state of STAT5 in RhoH underexpressing cells102. In this study it was 
confirmed that enhanced RhoH expression is able to inhibit the phosporylation of STAT5 and 
thereby its activation following IL-3 treatment (Fig. 4.6A), it was also found that the shRNA 
mediated regulation of RhoH expression resulted in enhanced levels of IL-3 induced STAT5 
phosphorylation (Fig. 4.6). The elevated STAT5 activation was difficult to reveal on the first 
sight using the STAT5 IP results, because of increased total STAT5 levels. However the 
signal quantification and additional FACS (Fig. 4.6B) experiments supported the increase in 
IL-3 induced STAT5 activation in siRhoH cells, which eventually leads to an increased 
transcription of genes, important for cell cycle progression and the recovery from IL-3 
starvation. A potent downregulation of p21waf/cip1 and p27kip1 protein levels was not detectable 
in siRhoH BaF3 cells, compared to control cells. This could be a result of the already weak 
expression levels of RhoH in BaF3 cells61. Further, shRNA mediated downregulation of 
RhoH in BaF3 cells may not cause a decrease in the expression of the CDKIs as this could 
probably be detected when endogenous RhoH expression levels are on a higher level. To thest 
this hypothesis shRNA mediated knock-downs of RhoH, in IL-3 dependent cell lines with 
higher endogenous RhoH expression remain to be performed and tested on the expression 
changes of p21waf/cip1 and p27kip1.  
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Although low levels of RhoH did not protect cells from apoptosis caused by cytokine 
withdrawal in the first instance, cells underexpressing RhoH were found to be able to recover 
from long-term IL-3 withdrawal in comparision to control cells (Fig. 4.7). This suggested that 
siRhoh cells are able to react with higher efficiency to the cytokine IL-3, while parental cells 
expressing higher levels of RhoH failed to respond with recovery and proliferation. This 
hyptothesis was confirmed by the finding that RhoH overexpressing cells showed decreased 
surface expression of the IL-3 receptor alpha chain CD123, while cells with low RhoH 
expression exhibited increased expression of CD123 (Fig. 4.8A). This increased in CD123 
surface expression in siRhoH cells was comparably low and showed high variation between 
experiments. It was assumed that the variations strongly depended on the shRNA mediated 
RhoH knock-down efficiency and that the slight increase in CD123 expression could be a 
result of already weak endogenous RhoH expression in BaF3 cells and further downregulation 
of RhoH as performed in this study would not lead to a stong induction of CD123 expression. 
Nevertheless, it was hypothised that low RhoH levels induce an enhanced activation of 
STAT5 in response to IL-3 and the elevated expression of the transcription factor IRF-1 (Fig. 
4.8B). The ability to recover from cytokine withdrawal as well as the increased proliferation 
rate of siRhoH cells can be dedicated to the enhanced delivery of proliferative and survival 
supporting signals by the increased IRF-1 mediated CD123 surface expression. 
 
IRF-1 is classically known to be involved in interferon-1/STAT1 dependent signal 
transduction140-142 but which was also reported to be a STAT5 dependent early response gene 
in G-CSF mediated signaltransduction in neutrophils10. The surface expression of CD123 is 
thought to be a result of STAT5 dependent IRF-1 expression in AML cells110. Interestingly, 
RhoH overexpressing cells also showed a slightly elevated level of IRF-1 expression (Fig. 
4.8B) compared to control cells, which is not surprising considering the elevated STAT1 
activation in response to IL-3 in RhoH BaF3 cells. As mentioned above, IRF-1 is classically 
described as a target of STAT1 mediated signalling25 therefore the enhanced STAT1 
phoshorylation in RhoH cells leads to elevated IRF-1 expression, with different signalling 
targets than the CD123 surface expression observed in siRhoH cells. Similar observations of 
insignificant STAT1 mediated IRF-1 regulation were made in studies investigating signalling 
pathways induced by G-CSF10. 
 
This result, in particular, highlights that RhoH expression may function as a tool to finetune 
IL-3 mediated proliferative and inhibitory STAT dependent signals by tandem activation of 
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either STAT1 or STAT5 and their target genes. In both cases, STAT5 and STAT1 activation, 
the outcome of experiments performed with an inactive RhoH mutant would be highly 
interesting. Although data from previously performed reporter gene assays of the Kubatzky 
lab exist, suggesting a RhoH modulated IL-3 dependent STAT1 and STAT5 transcriptional 
activity102, futher investigations of the transcriptional activity of STAT5 specifically leading 
to IRF-1 expression in comparison to appropriate control cells need to be conducted. 
Additionally experiments to investigate the IRF-1 regulated CD123 expression in BaF3 cells, 
remain to be performed. Additionaly, CD123 expression should be tested on cells with higher 
endogenous RhoH levels after shRNA mediated RhoH knock-down to further investigate the 
increase in CD123 expression. 
5.3  RhoH expression in THP-1 cells, correlates with 
increased IRF-1 and decreased CD123 expression 
 
Enhanced CD123 expression, together with increased STAT5 phosphorylation and elevated 
IRF-1 expression are reported to be characteristic features of primitive AML cells110. The 
observed effects are described to result in higher cell proliferation rates and are considered as 
negative factors for patient prognosis110,111. Other investigations demonstrated that RhoH gene 
expression in AML cells is remarkably decreased and that lower RhoH levels are also 
considered as poor prognostic marker for patient survival54. In this study the observed effects 
in siRhoH cells were connected to the AML characteristic features using the AML derived 
monocytic cell line THP-1 as model system (Fig. 4.9). It was demonstrated that reconstitution 
of RhoH expression in THP-1 cells lowered both IRF-1 expression and CD123 surface 
expression. RhoH reconstitution is suggested to inhibit the elevated STAT5 activation in these 
cells, thereby targeting the STAT5 induced IRF-1 expression, which finally leads to lower 
CD123 surface expression in THP-1 cells. However, complementary experiments showing the 
changes of STAT5 activation, following RhoH reconstitution in THP-1 cells remain to be 
carried out. Like in the BaF3 system, these studies need to include the investigation of 
eventually occurring RhoH dependent changes of the proliferation behaviour of THP-1 cells. 
Additionaly the transcriptional activity of IRF-1 remains to be determined to clarify the 
impact of RhoH modulated STAT5 activation. Studies investigating the treatment of AML 
have suggested targeting of CD123 on AML blasts with IL-3 ligand variants fused to catalytic 
portions of bacterial toxins143. However, the use of such a treatment in humans could cause 
unexpected and unfavourable adverse effects, since CD123 is also present on other cell types 
such as different progenitor subsets144. A promising approach to treat AML could therefore be 
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the targeted reconstitution of RhoH in AML cells or the attempt to find molecular candidates 
leading to an upregulation of endogenous RhoH expression in the malignant cells. 
5.3.1  RhoH is underexpressed in lymphoma derived cell lines with 
abberant signalling patterns and immunophenotype 
 
Elevated STAT5 activation, as well as the altered resistance to cytokine withdrawal and 
enhanced proliferation rates as observed in RhoH underexpressing cells during the course of 
this study, are broadly found among malignant hematopoetic disorders145,146. In a first attempt 
to identify additional hematopoietic malignancies where RhoH underexpression may be 
involved in cancer progression was performed by comparing the effects caused by a lack of 
RhoH with described leukemia features. Different cell lines derived from B-cell Non-Hodgkin 
lymphoma (B-NHL), as well as from ALCL lineages, were analysed upon their RhoH mRNA 
expression (Fig. 4.10).  
 
ALCL are described as a biologically and clinically heterogeneous subtype of peripheral T-
cell lymphoma, with an aberrant immunophentotype90. ALCL can commonly be detected to 
inhabit chromosomal translocations, of which mostly the tyrosine kinase, ALK is found to be 
under the promoter control of the nucleolar phosphoprotein NPM91-92. Studies indicate that 
upon expression of NPM-ALK enhanced STAT3 and STAT5 phosphorylation results 
correlating with higher cell cycle progression rates and cytokine independent growth 95,96. 
There is growing evidence that the constitutive activation of small GTPases such as Rac1 and 
Cdc42 are contributing to the oncogenic features of NPM-ALK rearrangements in systemic 
ALCL97,98 and the enhanced expression of RhoH is reported to have an inhibitory effect on 
the activity of other GTPases, such as Rac1and Cdc42 61,87. Proteomic analysis of NPM-ALK 
positive and negative cells also revealed also the downregulation of the phosphatase PTP, 
which was demonstrated during this work to be an interaction partner of RhoH (Fig 4.18), to 
the cancer progressive attributes of NPM-ALK positive cells147. Most interestingly ALCL 
cells are reported displaying peculiar T-cell immunophentoypes, which is the phenotype of 
cells of hematopoietic neoplasms defined according to their resemblance to normal T-cells. 
ALCL are commonly deficient for TCR and T-cell receptor associated molecules Zap70 and 
CD3 expression148and CD4/CD8 expression148. Studies of RhoH in T-cells revealed its 
importance for TCR mediated thymocyte selection and maturation and for TCR mediated 
CD3ζ phosphorylation and Zap70 recruitment to the immunological synapse, indicating that 
RhoH is a component of the TCR signalling complex88,89. Together with the previous findings 
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of this work, in which RhoH acted as an inhibitor of IL-3 induced proliferation via 
modulation of the JAK-STAT signalling pathway it was hypothised that in particular ALCL 
derived cell lines, and in more detail the NPM-ALK+ ALCL types, because of their reported 
STAT signalling signature, would show a characteristic downregulation of RhoH. The 
analysis of the RhoH mRNA levels demonstrated that NPM-ALK positive, as well as NPM-
ALK negative ALCL types, exhibited significantly lower expression of RhoH than control 
cells (Fig. 4.10A, 4.10B). Further studies will be required to address the question of the role 
and consequences of a loss of RhoH expression in ALCL subtypes. Sequential 
phosphoproteomic analysis or cDNA microarrays performed with ALCL subtypes, or ALCL 
cells with different RhoH expression levels, could indicate in which direction the 
reconstitution of RhoH, which was shown to be required for proper TCR signalling, would 
drive the ALCL characteristic immonophenotype. In order to gain further insight into the role 
of RhoH in ALCL disease progression further investigations including the abnormal ALCL 
phentoype, will be cruical to our understanding of the molecular mechansims of this disease.  
 
Interestingly most of the the analysed B-NHL subtypes also showed prominent and significant 
downregulation of RhoH on mRNA level (Fig. 4.10D). This lymphoma type exhibits 
constitutive STAT5 activation, which allows the generation of B-cell precursors growing and 
surviving in a cytokine independent state149. Remarkably RhoH was reported to be targeted 
for aberrant somatic hypermutations99,150, as well as aberrant chromosomal rearrangements151 
but not described to be underexpressed in this lymphoma subtype. The results of this study 
showed that these cells seem to underexpress RhoH as well, although the T-lymphocyte 
Jurkat served as a control cell line and not a B-cell line, which would be more comparable in 
terms of proper gene expression analysis. In the future studies of RhoH underexpression and 
its consequences should be subject of further investigation. However, cell lines of other B-cell 
lineages, the so called NHL mantle cell lymphoma subtypes, were also analysed to determine 
the RhoH expression levels. Surprisingly, in this subtype the RhoH expression was slightly 
higher than the expression levels detected in Jurkat cells (Fig. 4.10C).  
 
Mantle cell lymphoma, is an aggressive lymphoma type with t(11;14)(q13;q32) translocation 
that is reported to express uniquely high levels of cyclin D1, approximately four-fold higher 
than detected in other B-cell lymphoma types. The oncogenic protein cyclin D1 is a major 
activator of the cell cycle machinery and is described to be transcriptionally regulated by 
STAT5152. In healthy mature B-lymphocytes cyclin D1 is known to be downregulated 153. 
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Considering the connection of RhoH to the cell cycle machinery via counterregulating the IL-
3 dependent STAT1 /STAT5 activation, in particular through the modulation of the STAT1 
dependent CDKIs, the detected upregulation of RhoH in mantle cells could be the result of the 
cells effort to use inhibitory mechanisms to neutralise elevated cell cycle progression. 
However, mantle cell lymphoma shows an increased proteosomal degradation of CDKIs, 
leading to their depletion154. Therefore the attempt of the cell to inhibit cell cycle progression 
by enhanced RhoH expression is unlikely to succeed. Even so, studies made with B-cell 
chronic lymphocytic leukaemia (CLL) also showed an upregulation of RhoH mRNA levels, 
positively correlating with the expression of Zap70 which is a prognostic marker in aggressive 
CLL (approx. 65% of all diagnosed patient samples)155. Zap70, which enhances B cell 
receptor signalling and thereby contributes to the pathogenesis of CLL, is known to interact 
with RhoH in order to mediate proper T-cell receptor signalling89. It was demonstrated that 
the loss of RhoH contributes to a significant delay in disease progression101. However, only 
8% of mantle cell lymphomas are found to overexpress Zap70 155, which highlights that in the 
case of mantle cell lymphoma, RhoH may play a different functional role.  
 
5.4  RhoH interaction partner binding is IL-3 dependent 
 
Proteomics is a powerful tool for gaining insight into target protein interactions as well as 
signalling cascades involved in the function of the investigated protein. In order to obtain a 
detailed understanding of how RhoH interferes with IL-3 dependent signalling, and is thereby 
able to modify major hematopoietic signalling cascades such as the JAK-STAT pathway, 
GST-pulldown assays were performed with recombinant GST-fusion proteins. These assays 
were carried out with recombinant GST-fusion proteins of wt RhoH and the T36A effector 
domain mutant variant of RhoH, being incubated with lysates of IL-3 treated and untreated 
BaF3 cells. The resulting protein eluates were subject to mass spectrometry analysis (Fig 
4.18). The aim was to identify new interaction partners of RhoH, with particular relevance for 
IL-3 dependent signalling and more-over to understand other as yet unresolved questions 
about the function of RhoH in the IL-3 dependent cell system.  
 
Mass spectrometry is a highly sensitive method, which increases the tendency for false 
positive hits. GST-fusion proteins were produced and purified from E.coli. In theory, only 
proteins with GST-tag should stick to GSH-beads. However, many bacterial proteins are 
  Discussion 
 
 
86 
 
known to interact unspecifically with the target protein and the complete removal from the 
final GST-fusion protein is not possible. This is why the GST-only sample was included as a 
negative control into the experimental layout. Detected proteins from thsese samples were 
excluded for further evaluation. Additionally the results of all mass spectrometry runs were 
cross analysed in an E.coli peptide data base. This was required to exclude potential E.coli 
proteins from further investigations, although there is chance that some highly conserved 
proteins of eukaryotic origin might also be excluded. Another common source of error are 
protein clusters. Many proteins are forming signalling complexes by physical interactions. 
Even if only one candidate of the cluster is actually able to directly interact with the target 
protein there is a high possibility to detect several proteins of the cluster with mass 
spectrometry. Multiple washing steps within the purification procedure, as well as technical 
and biological replicates as applied in this study are thought to diminish but not to fully erase 
unspecific hits. To further optimize the statistical relevance of the detected hits irregular 
occurring peptides, such as non-reproducable hits (within the biological/technical replicates) 
and single peptide hits (from one protein, in one run) were also removed from the list of 
potential RhoH interaction candidates. Despite all these procedures, the resulting protein hits 
obtained from the mass spectrometry data were considered only as indications for a possible 
protein interaction between RhoH and the corresponding protein. 
 
The statistical analysis of the results of these studies was remarkable and gave raise to a 
number of new questions. The study of protein binding to the target proteins resulting from 
the differently cytokine treated cells confirmed that protein binding and therefore downstream 
signalling of RhoH, depends to a great extend on the prior presence of the IL-3 stimulus 
(Fig.4.13). A closer look at the gene ontology function of the identified IL-3 dependent 
interaction partners, confirmed not only that the number of binding partners differs, but also 
their mediated cellular functions (Fig. 4.15). 35% of the candidates interacting with RhoH 
under IL-3 treated conditions were found to be involved in nucleic acid processes. The 
precentage of interacting partners with the same gene ontology increases to 46% when cells 
were starved before. Another example for the functional shift depending on the IL-3 treatment 
are proteins with functional responsibilities in the cytoskeleton. The proportion of proteins 
found in lysates of cytokine treated cells is about 16% and drops, in regard to the total number 
of interactions, to 9% in the group of cytokine independent bindings and is even lower with 
7% after cytokine withdrawal (Tab. 6.1.2.1 Appendix). 
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The explanation for this phenomenon of the cytokine treatment dependent changes of the 
function of interacting proteins, are most likely posttranslational modifications. The previous 
cytokine treatment leads to the activation or inactivation of proteins allowing or preventing 
specific interactions with RhoH. However, not only posttranslational modifications can 
depend on cytokine treatment, but also the protein expression of the found interaction partners 
may be affected by the cytokine treatment. The transcription and protein expression of 
particular genes is initiated when the IL-3 signal is received. Posttranslational modifications 
initiated by cytokines are broadly reported and are known to influence the protein interaction 
ability of proteins. The same is true for the expression and synthesis of new proteins, which is 
only efficiently promoted when cells are receiving sufficient signals to enter the interphase 
state. Also, IL-3 deprivation of BaF3 cells is able to introduce apoptosis leading to the 
subsequent degradation of proteins which otherwise would be able to interact with RhoH. 
Taken together these data support the IL-3 dependent involvement of RhoH in signalling 
pathways through altered protein binding patterns depending on IL-3 treatment.  
 
5.4.1  Similar proteins can bind to RhoH and to its effector domain 
mutant variant  
 
An unexpected functional conlusion was made about RhoH regarding its ability to interact 
with proteins when studying the interactions occurring between wt RhoH and with its 
supposed loss-of-function mutant T36A. The effector domain T36 in GTP binding proteins is 
reported to be fundamental for GTP binding, as well as for the interaction with downstream 
effectors60. The analysis of the binding patterns of proteins (Tab. 4.1) to the different RhoH 
versions suggested that there are indeed several proteins which are able to bind to RhoH 
despite the T36A mutation. As these interactions never occurred in GST-only samples the 
detected candidates were considered to be solid and specific interactions. There is only one 
report using the T36A variation of RhoH as an inactive control, for HPC growth assays. The 
proliferation assays performed with the mutant variant demonstrated that the inhibitory 
function of RhoH on SCF-1 mediated proliferation is lost when cells were transduced with the 
T36A mutant variant instead of wt RhoH85. The authors suggest that this is simply due to the 
inability of the protein to interact with its downstream effectors85,156. However, the results of 
the RhoH proteomic analysis performed in this study suggest a broader answer to the 
observed phenomenon.  
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The observations of this study indicate that in the case of the atypical GTPase RhoH a simple 
mutation of its key threonin, located at the switch region, is not sufficient to abolish possible 
interactions in IL-3 mediated signalling. Even if the T36A mutation is still crucial for the 
RhoH mediated suppression of growth factor induced effects in HPCs85, there could be 
different interactions and functions of RhoH, still mediated by its other Rho protein typical 
structural compartments (Fig. 5.1). Different publications have described the importance of 
the C-terminal CAAX-box of small GTPases, which is required for the proper localisation of 
GTPases for protein interactions, as well as for the GTPase function and for the interaction of 
GTPases with other proteins68,157. Similar observations were made for RhoH´s C-terminal 
CKIF motif, where the cross-talk between RhoH and Rac1 in the regulation of the actin 
cytoskeleton of hematopoietic progenitor cells was proven to depend on RhoH CAAX box83. 
RhoH also inhabits a unique ITAM motif, which most likely serves as a docking site for 
Zap7089 and Syk101,114. In this study the interaction of RhoH with Syk was only detectable 
among the interactions which were able to bind to wt RhoH (when cells were previously 
treated with IL-3). Other reported interaction partners of RhoH are GDIs61. In contrast to the 
interaction of RhoH with Syk, the α isoform of RhoGDI detected during the mass 
spectrometry analysis, appeared as an interaction partner of RhoH that seems to bind 
independent of the presence of threonine on position 36 in RhoH, (Tab.6.1.1.2 Appendix) but 
only in IL-3 treated cells. To further clarify and understand the importance of structural key 
elements of RhoH and their importance for RhoH modulated IL-3 dependent signal 
transduction it is required to continue the mass spectrometry based, as well as biochemical 
and immunological protein interaction, investigations of RhoH interacting proteins with 
different structural modified versions of RhoH, such as the deletion of the putative NLS in the 
polybasic region, the CKIF motif as well as with mutation variants of the RhoH ITAM-motif 
and again the T36A variant of RhoH.  
 
 
Fig. 5.1 Structural 
domains of GTPases 
serving as protein 
interaction sites  
The different regions of 
RhoGTPases are serving as 
interaction sites for 
regulatory and effector 
proteins (switch I, switch 
II, Rho insert, Polybasic 
region (PBR), CAAX motif 
) (modified from 
DerMardirossian and 
Bokoch, 2005) 
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5.4.2  IL-3 treatment determines the subcellular localisation of RhoH 
interacting proteins 
 
Cytokine stimulation causes protein trafficking and recruitment in the cell. This process of 
protein recruitment is important for various ongoing signal transduction mechanisms inducing 
cell proliferation, polarisiation, migration and motility. Cytokine induced posttranslational 
modifications of proteins can influence their ability to bind to certain adaptor proteins, which 
introduce the accumulation of proteins into different cell compartments117,157 The subdivision 
of all detected interaction partner of each sample (wt, T36A-RhoH) under each condition 
(with IL-3 treatment, without IL-3 treatment) according to their “classical” cellular 
localisation gave further insight on the subcellular mechanisms RhoH may be involved in 
(Fig. 4.15). The majority of protein hits showed a clear affiliation to one of the resulting 
groups but there was also a cluster of proteins of randomly occurring hits (Tab. 4.1) “No 
pattern”). Assuming that these proteins are most likely unspecific interactions, this study 
focused on the proteins of the remaining groups with clear affiliation patterns. IL-3 treatment 
caused interactions of RhoH with proteins that were localised to the cytoskeleton, while this 
compartment disappeared when comparing to the sorted T36A group. This compartment also 
was not present in the samples of the cytokine withdrawed samples (Fig. 4.15). On the other 
hand, among the hits specifically for IL-3 starved samples and for the mutant RhoH variant, 
there were increased fractions of nuclear proteins detectable (Fig. 4.15). This strongly 
indicated that the stimulation level not only defined the interacting protein but in more detail 
also seemed to affects the localisation and the functional role of the interacting protein. The 
mutation of T36A(+IL-3), which is thought to result in a loss-of-function mutant of RhoH, 
showed remarkable differences in the subcellular distribution of the binding partners when 
compared to those found in wt RhoH. This circumstance, however, highlights that this region 
of fundemental functional importance for typical GTPases, may also play a profound role in 
RhoH, when defining the origin of proteins that can bind to RhoH.  
 
5.4.3.1 IL-3 dependent subcellular localisation of RhoH  
The statistical evaluation of the mass spectrometry data implied a cytokine dependent cycling 
of RhoH into different cell compartments since the absence or presence of the cytokine was a 
major factor in defining the nature and the subcellular distribution of the interacting 
candidates. The Rho GTPase Rac1 facilitates different functions in the cell which are 
specified by its subcellular localisation, it is shown to cycle between cytoplasm and the 
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nucleus where it is thought to play a role in cell proliferation158. In response to growth factors 
and chemokines, Rho GTPases such as Rac1 and RhoA are known to accumulate in the cell 
membrane where they direct cytokineses and focal adhesion159. Initial experiments with the 
IL-3 dependent cell line BaF3 suggested that at least in the IL-3 dependent system, there may 
be an IL-3 induced recruitment of RhoH from the cytoplasmic fraction to the nuclear 
compartment (Fig. 4.16B). Cytokine withdrawal seem to drive the GTPase RhoH to nuclear 
compartments, while shortly after retreatment with cytokine there is an ubiquitous distribution 
of the GTPase. Several Rho GTPases, such as Rac1, do contain a canonical NLS within their 
polybasic region (PBR)160. PBRs are of importance for the proper function of the GTPases as 
well as for their membrane localisation160. In the case of Rac1 it was shown that the NLS, is 
of importance for the regulation of its nuclear transport, when it is coupled to larger protein 
complexes that are unable to pass through nuclear pores161,162. It remains to be clarified 
whether the polybasic region of RhoH which lacks the canonical NLS, as described by 
Williams160, is still able to mediate a regulated transport of RhoH to the nucleus. If this IL-3 
induced transport turns out to be the case then the consequences would be a more thorough 
understanding of how RhoH is able to interfere with the IL-3 dependent JAK-STAT 
signalling pathway. If the PBR of RhoH does not induce the nuclear localisation of RhoH, 
another interesting aspect would be the identification of the nuclear transport mechanism of 
RhoH. A possible mechanism could be the binding to the protein Importin containing 
complexes, which were observed to facilitate the nuclear import of Rac1-STAT5 complexes 
as well163. Moreover if there is a cytokine dependent recruitment of RhoH to the nucleus by 
starvation; this should be validated by investigations of recruitment-kinetics. The 
microscopical analysis of the cells implies additionally reduced RhoH protein levels after 
starvation (Fig. 4.16A). The western-blot, as well as the microscopic analysis of RhoH 
localisation are only initial experiments and of low quality, for instance future western-blot 
anaylsis, need to include proper controls for the cytoplasmic and nuclear compartmens. RhoH 
is known to be subject to proteosomal degradation after TCR stimulation72. Follow-up 
investigations need to include the observation of RhoH degradation at the protein level in 
order to gain further insight into the functional role of RhoH and the mechanisms by which it 
can be regulated in the IL-3 dependent system.  
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5.4.3  RhoH interacts with Cofilin-1 in HEK cells 
 
Western-blot validations of the mass spectrometry detected interaction partners in HEK cells 
involved Cofilin-1, were carried out (Fig. 4.17). Commonly known as a downstream effector 
of the GTPases Rac1 and Cdc42, Cofilin-1 is a key molecule of cytoskeleton rearrangement 
74
. Rac1 and Cdc42 regulate Cofilin-1 induced actin turn-over by the activation of the p21-
activated kinase (PAK1) which is able to induce the Cofilin-1 inhibiting LIM-kinase 58. RhoH 
itself is reported to take part in the regulation of chemotaxis and homing of hematopoietic 
progenitor cells, mainly by inhibiting proper Rac1 activation and recruitment85,87. However, 
the direct protein interaction of RhoH and Cofilin-1 implies that there could be different 
mechanisms, by which RhoH can modulate cytoskeleton mediated processes. Besides of the 
known “classical” cytoskeleton dependent processes, signal transduction is also known to be 
affected by the cytoskeleton164. JAK-STAT signalling is described to be modulated by actin 
polymerisation events. The downregulation of Growth Hormone (GH) mediated STAT5 
activation is reported to strongly depend on a functional cytoskeleton, since the treatment with 
actin polymerisation inhibitors causes prolonged STAT5 activity165. In this study a lack of 
RhoH was reported to enhance IL-3 induced STAT5 phosphorylation, additionally there were 
preliminary data suggesting a prolonged STAT5 activation as well. However, a possible IL-3 
induced interaction of RhoH with Cofilin-1 could be indicative for the stabilisation of the 
required actin remodelling in the cytoskeleton. In this role, a lack of RhoH would cause a 
disruption in Cofilin-1 mediated actin polymerisation, which eventually leads to the observed 
prolonged STAT5 activity. Also, the observed enhanced STAT5 phosphorylation (Fig. 4.6) 
could be a direct result of the cytoskeletal disturbance as in cells with functional cytoskeleton 
the downregulation of the signal would work more efficient than in cells with defective actin 
polymerisation165. To clarify whether the binding of RhoH modulates the activation of 
Cofilin-1, experiments in which the IL-3 dependent phosphorylation state of Cofilin-1, with 
and without cotransfection of RhoH should be carried out. The experiments in this study were 
carried out in HEK cells, providing high transfection efficiency and uncomplicated handling. 
However, to address the role of the IL-3 stimulus in the formation of the RhoH-Cofilin-1 
binding, the interaction has to be examined in BaF3 cells. Also the initial experiments 
performed in HEK cells require further controls such as a GFP only containing vector 
transduced sample to exclude unspecific protein binding. 
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5.4.4  RhoH interacts with PTP1B in HEK cells 
 
Another interaction of RhoH in the IL-3 dependent system occurs with the protein tyrosine 
phosphatase PTP1B (Fig. 4.18). This interaction was again due to uncomplicated handling 
and high transfection efficiency validated in HEK cells. PTP1B is widely expressed in tissues 
and, due to a C-terminal hydrophobic stretch, (exclusively) localised at the cytoplasmatic face 
endoplasmatic reticulum (ER)122. Different reports confirm PTP1Bs regulatory effect on the 
JAK-STAT pathway 19,120,166. JAK2, TYK 2 as well as both isoforms of STAT5 were found to 
serve as PTP1B substrates. Additionally this phosphatase was found to negatively regulate IL-
3 induced proliferation123. RhoH contains five possible tyrosine phosphorylation sites. In the 
case of the reported interactions between RhoH and Zap70/Syk the phosphorylation of the 
tyrosines in the ITAM motif seem to play a pivotal role89,114, although recent studies are 
controversely discussing the phosphorylation of the putative ITAM in RhoH167. The RhoH-
PTP1B interaction in HEK cells indicates that tyrosine phosphorylated RhoH may serve as a 
substrate for PTP1B. Dephosphorylation of RTKs, by PTP1B, requires the internalisation of 
the phosphorylated receptor168. After dephosphorylation the RTKs are targeted for lysosomal 
degradation169,170. The re-localisation or accumulation of the Rho GTPases at the ER 
however, is indicative for their lysosmal degradation 66. RhoH is thought to be targeted for 
lysosomal degradation with and without activation of the TCR-complex72. To be functional in 
TCR signalling, RhoH is thought to be phosphorylated at its specific ITAM tyrosines89. If IL-
3 induced signal transduction requires RhoH phosphorylation either on its ITAM or on its 
remaining tyrosines this could raise the need for the involvement of a tyrosine phosphatase in 
RhoH modulated IL-3 mediated signal transduction, which introduces the lysosomal 
processing of RhoH by its dephosphorylation. The binding of PTP1B to RhoH was not 
detectable in the Na4VO3 untreated sample, at the same time the results imply lower 
expression level of PTP1B in the same (Fig. 4.18) which could explain why the interaction 
was not detectable in this sample. To learn more about RhoH and its regulatory mechanisms it 
needs to be clarified whether in BaF3 cells, the interaction of RhoH and PTP1B is indeed IL-3 
dependend, and furthermore, if, and on which tyrosines, RhoH gets phosphorylated by the IL-
3 stimulus. PTP1B recognise substrates containing the aa sequence (E/D)-pY-pY-(R/K). The 
screening of the RhoH aa sequence shows no clear evidence for this recognition motif 
(Appendix 6.2), indicating that RhoH might serve as a PTP1B substrate, via a yet unknown 
recognition motif. 
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5.5  Summary and outlook (I): RhoH modulates IL-3 induced 
proliferation by fine-tuning IL-3 dependent JAK-STAT 
signalling  
 
 
Fig. 5.3 Proposed model for RhoH modulated IL-3 induced signaling 
In the case of low RhoH expression IL-3 induces enhanced STAT5 activation followed by an induction of the 
transcriptionfactor IRF-1 which results in enhanced CD123 surface expression eventually leading to increased cell 
proliferation. High RhoH expression leads to enhanced STAT1 phosphorylation and less STAT5 activation. RhoH modulated 
STAT1 activation causes an upregulation of CDKIs p21cip1 and p27kip1 and decreased cell counts by the induction of cell 
cycle arrest.The physical interaction of RhoH with PTP1B and Cofilin-1 are most likely taking part in tandem regulation of 
IL-3 mediated STAT5/STAT1 activation. However, the mechanistic details and functional consequences of these interactions 
remain to be clarified 
 
Of particular interest would be in the future to investigate the effects of T36A variant of 
RhoH on IL-3 mediated proliferation, the phosphorylation of STAT5/STAT1 and on the 
induced gene expression of IRF-1 and CD123. These investigations can be essential to 
address the structural key elements of RhoH for signal transduction and as a negative control 
for experimental procedures. It is of particular interest to address the function of RhoH in IL-3 
mediated signal transduction to the interaction of one or two of the identified interaction 
candidates in this work, to be able to complete the IL-3-RhoH mediated signaltransduction 
pathway. The interaction of RhoH with PTP1B and Cofilin-1 are required to be verified in the 
IL-3 dependent BaF3 system to determine the role of cytokine treatment for the interaction of 
RhoH with its interaction partners. To gain better insight into the function of RhoH structural 
key elemets such as the CKIF motif within the PBR, or the conserved T36, the use of different 
mutant variants for protein interaction and signalling experiments need to be carried out. For 
the future a strong focus could be set on eventually occurring posttranslational modifications, 
also in regard on distinct structural features of RhoH, following IL-3 treatment. This work 
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suggests the involvement of a protein tyrosine phosphatase in RhoH modulated IL-3 
signalling, it needs to be clarified whether IL-3 stimulation is able to induce targeted 
posttranslational modifications of RhoH, such as tyrosine phosphorylation or targeted lipid 
modifications. The overerxpression of different tyrosine mutant variants could further resolve 
the question of the functional importance of the tyrosine phosphorylated residues. The use of 
prenylation inhibitors could provide additional insight into the relevance of C-terminal 
modifications for RhoH modulated IL-3 induced signalling. Also of importance is to draw 
final conlusions about the IL-3 dependent shuttling of RhoH between nuclear and cytoplasmic 
compartments and the relevance of this process for IL-3 mediated signalling. Future work 
needs to further clarify RhoHs involvement in hematopoetic malignancies. In this study the 
focus was set on malignancies which potentially bear siRhoH related “phenotype”. The 
accumulating knowledge about RhoH involvement into TCR signalling was also used to 
profile potential malignancies with RhoH involvement. Ongoing investigations need to 
include RhoH reconsitution experiments in lymphoma derived cell lines, to be able to 
investigate the impact on cancer progression and signalling. Of particular interest could be the 
reconstutiton of RhoH in ALCL gernerated cells and the effects RhoH reconstitution would 
have on the described T-cell phenotype in ALCL gernerated cells and whether RhoH 
expression modulates disease progression or previously described prognostic markers. 
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5.6  The function of RhoH in IL-3 mediated MC differentiation 
and function  
 
Mast cells are most commonly known as mediators of anaphylactic reactions; however, these 
cells also play important roles in innate and adaptive immunity44,171. IL-3 plays a central role 
in the differentiation and maturation of erythroid, megakaryocytic and myeloid lineages172, 
such as MCs171. Processes regulating stem-cell self-renewal and cell differentiation are 
thereby controlled and influenced by cellular signalling pathways which can be activated by 
IL-313 such as STAT5 activation173,174. STAT5 was also demonstrated to play a pivotal role in 
MC development since MCs were reported to be completly absent in tissues of STAT5 a/b 
null mice. In vitro generation of STAT5 deficient MCs was only successful when cells were 
incubated with both cytokines IL-3 and SCF-1. The lack of STAT5 also had a large impact on 
cell cycle progression and cell survival and on late phase response of MCs 37,175. STAT1 
activation, however, is known to play an important role in MC survival and MC mediated 
inflammation176. The studies discussed in this work demonstrated that expression levels of 
RhoH strongly modulated IL-3 dependent STAT5/ STAT1 induced processes in the model 
cell line BaF3. To gain further insight into the physiologic relevance of RhoH and its 
involvement in IL-3 dependent differentiation and signalling, as well as its role for allergic 
reactions, the studies of RhoH in the IL-3 dependent system were continued and emerged 
using murine MCs in vitro differentiated in a strictly IL-3 dependent manner from murine 
femur progenitor cells. 
5.6.1  RhoH mRNA expression is regulated during MC differentiation 
 
The expression of the GTPase RhoH was previously reported to be restricted on 
hematopoietic lineages82. As RhoH is an atypical member of the Rho GTPases lacking an 
intrinsic GTPase activity it is assumed that transcriptional control is an important regulatory 
mechanism for RhoH86. To get a basic idea of the involvement and regulation of RhoH during 
IL-3 dependent MC development, BMCs from wt mice were generated into MCs and RhoH 
mRNA level at distinct time points were measured (Fig 4.19). The outcome of this 
experiment showed a relatively high RhoH expression in freshly isolated bone marrow cells, 
which drops after 5 days of cultivation in IL-3 containing medium. However, this decrease in 
RhoH levels may be explained by a strong IL-3 induced expansion of precursor cells in the 
early phases of differentiation which would most probably require the downregulation of 
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RhoH, a described inhibitor of HPC proliferation85. The IL-3 containing medium 
suppositionally induces a boost in proliferation in the early phases of MC differentiation, 
which would be accompanied by a lower differentiation potential of the progenitor cells. Wt 
BMMCs are described to show a high level of S-phase progression in response to IL-3 or 
SCF-1, peaking by 36 h37. However, cell fate decisions are known to be assessed mainly 
during G1 phase, when cells are in a state of cell cycle arrest177. During the course of MC 
differentiation however, RhoH levels are increasing until the attainment of a plateau value 
which is approx. 2-fold the relative mRNA expression from day 5. This observation strongly 
implicated that RhoH in general seem to play an important role in MC development and 
signalling. Studies investigating the stimulus dependent RhoH mRNA alterations performed 
in T cell derived cell lines or in primary neutrophils were interpreted as indications for a cell 
type specific functional role of RhoH61,106. For final conclusions about the role of RhoH 
during the early phase of IL-3 dependent MC development and in particular for its 
significance for IL-3 induced differentiation, endogenous RhoH levels need to be measured in 
progenitor cells during different states of MC differentiation, in response to SCF-1 another 
reported MC differentiation factor178. A similar RhoH induction caused by SCF-1 during MC 
development would be indicative for an IL-3 independent regulatory mechanism of RhoH in 
MCs. Due to highly varying mRNA levels, the presented results were from one representative 
experiment from a series of 3 independently performed experiments, showing the clearest 
RhoH mRNA differences between day 5 and the following days. However scientifly solid 
data should summarise the outcome of different experiments to provide insight into biologic 
and statistical relevance.  
5.6.2  RhoH null MC progenitors show enhanced proliferation in early 
phases of cultivation in IL-3 containing medium 
 
To test whether the progenitor cells of RhoH null mice cultivated in IL-3 would show similar 
proliferation behaviour as siRhoH cells, a Cell Titer Glo assay was performed using freshly 
isolated cells (Day 3-5 after bone marrow preparation) (Fig. 4.20 A). Several studies showed 
that in vitro exposure of HPCs to cytokines causes a dramatic shift of gene expression patterns 
in which cell division genes are turned on or off in different phases than genes responsible for 
cell engraftment 179-181. The early time frame was chosen upon the hypothesis that with 
proceeding maturation level of the cells the proliferation potential of hematopetiec cells 
decreases considerably182, which would have complicated the detection of proliferation 
differences. However, the results of ATP measurement showed an impressive proliferative 
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difference in response to IL-3 between RhoH null and wt mice progenitors. This leads to the 
conclusion that the lack of RhoH in progenitor cells results, as expected, in elevated 
proliferation. A similar observation was made in siRhoH cells, where RhoH underexpression 
was demonstrated to result in enhanced IL-3 dependent STAT5 phosphorylation leading to 
accelerated proliferation and increased IRF-1 dependent CD123 surface expression. However, 
the observed altered proliferation rate of RhoH deficient progenitors is supposally a result of 
enhanced IL-3 induced STAT5 activation, which is reported to be essential for progenitor cell 
and MC proliferation36,37,109. For final conclusions about the effects caused by lack of RhoH, 
impacting specifically IL-3 induced proliferation of HPCs, the investigation of HPC 
expansion in response to SCF-1 is required. To address the relevance of RhoH for IL-3 
dependent MC development the effects of SCF-1 on progenitor cells deficient for RhoH need 
to be compared. Furthermore, the hypothesis of increased STAT5 activity in RhoH deficient 
progenitor cells in response to IL-3 remain to be confirmed and ideally compared to STAT5 
activation in response to SCF-1, since both cytokines are described to have fairly similar 
effects on STAT activation in MC deveopment178. Again this experiment was performed 
twice and due to high variance between the results only the proliferation assay with optimal 
outcome was presented. For final conlusions however, the assay needs to be optimized for 
solid understanding of the role of RhoH for progenitor proliferation in IL-3 containing 
medium.  
 
To understand the extent of the similarities between the model system BaF3 and the primary 
progenitor cells lacking RhoH, further analysis of the CD123 receptor surface expression was 
performed (Fig. 4.20B). CD123 presence on RhoH null progenitor cells was elevated as 
detected in siRhoH cells. Finally, the mRNA analysis of IRF-1 was also found to be 
upregulated in RhoH null progenitor cells (Fig. 4.20C). Gene expression pattern in stem and 
progenitor cells are changing during developmental processes in response to a cytokine, 
especially the expression of cell cycling genes179-181. Future experiments need to clarify 
whether the altered CD123 and IRF-1 expression, observed in freshly isolated progenitors, 
would be detectable at latter time points, when cells have fully differentiated into MCs. 
Another interesting aspect would be to observe whether SCF-1 as differentiation factor would 
cause similar effects in regard to IRF-1 and CD123 expression in RhoH null progenitors. 
Given the case that SCF-1 and IL-3 mediated MC differentiation of RhoH deficient progenitor 
have different effects regarding proliferation and STAT5 mediated IRF-1 and CD123 
activation, cDNA microarrays and comparison of the gene expression shifts during 
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differentiation could be used to identify particular genes that are significantly regulated by a 
lack of RhoH leading to the final cytokine dependnent phenotype, and eventually to the 
compensation of altered gene expression caused by a lack of RhoH.  
 
The observed enhanced proliferation in response of IL-3 of MC progenitors is in particular 
interesting, since abnormal MC expansion is a major feature of mastocytosis183. Mastocytosis 
is a myeloproliferative disease with unknown prevalence and variants and is known to have 
complex pathologic consequences183,184. Furthermore, the progenitor cells of a subset of 
patients suffering from mastocytosis were found to express higher levels of CD123 surface 
receptor183,184, similar findings were made with progenitors of AML patients185. Nevertheless 
altered CD123 is not described as a diagnostic marker for mastocytosis. It needs to be 
clarified whether RhoH deficiency contributes to the abnormal proliferation pattern of 
mastocytic cells. Also neoplastic MCs in mastocytosis are reported to show altered STAT5 
activation, which is another parallel to the effects detected in siRhoH cells186. To define a role 
of RhoH in mastocytosis, RhoH expression pattern in a subset of systemic and coutaneous 
mastocytosis samples should be determined and the correlation with the STAT5 activation 
found in the samples needs to be investigated. Since mastocytosis and its different subtypes 
are considered to be difficult to distinguish from each other and from other diseases such as 
the hypereosinophilic syndrome187-188, RhoH expression patterns could serve as a additional 
prognostic or diagnostic marker. In the human MC system the functions of the cytokine IL-3 
is replaced by IL-4189. Follow-up studies could include work with human MCs to further 
clarify the context between RhoH and the MC relevant cytokine. The question of whether 
RhoH serves as an IL-3 specific inhibitor of proliferation in this system remains to be 
speculative, since SCF-1 dependent proliferation studies made with RhoH overexpressing 
murine progenitor cells indicated similar inhibitory effects of RhoH on cell proliferation85. 
Due to highly varying IRF-1 mRNA levels, the presented results were from one representative 
experiment from only two successfully performed experiments, showing the clearest IRF-1 
mRNA differences. This is a relatively reduced set of data and the parallels between the 
primary cells and the BaF3 model system remain questionable as long results are not 
standardised.  
5.6.3  No morphologic differences between RhoH null and wt MC 
 
Mature MCs can be distinguished from other cell types such as eosinophils or basophils by 
the expression of the surface markers FcεRI and c-Kit 44. The IL-3 dependent generation of 
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progenitors to MCs in this study was observed by weekly (4 weeks) measurements of the 
FcεRI and c-Kit surface expression, after IgE mediated activation of the cells (Fig.4.22). In 
contrast to Lius` experimental outcomes 102, the results of these experiments suggested no 
obvious developmental abnormalities of RhoH deficient MCs when analysing MC surface 
marker c-Kit and FcεRI. Additionally, the proper expression of the MC specific protease 
MMP-6 was demonstrated and MC specific Toluidine Blue staining of RhoH KO MCs was 
performed showing no developmental differences between wt and ko MCs. However, alcian 
blue stainings190 as well as the analysis of CD13 and T1/ST2191 expression could help to draw 
final conclusions about the proper MC morphology and development. During the course of 
this study, the group of Shirai published their work, investigating FcεRI signalling in RhoH 
KO MCs, in which they confirmed normal MC development of RhoH deficient MCs in vivo 
and in vitro114.  
 
Normal MC development of RhoH KO progenitors was unexpected considering the earlier 
finding of the elevated proliferation rates detected in RhoH KO progenitors, which were 
thought to be indicative for impaired cell development. Since stem cells and the derivative 
progenitor cells are very complex systems and in particular the differentiation of MCs is 
reported to be influenced by numerous factors of their microenviroment49,50 it can be assumed 
that MCs inhabit regulatory feedback mechanisms which can eventually compensate possible 
developmental consequences. It is reported that CDKIs such as p21waf/cip1 and p27kip1, are 
important key molecules contributing to cell fate decisions in HPCs192-196. HSCs from mice 
lacking CDKIs were found to proliferate at elevated rates, and showed altered differentiation 
potential192,193. In the BaF3 model system RhoH-BaF3 cells showed decreased IL-3 induced 
proliferation, resulting from enhanced CDKI levels. It was hypothised that in contrast to the 
observations in siRhoH cells, due to a complete lack of RhoH in the KO animal, the p21waf/cip1 
and p27kip1 may be decreased in early time points after isolation, leading to the enhanced 
proliferation rates in RhoH KO progenitor cells. The results of p21waf/cip1 and p27kip1 mRNA 
measurements in freshly isolated (day 3-5 after preparation) progenitor cells from RhoH null 
and wt mice, cultivated in the presence of IL-3, confirmed this hypothesis (Fig 4.21A). It was 
further hypothised that intracellular feedback mechanisms may be induced, during the course 
of cultivation, which were rapidly regulating the expression of p21waf/cip1 and p27kip1 to a 
normal level, to compensate developmental defects. Repeated measurements of p21waf/cip1 and 
p27kip1 mRNA levels at latter time points (after day 7) consistently showed comparable 
expression levels in RhoH null and wt mice (Fig 4.21B). This observed dynamic adjustment 
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of CDKI levels in RhoH ko progenitors explains at least partly the lack of any developmental 
failures in RhoH ko MCs. The enhancement of the CDKI expression could be a result of a 
stronger regulation of other signalling pathways such as NOTCH2 signalling197 or 
transcripton factors such as members of the EBF family of transcription factors198, which 
were reported to be involved into cell fate decision determination and cell cycle regulation. 
Also an upregulation of STAT1 phosphorylation and activation in RhoH null progenitiors in 
response to IL-3, induced by a RhoH independent, alternative pathway remain to be carried 
out.  
 
5.6.4  The lack of RhoH causes functionial defects in IL-3 derived MCs 
 
Earlier studies made with RhoH ko mice only reported a strong T-cell related phenotype88,89 . 
Nevertheless, later studies performed with in vitro generated neutrophils derived from RhoH 
KO mice showed that these cells exhibited functional defects, despite the lack of 
developmental deficiencies or morphologic abnormalities106. Therefore, and because of the 
significant similarities between Zap70 mediated TCR and Syk mediated FcεRI signalling in 
MCs199-201, it was necessary to gain insight into the functional attributes of RhoH ko MCs. 
The reported T-cell defects in RhoH ko mice were found to be related to the defective 
recruitment and phosphorylation of Zap70 to the immunological synapse89. Syk, which is a 
Zap70 homologue, plays a similar role in FcεRI mediated MC signalling and initiating of 
down-stream effects such as histamine release and cytokine production, following MC 
activation202. Preliminary experiments of Liu already indicated possible functional defects of 
RhoH ko MCs regarding FcεRI mediated β-hexosaminidase release102. These initial 
functional experiments were repeated because in contrast to Lius` data no developmental 
deficiencies in MC development were detectable in this study. Antigen mediated histamine 
release between RhoH null and wt MCs was compared, when antigen was applied in different 
concentrations.  
 
In RhoH deficient MCs reduced amounts of β-hexosaminidase (indicative for histamine) were 
detectable (Fig 4.23); the measurement of the reduced histamine levels was thought to be 
either caused by defective synthesis of the MC mediators, or by inappropriate production of 
the mediators as a consequence of defective FcεRI signalling following antigen challenge. A 
scenario in which both defective mediator production, as well as defective mediator release 
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leads synergistically to the detected results was also considered as possible. Shirais` group 
published their work during the course of this study and they also demonstrated reduced 
histamine release from RhoH null MCs114. In their studies, they included an ionomycin 
control. Ionomycin leads to the perforation of the cell membrane and helps to gain insight into 
the over-all content of intracellular mediators. Their results showed that RhoH null MCs are 
able to produce equal amounts of histamine indicating that RhoH is dispensable for granule 
biogenesis, which lead them to the conclusion that these RhoH deficient MCs show, instead, 
impaired FcεRI mediated degranulation. They also checked for passive systemic anaphylaxis 
and found that indeed RhoH KO mice also show in vivo defects of proper MC response114. 
During the studies of this thesis, it was aimed to further characterise functional defects in 
RhoH null mice by the quantification of the main MC cytokines: IL-6 and TNF-α (Fig. 
4.24)44. The released TNF-α is upregulating endothelilal and epithelial adhesion molecules, 
enhances bronichial responsiveness and inhibits tumor progression44. The release of IL-6 by 
MCs is known to contribute to MC mediated immune stimulatory functions, such as host 
defense during bacterial infections203,204. The outcome of this study showed that at least the 
release of these important cytokines was dramatically impaired in RhoH null mice (Fig. 4.24). 
Again, studies of the Sharai group confirmed the observed effects and they additionaly 
showed that this defect was not based on impaired exocytosis of the cytokines, but instead 
demonstrated that upon antigen treatment already mRNA levels, indicative for a lower 
expression of these cytokines was significantly reduced114. The functional deficiencies in 
MCs are indicative for impaired FcεRI mediated signalling. The group of Shirai observed 
impaired ion-flux as a result of inefficient phosphorylation of FcεRI downstream positioned 
adaptor proteins PLCγ1, PLCγ2, SLP76 and LAT upon activation of FcεRI. They assumed 
that the activation upstream of the adaptor proteins might be the cause for the lack of 
phosphorylation detected in RhoH deficient MCs. Since the given similarities between TCR 
and MC signalling205 and the impaired recruitment and phosphorylation of Zap70 (Syk in 
MCs) in TCR mediated signal transduction in RhoH KO mice88,89, they investigated the 
phosphorylation of the Syk kinase in response to antigen challenge. It was found that the 
phosphorylation and activation of the kinase Syk in MCs strongly depends on the presence of 
RhoH and that Syk is able to bind to RhoH in a MC unstimulated and even stronger after 
activation of the FcεRI, which most likely indicates that RhoH similar to its identified role in 
TCR signalling is necessary to mediate activation and recruitment of Syk to the proper 
signalling subunits in MCs to guarantee proper MC activation.  
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5.7  Summary and outlook (II): The consequences of RhoH 
deficiency for IL-3 derived MCs 
 
 
Fig. 5.4 Effects of RhoH deficiency for IL-3 derived mast cells 
RhoH -/- progenitors show increased proliferation and decreased p21waf/cip1 and p27kip1 levels in early phase of cultivation. 
(after d 7) RhoH null progenitors show enhanced CD123 surface expression correlating with increased IRF-1 mRNA levels, 
while p21waf/cip1, p27kip1 levels as well as MC specific marker expression are comparable to that of wt cells. Fully 
differentiated MCs show decreased histamine release and secreation of the cytokines IL-6 and TNF-α following FcεRI 
activation.  
 
The results from IL-3 derived RhoH null MCs suggest that although RhoH is not essential for 
the development of MCs the lack of RhoH causes functional defects in FcεRI mediated signal 
transduction, most likely through a defective activation of the Syk kinase. However to cut 
down the relevance of IL-3 and IL-3 mediated signalling in MCs, the observed effects such as 
enhanced proliferation of RhoH deficient progenitor cells need to be further investigated and 
compared to results obtained from experiments using the MC differentiation factor SCF-1. 
RhoH deficiency resulted in enhanced MC progenitor proliferation in IL-3 containing 
medium. The proliferation rate of mature RhoH ko MCs remains to be determined and also 
whether the altered proliferation correlates with increased STAT5 activity. In this context, it 
should be clarified whether the dynamic upregulation of CDKIs during MC maturation is able 
to decrease the observed proliferation rate at latter time points. Future studies should include 
the investigation of endogenous pathways responsible for the compensation of the effects 
caused by the lack of RhoH. The answer to this question could potentially provide major 
insight into RhoH modulated pathways. Due to high variations between biologic replicates, 
the data obtained from analysis of primary MCs are widely speculative. In the future 
experimental layouts have to be standardised to receive trustworthy results which will help to 
understand the biology of this highly interesting GTPase
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6. Appendix 
 
6.1  Supplementary tables 
 
6.1.1 Thesis relevant protein hits  
 
6.1.1.1 RhoH wt +IL3 
Accession # Gene Aliases 
IPI00139795 Rplp2 Renal carcinoma antigen NY-REN-44, P2,RPP2,  60S acidic ribosomal protein P2 
IPI00225634 Rps12 ribosomal protein S12 
IPI00113377 Rplp1  acidic ribosomal protein P1, RLA1,PI, RPP1 
IPI00115477 Ccdc46  Isoform 1 of Coiled-coil domain-containing protein 46 
IPI00132352 Cxorf26 homo CXO26,  
IPI00848599 Dnahc7l  Hsp40 homolog subfamily B , member14 
IPI00121297 Naca  HSD48, NAC-alpha 3, Nascent polypeptide-associated complex subunit alpha 
IPI00111265 Capza2  F-actin-capping protein subunit alpha-2 
IPI00269481 Capzb f F-actin-capping protein subunit beta 
IPI00896602 Ppfia1  Liprin alpa 1, LIP1, PTPRF interacting protein alpha 1 
IPI00132966 Ppid  PPIase, Cyclophilin-40, CYP40 
IPI00623545 Ppp1r14b Protein phosphatase 1 regulatory subunit 14B,  PHI1 PLCB3N  
IPI00265471 Adsl ASL, adenylosuccinate lyase  
IPI00118757 Phpt1  PHP14,HSPC141, Protein janus-A homolog  
IPI00228633 Gpi1  PIG-Q, phosphatidylinositol glycan, class Q 1, Glucose-6-phosphate isomerase 
IPI00122565 Gdi2 Iso Rab GDI beta, Rab GDP dissociation inhibitor beta iso1 
IPI00266281 Txnl1  TPR32, TXL1, Thioredoxin-like protein 1 
IPI00856350 Clip1  restin, RSN, CYLN1 
IPI00110753 Tuba1a  Tubulin alpha-1A chain 
IPI00307837 Eef1a1  CTCL tumor antigen, Leukocyte receptor cluster member 7 
IPI00169707 Tpm3  Tropomyosin3, gamma 
IPI00227918 Tpm2 tropomyosin2, DA2B,TMSB 
IPI00136929 Actg1 Actin gamma actin like 
IPI00123039 Ptpn1  PTP-1B, Tyrosine-protein phosphatase non-receptor type 1 
IPI00621468 EG665964  similar to ubiquitin A-52 
IPI00377342 EG383341  similar to ubiquitin A-52  
IPI00114894 Myh11  Myosin1 isoform1 
IPI00129105 Sae1 Iso1 Sua, AOS, SUMO1 activating enzyme subunit 1  
IPI00648513 Zc3h18 Iso1  NHN1, zinc finger CCCH-type containing 18  
IPI00845851 Syne2  nesprin2, NUA, NUANCE, synaptic nuclear envelope 2 
IPI00119959 Banf1  BAF, BCRG1, Barrier-to-autointegration factor 
IPI00331146 Cmpk1  KCY, CM, KCytidylate kinase , UMP-CMP kinase 
IPI00606189 Jarid1a  Jumonji, AT rich interactive domain 1A (RBBP2-like), 14 kDa phosphohistidine phosphatase 
IPI00131186 Btf3 Iso2 basic transcription factor 3 
IPI00129417 Hnrpdl  JKT41-binding protein, JKTBP1, Heterogeneous nuclear ribonucleoprotein D-like 
IPI00463344 Dnajc8  DnaJ (Hsp40) homolog, subfamily C, member 8 
 
 
6.1.1.2 RhoH wt and T36A +IL-3 
Accession # Gene  Aliases 
IPI00118892 Lcp1  L-Plastin, Lymphocyte cytosolic protein 1,Plastin2 
IPI00453599 Cfdp1  Craniofacial development protein 1, CP27, bucentaur 
IPI00331556 Hspa4  Heat shock 70 kDa protein 4, APG4 
IPI00127989 ptges3 Prostaglandin E synthase 3 
IPI00125923 Ostf1  Osteoclast-stimulating factor 1 
IPI00323600 Coro1a  Coronin-1A, p57 
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IPI00111560  SET Iso 1 SET translocation, leukemia associated protein SET, Iso 1 
IPI00322312 Arhgdia  Rho GDP-dissociation inhibitor 1 
IPI00555059 Prdx6  Peroxiredoxin-6, PRX6  
IPI00405227 Vcl  Vinculin 
IPI00131459 Nme1; Nucleoside diphosphate kinase A, expressed in non-metastatic cells 1 
IPI00227392 Ywhah 14-3-3 ε tyrosine 3-monooxygenase 
IPI00230707 Ywhag 14-3-3γ 14-3-3 gamma 
IPI00465786 Tln1  Talin-1 
IPI00377351 Apoa4  Apolipoprotein A-IV, apo A-IV  
IPI00230427 Mif r Macrophage migration inhibitory facto 
IPI00221402 Aldoa  Fructose-bisphosphate aldolase A 
IPI00109061 Tubb2b  Tubulin beta 2b, Tubulin beta-2B chain 
IPI00119458 Aldoc  Aldolase C,zebrin2, fructose-biphosphate 
IPI00273646 GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
IPI00123181 Myh9  Myosin-9 
IPI00113870 Pcna  Proliferating cell nuclear antigen 
IPI00128904 Pcbp1  Poly(rC)-binding protein 1 
IPI00123199 Nap1l11  Nucleosome assembly protein 1-like  
IPI00230139 Fkbp4  p59, FK506 binding protein 4 
IPI00462934 Khsrp KH type splicing regulatory protein, FUSE-binding protein 2,   
IPI00474446 Eif2s1  Eukaryotic translation initiation factor 2 subunit 1 
IPI00890117 Cfl1  Cofilin-1 
IPI00622235 Vcp   valosin containing protein, p97 
IPI00320645 Zfp830 Ccdc16,  Zinc finger protein 830 
IPI00117011 Hcls1  haematopoietic cell specific Lyn substrate 1 
IPI00131138 Flna Isoform 1 Filamin alpha 
IPI00138892 Uba52; ubiquitin and ribosomal protein L40, ubiquitin-CEP52 
IPI00223253 Hnrnpk Isoform 1  KBBP, NOVA, Heterogeneous nuclear ribonucleoprotein K isof 1 
IPI00225307 Sars  Seryl-aminoacyl-tRNA synthetase, isoform CRA_b, seryl-tRNA synthetase  
IPI00277930 Capg  gesolin like capping protein 
IPI00321147 Samsn1  ,SH3 domain and nuclear localization signals, 1, isoform CRA_SAM domainb 
IPI00407130 Pkm2   PK3, pyruvate kinase, muscle Isoform M2, CTHBP, THBP1 
IPI00467266 Dut  Deoxyuridine triphosphatase, isoform CRA_a 
IPI00469103 Kars  lysyl-tRNA synthetase isoform 1, KRS, LysRS 
IPI00756894 Nsfl1c  p47 , SHP1 homolog, UBX domain protein 2,cNSFL1 (P97) cofactor 
IPI00850795  A-52  residue ribosomal protein fusion product 1 isoform 1, similar to ubiquitin 
IPI00330767 Cnbp  Isoform 1 of Cellular nucleic acid-binding protein 
IPI00108206 Mela  melanoma antigene, Gag-Pol polyprotein 
IPI00118676 Eif4a1 I Eukaryotic translation initiation factor 4A- 
IPI00121427 S100a6  Calcyclin 
IPI00130883 Rbm3   RNA-binding motif protein 3 
IPI00132080 Pgls 6 6- phosphogluconolactonase 
IPI00137409 Tkt  Transketolase, p68 
IPI00317309 Anxa5 Annexin A5 
6.1.2  Gene ontology  
 
6.1.2.1 Gene ontology in precent 
 
RhoH wt Hits % Hits % Hits % 
Treatment (+ )IL-3 (+ )IL-3 (+/- )IL-3 (+/- )IL-3 (-) IL-3 (-) IL-3 
Total 82 100% 33 100% 26 100% 
Apoptosis 3 4% 2 6% 0 0 
Signal transduction 7 9% 3 9% 2 8% 
Cell cycle 3 4% 3 9% 2 8% 
  Appendix 
 
 
105 
 
Cytoskeletal 13 16% 3 9% 2 8% 
Differentiation 1 1% 1 3% 1 4% 
Metabolism 16 20% 4 12% 2 8% 
Nucleic Acid 29 35% 11 33% 12 46% 
Stress response 2 2% 2 6% 2 8% 
Unkown 5 6% 2 6% 2 8% 
Others 4 5% 2 6% 1 4% 
 
6.2  RhoH protein sequence (mouse) 
 
(Sequence as obtained from: http://www.ncbi.nlm.nih.gov/protein/AAH94937.1) 
 
1  MLSSIKCVLV GDSAVGKTSL LVRFTSETFP EAYKPTVYEN TGVDVFMDGI QISLGLWDTA  
61  GNDAFRSIRP LSYGGADVVL MCYSVANHNS FLNLKNKWIS EIRSNLPCTP VLVVATQTDQ 
121  REVGPHRASC INAIEGKRLA QDVRAKGYLE CSALSNRGVQ QVFECAVRTA VNQARRRNRR  
181  KLFSINECKIF 
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